

Prolyl Hydroxylase Inhibitors

FIELD OF THE INVENTION

This invention relates to certain heteroaromatic N-substituted glycine derivatives that are inhibitors of HIF prolyl hydroxylases, and thus have use in treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

BACKGROUND OF THE INVENTION

Anemia occurs when there is a decrease or abnormality in red blood cells, which leads to reduced oxygen levels in the blood. Anemia occurs often in cancer patients, particularly those receiving chemotherapy. Anemia is often seen in the elderly population, patients with renal disease, and in a wide variety of conditions associated with chronic disease.


Frequently, the cause of anemia is reduced erythropoietin (Epo) production resulting in prevention of erythropoiesis (maturation of red blood cells). Epo production can be increased by inhibition of prolyl hydroxylases that regulate hypoxia inducible factor (HIF).

One strategy to increase erythropoietin (Epo) production is to stabilize and thus increase the transcriptional activity of the HIF. HIF-alpha subunits (HIF-1alpha, HIF-2alpha, and HIF-3alpha) are rapidly degraded by proteosome under normoxic conditions upon hydroxylation of proline residues by prolyl hydroxylases (EGLN1, 2, 3). Proline hydroxylation allows interaction with the von Hippel Lindau (VHL) protein, a component of an E3 ubiquitin ligase. This leads to ubiquitination of HIF-alpha and subsequent degradation. Under hypoxic conditions, the inhibitory activity of the prolyl hydroxylases is suppressed, HIF-alpha subunits are therefore stabilized, and HIF-responsive genes, including Epo, are transcribed. Thus, inhibition of prolyl hydroxylases results in increased levels of HIF-alpha and thus increased Epo production.

The compounds of this invention provide a means for inhibiting these hydroxylases, increasing Epo production, and thereby treating anemia. Ischemia, myocardial infarction, stroke, and cytoprotection may also benefit by administering these compounds.

SUMMARY OF THE INVENTION

In the first instance, this invention relates to a compound of formula (I):



wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, $-NR^5R^6$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl- C_1-C_{10} alkyl, C_3-C_8 cycloalkenyl, C_5-C_8 cycloalkenyl- C_1-C_{10} alkyl, C_3-C_8 heterocycloalkyl, C_3-C_8 heterocycloalkyl- C_1-C_{10} alkyl, aryl, aryl- C_1-C_{10} alkyl, heteroaryl and heteroaryl- C_1-C_{10} alkyl;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1-C_4 alkyl;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkyl- C_1-C_{10} alkyl, C_3-C_8 heterocycloalkyl, C_3-C_8 heterocycloalkyl- C_1-C_{10} alkyl, aryl, aryl- C_1-C_{10} alkyl, heteroaryl, heteroaryl- C_1-C_{10} alkyl, $-C(O)C_1-C_4$ alkyl, $-C(O)C_3-C_6$ cycloalkyl, $-C(O)C_3-C_6$ heterocycloalkyl, $-C(O)$ aryl, $-C(O)$ heteroaryl and $-S(O)_2C_1-C_4$ alkyl, or, when R^5 and R^6 are attached to the same nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom

selected from oxygen, nitrogen and sulphur,

R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_8 cycloalkyl, C_3-C_8 heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1-C_{10} alkyl which is unsubstituted or substituted with one or more substituents, suitably from 1 to 6 substituents, suitably from 1 to 3 substituents, independently selected from the group consisting of C_3-C_6 cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;

where any carbon or heteroatom of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 is unsubstituted or, where possible, is substituted with one or more substituents, suitably from 1 to 6 substituents, suitably from 1 to 3 substituents, independently selected from C_1-C_6 alkyl, C_1-C_6 haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6 cycloalkyl, C_3-C_6 heterocycloalkyl, aryl, C_1-C_6 alkyl-aryl, heteroaryl and C_1-C_6 alkyl-heteroaryl, wherein R^5 and R^6 are the same as defined above and R^{10} is selected from hydrogen, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, $-C(O)C_1-C_4$ alkyl, $-C(O)$ aryl, $-C(O)$ heteroaryl, $-C(O)C_3-C_6$ cycloalkyl, $-C(O)C_3-C_6$ heterocycloalkyl, $-S(O)_2C_1-C_4$ alkyl, C_3-C_8 cycloalkyl, C_3-C_8 heterocycloalkyl, C_6-C_{14} aryl, aryl- C_1-C_{10} alkyl, heteroaryl and heteroaryl- C_1-C_{10} alkyl;

and/or a pharmaceutically acceptable salt or solvate thereof.

In a second aspect of the present invention, there is provided a compound of formula (I) and/or a pharmaceutically acceptable salt or solvate thereof for use in mammalian therapy, including human therapy, e.g. treating amenia. An example of this therapeutic approach is that of a method for treating anemia which is effected by increasing the production of erythropoietin (Epo) by inhibiting HIF prolyl hydroxylases comprising administering a compound of formula (I) and/or a pharmaceutically acceptable salt or solvate thereof, to a patient in need thereof, neat or admixed with a pharmaceutically acceptable excipient or excipients, in an amount sufficient to increase production of Epo.

In a third aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of formula (I), and/or a pharmaceutically acceptable salt or solvate thereof, and one or more of pharmaceutically acceptable carriers, diluents and excipients.

In a fourth aspect, there is provided the use of a compound of formula (I) and/or a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for use in the treatment of a disorder mediated by inhibiting HIF prolyl hydroxylases, such as an anemia, that can be treated by inhibiting HIF prolyl hydroxylases.

In a fifth aspect, there is provided methods of co-administering the presently invented compounds of formula (I) with further active ingredients.

DETAILED DESCRIPTION OF THE INVENTION

For the avoidance of doubt, unless otherwise indicated, the term “substituted” means substituted by one or more defined groups. In the case where groups may be selected from a number of alternative groups the selected groups may be the same or different.

The term “independently” means that where more than one substituent is selected from a number of possible substituents, those substituents may be the same or different.

An “effective amount” means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term “therapeutically effective amount” means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

As used herein the term “alkyl” refers to a straight- or branched-chain hydrocarbon radical having the specified number of carbon atoms, so for example, as used herein, the terms “C₁-C₄alkyl” and “C₁-C₁₀ alkyl” refers to an alkyl group having at least 1 and up to 4 or 10 carbon

atoms respectively. Examples of such branched or straight-chained alkyl groups useful in the present invention include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, t-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl, and branched analogs of the latter 5 normal alkanes.

5 When the term "alkenyl" (or "alkenylene") is used it refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and at least 1 and up to 5 carbon-carbon double bonds. Examples include ethenyl (or ethenylene) and propenyl (or propenylene).

10 When the term "alkynyl" (or "alkynylene") is used it refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms and at least 1 and up to 5 carbon-carbon triple bonds. Examples include ethynyl (or ethynylene) and propynyl (or propynylene).

 "Haloalkyl" refers to an alkyl group group that is substituted with one or more halo substituents, suitably from 1 to 6 substituents. Haloalkyl includes trifluoromethyl.

15 When "cycloalkyl" is used it refers to a non-aromatic, saturated, cyclic hydrocarbon ring containing the specified number of carbon atoms. So, for example, the term "C₃-C₈cycloalkyl" refers to a non-aromatic cyclic hydrocarbon ring having from three to eight carbon atoms. Exemplary "C₃-C₈cycloalkyl" groups useful in the present invention include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

20 The term "C₅-C₈cycloalkenyl" refers to a non-aromatic monocyclic carboxycyclic ring having the specified number of carbon atoms and up to 3 carbon-carbon double bonds. "Cycloalkenyl" includes by way of example cyclopentenyl and cyclohexenyl.

 Where "C₃-C₈heterocycloalkyl" is used, it means a non-aromatic heterocyclic ring containing the specified number of ring atoms being, saturated or having one or more degrees of
25 unsaturation and containing one or more heteroatom substitutions independently selected from O, S and N. Such a ring may be optionally fused to one or more other "heterocyclic" ring(s) or cycloalkyl ring(s). Examples of "heterocyclic" moieties include, but are not limited to, aziridine, thiirane, oxirane, azetidine, oxetane, thietane, tetrahydrofuran, pyran, 1,4-dioxane, 1,3-dioxane, piperidine, piperazine, 2,4-piperazinedione, pyrrolidine, imidazolidine, pyrazolidine, morpholine,
30 thiomorpholine, tetrahydrothiopyran, tetrahydrothiophene, and the like.

 "Aryl" refers to optionally substituted monocyclic and polycarbocyclic unfused or fused groups having 6 to 14 carbon atoms and having at least one aromatic ring that complies with Hückel's Rule. Examples of aryl groups are phenyl, biphenyl, naphthyl, anthracenyl, phenanthrenyl and the like.

35 "Heteroaryl" means an optionally substituted aromatic monocyclic ring or polycarbocyclic fused ring system wherein at least one ring complies with Hückel's Rule, has the specified number

of ring atoms, and that ring contains at least one heteratom independently selected from N, O and S. Examples of "heteroaryl" groups include furanyl, thiophenyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, oxo-pyridyl, thiadiazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrazinyl, pyrimidinyl, quinolinyl, isoquinolinyl, benzofuranyl, benzothiophenyl, indolyl and indazolyl.

The term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.

The term "solvate" refers to a complex of variable stoichiometry formed by a solute and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without limitation, water, ethanol and acetic acid. Most preferably the solvent used is water.

Herein, the term "pharmaceutically-acceptable salts" refers to salts that retain the desired biological activity of the subject compound and exhibit minimal undesired toxicological effects. These pharmaceutically-acceptable salts may be prepared *in situ* during the final isolation and purification of the compound, or by separately reacting the purified compound in its free acid or free base form with a suitable base or acid, respectively.

By the term "co-administering" and derivatives thereof as used herein is meant either simultaneous administration or any manner of separate sequential administration of a prolyl hydroxylase inhibiting compound, as described herein, and a further active ingredient or ingredients, known to be useful in treating diseases of the hematopoietic system, particularly anemias, including EPO or a derivative thereof. The term further active ingredient or ingredients, as used herein, includes any compound or therapeutic agent known to or that demonstrates advantageous properties when administered to a patient in need of treatment for diseases of the hematopoietic system, particularly anemias or any compound known to be useful when used in combination with a prolyl hydroxylase inhibiting compound. Preferably, if the administration is not simultaneous, the compounds are administered in a close time proximity to each other. Furthermore, it does not matter if the compounds are administered in the same dosage form, e.g. one compound may be administered topically and another compound may be administered orally.

In certain embodiments, compounds according to Formula I may contain an acidic functional group, one acidic enough to form salts. Representative salts include pharmaceutically-acceptable metal salts such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc salts; carbonates and bicarbonates of a pharmaceutically-acceptable metal cation such as sodium, potassium, lithium, calcium, magnesium, aluminum, and zinc; pharmaceutically-acceptable organic primary, secondary, and tertiary amines including aliphatic amines, aromatic

amines, aliphatic diamines, and hydroxy alkylamines such as methylamine, ethylamine, 2-hydroxyethylamine, diethylamine, triethylamine, ethylenediamine, ethanolamine, diethanolamine, and cyclohexylamine.

In certain embodiments, compounds according to Formula (I) may contain a basic functional group and are therefore capable of forming pharmaceutically-acceptable acid addition salts by treatment with a suitable acid. Suitable acids include pharmaceutically-acceptable inorganic acids and pharmaceutically-acceptable organic acids. Representative pharmaceutically-acceptable acid addition salts include hydrochloride, hydrobromide, nitrate, methylnitrate, sulfate, bisulfate, sulfamate, phosphate, acetate, hydroxyacetate, phenylacetate, propionate, butyrate, isobutyrate, valerate, maleate, hydroxymaleate, acrylate, fumarate, malate, tartrate, citrate, salicylate, *p*-aminosalicylate, glycollate, lactate, heptanoate, phthalate, oxalate, succinate, benzoate, *o*-acetoxybenzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, mandelate, tannate, formate, stearate, ascorbate, palmitate, oleate, pyruvate, pamoate, malonate, laurate, glutarate, glutamate, estolate, methanesulfonate (mesylate), ethanesulfonate (esylate), 2-hydroxyethanesulfonate, benzenesulfonate (besylate), *p*-aminobenzenesulfonate, *p*-toluenesulfonate (tosylate) and naphthalene-2-sulfonate.

Compounds of formula (I) that are of particular interest include those wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl, C_5 - C_8 cycloalkenyl, C_5 - C_8 cycloalkenyl- C_1 - C_{10} alkyl, C_3 - C_8 heterocycloalkyl, C_3 - C_8 heterocycloalkyl- C_1 - C_{10} alkyl, aryl, aryl- C_1 - C_{10} alkyl, heteroaryl and heteroaryl- C_1 - C_{10} alkyl;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1 - C_4 alkyl;

where R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_8 cycloalkyl, C_3 - C_8 heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1 - C_{10} alkyl which is unsubstituted or substituted with one or more substituents, suitably from 1 to 6 substituents, suitably from 1 to 3 substituents, independently selected from the group consisting of C_3 - C_6 cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

where any carbon or heteroatom of R^1 , R^2 , R^3 , R^4 , R^7 , R^8 , R^9 is unsubstituted or, where possible, is substituted with one or more substituents, suitably from 1 to 6 substituents, suitably from 1 to 3 substituents, independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$,

-S(O)₂R¹⁰, -NR⁵R⁶, -CONR⁵R⁶, -N(R⁵)C(O)R¹⁰, -N(R⁵)C(O)OR¹⁰, -OC(O)NR⁵R⁶,
 -N(R⁵)C(O)NR⁵R⁶, -SO₂NR⁵R⁶, -N(R⁵)SO₂R¹⁰, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl,
 C₃-C₆cycloalkyl, C₃-C₆heterocycloalkyl, aryl, C₁-C₆alkyl-aryl, heteroaryl and C₁-C₆alkyl-
 heteroaryl, wherein R⁵, and R⁶ are the same as defined above and R¹⁰ is selected from
 5 hydrogen, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, -C(O)C₁-C₄ alkyl, -C(O)aryl,
 -C(O)heteroaryl, -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -S(O)₂C₁-C₄ alkyl,
 C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, C₆-C₁₄aryl, aryl-C₁-C₁₀alkyl, heteroaryl and
 heteroaryl-C₁-C₁₀alkyl;

and/or a pharmaceutically acceptable salt or solvate thereof.

10

Compounds of formula (I) that are of further interest are those wherein:

X is O;

Y is O;

R¹ and R⁴ are each independently selected from the group consisting of hydrogen,

15 C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkyl-C₁-C₁₀alkyl,
 C₅-C₈cycloalkenyl, C₅-C₈cycloalkenyl-C₁-C₁₀alkyl, C₃-C₈heterocycloalkyl, C₃-C₈heterocycloalkyl-
 C₁-C₁₀alkyl, aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl;

R² is -OR⁹;

R³ is H or C₁-C₄alkyl;

20 R⁹ is H or a cation, or C₁-C₁₀alkyl which is unsubstituted or is substituted with one or more
 substituents, suitably from 1 to 6 substituents, suitably from 1 to 3 substituents,
 independently selected from the group consisting of C₃-C₆ cycloalkyl, heterocycloalkyl,
 aryl and heteroaryl;

25 where any carbon or heteroatom of R¹, R², R³, R⁴, R⁹ is unsubstituted or, where possible, is
 substituted with one or more substituents, suitably from 1 to 6 substituents, suitably from 1
 to 3 substituents, independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, halogen, -OR¹⁰,
 -NR⁵R⁶, oxo, cyano, nitro, -C(O)R¹⁰, -C(O)OR¹⁰, -SR¹⁰, -S(O)R¹⁰, -S(O)₂R¹⁰, -NR⁵R⁶,
 -CONR⁵R⁶, -N(R⁵)C(O)R¹⁰, -N(R⁵)C(O)OR¹⁰, -OC(O)NR⁵R⁶, -N(R⁵)C(O)NR⁵R⁶,
 -SO₂NR⁵R⁶, -N(R⁵)SO₂R¹⁰, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₃-C₆cycloalkyl,
 30 C₃-C₆heterocycloalkyl, aryl, C₁-C₆alkyl-aryl, heteroaryl and C₁-C₆ alkyl-heteroaryl,
 wherein R⁵, and R⁶ are the same as defined above and R¹⁰ is selected from hydrogen,
 C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, -C(O)C₁-C₄alkyl, -C(O)aryl, -C(O)heteroaryl,
 -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -S(O)₂C₁-C₄alkyl, C₃-C₈cycloalkyl,
 C₃-C₈heterocycloalkyl, C₆-C₁₄aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl;

35 and/or a pharmaceutically acceptable salt or solvate thereof.

Of further interest are those compounds of formula (I) where:

X is O;

Y is O;

R¹ and R⁴ are each independently selected from the group consisting of hydrogen,

5 C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkyl-C₁-C₁₀alkyl, C₅-C₈cycloalkenyl, C₅-C₈cycloalkenyl-C₁-C₁₀alkyl, C₃-C₈heterocycloalkyl, C₃-C₈heterocycloalkyl-C₁-C₁₀alkyl, aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl;

R² is -OR⁹;

R³ is H;

10 R⁹ is H or a cation;

where any carbon or heteroatom of R¹, R², R³, R⁴ is unsubstituted or, where possible, is substituted with one or more substituents, suitably from 1 to 6 substituents, suitably from 1 to 3 substituents, independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, halogen, -OR¹⁰, -NR⁵R⁶, oxo, cyano, nitro, -C(O)R¹⁰, -C(O)OR¹⁰, -SR¹⁰, -S(O)R¹⁰, -S(O)₂R¹⁰, -NR⁵R⁶,
15 -CONR⁵R⁶, -N(R⁵)C(O)R¹⁰, -N(R⁵)C(O)OR¹⁰, -OC(O)NR⁵R⁶, -N(R⁵)C(O)NR⁵R⁶, -SO₂NR⁵R⁶, -N(R⁵)SO₂R¹⁰, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₆cycloalkyl, C₃-C₆heterocycloalkyl, aryl, C₁-C₆alkyl-aryl, heteroaryl and C₁-C₆alkyl-heteroaryl, wherein R⁵, and R⁶ are the same as defined above and R¹⁰ is selected from hydrogen, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, -C(O)C₁-C₄alkyl, -C(O)aryl, -C(O)heteroaryl, -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -S(O)₂C₁-C₄alkyl, C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, C₆-C₁₄aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl;
20 and/or a pharmaceutically acceptable salt or solvate thereof.

Specific compounds that are exemplified herein and that are useful in the present invention

25 are:

N-{[1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-{[2,4-bis(methyloxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

30 N-{[1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

35 N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-(1,1-dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

5

N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

10 *N*-{[6-Hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-[(3-Cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

15 *N*-[(6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

N-{[1-[(3,4-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

20 *N*-{[6-Hydroxy-1-{[3-(methyloxy)phenyl]methyl}-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-[(2,6-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[6-Hydroxy-1-methyl-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

25 *N*-{[1-Cyclohexyl-3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

30 *N*-{[1-Hexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Ethyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

35 *N*-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Butyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[6-Hydroxy-2,4-dioxo-1-(2-phenylethyl)-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

5 *N*-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-1-(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

10 *N*-{[6-Hydroxy-1,3-bis(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-[(2-Bromophenyl)methyl]-1-(1,1-dimethylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

15 *N*-[(1-(2,4-dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

N-[(1-(2-Bromophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

20 *N*-[(1-(2-Biphenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

25 *N*-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(2-thienyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({1-Cyclohexyl-6-hydroxy-3-[3-(4-morpholinyl)propyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

30 *N*-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(3-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({1-Cyclohexyl-3-[(2-fluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

N-({3-[(2-Chlorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

35 *N*-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

N-({1-Cyclohexyl-3-[(2,4-dimethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trifluorophenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

5 *N*-[(1-Cyclohexyl-6-hydroxy-3-{[4-(1-methylethyl)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-Cyclohexyl-3-[(2-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

10 *N*-({1-Cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trimethylphenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[{1-Cyclohexyl-3-(2-cyclohexylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl]glycine;

15 *N*-[3-{[3,5-Bis(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[{1-Cyclohexyl-6-hydroxy-3-(2-naphthalenylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl]glycine;

20 *N*-({1-Cyclohexyl-6-hydroxy-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[{3-(4-Biphenylmethyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl]glycine;

N-[3-{[4-(1,3-Benzoxazol-2-yl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

25 *N*-({3-[2-(4-Biphenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1,3-Bis{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

30 *N*-[{1-Cyclohexyl-6-hydroxy-3-(4-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl]glycine;

N-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)cyclohexyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

35 *N*-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-3-(cyclohexylmethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-Cycloheptyl-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

5 *N*-[(3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-[(1*R*,2*R*,4*S*)-Bicyclo[2.2.1]hept-2-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

10 *N*-{[1-Cyclohexyl-6-hydroxy-3-(3-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-Cyclohexyl-1-cyclopropyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-Cyclobutyl-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

15 *N*-[(3-Cyclohexyl-1-cyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-Hydroxy-1,3-bis(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

20 *N*-[(6-Hydroxy-1,3-bis{[2-(methyloxy)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1,3-Bis[(2-chlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1,3-Dihexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

25 *N*-{[1-Cyclohexyl-6-hydroxy-3-(2-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(2-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

30 *N*-[(1-Cyclohexyl-3-hexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-Dicycloheptyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-Dicyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

35 *N*-{[1-Cyclohexyl-3-(2,3-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

4-[5- {[(Carboxymethyl)amino]carbonyl} -3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N- {[1-Cyclohexyl-3-(4-ethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

5 *cis*-4-[3-Cyclohexyl-5- {[2-(ethyloxy)-2-oxoethyl]amino} carbonyl)-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N- {[1-Cyclohexyl-6-hydroxy-3-(1-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

10 3-[5- {[(Carboxymethyl)amino]carbonyl} -3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N- {[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- [(1-Cyclohexyl-6-hydroxy-3- {2-[4-(methyloxy)phenyl]-2-oxoethyl} -2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

15 *N*- ({1-Cyclohexyl-6-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

N- {[1-Cyclohexyl-3-(3,3-dimethyl-2-oxobutyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

20 *N*- ({1-Cyclohexyl-3-[2-(4-fluorophenyl)-2-oxoethyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

N- ({3-[2-(4-Cyanophenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

N- ({3-[2-(1-Benzofuran-2-yl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

25 *N*- {[3-Cyclohexyl-6-hydroxy-1-(1-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[3-Cyclohexyl-1-(4,4-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

30 *N*- ({1-Cyclohexyl-3-[(2,3-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl) glycine;

Ethyl *N*- [(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl] glycinate;

N- [(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl] glycine;

35 6-[5- {[(Carboxymethyl)amino]carbonyl} -3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]hexanoic acid;

6-[5- {[(Carboxymethyl)amino]carbonothioyl} -3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]hexanoic acid;

N-({1-Cyclohexyl-3-[(3,4-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

5 *N*-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-Cyclohexyl-6-hydroxy-1-[*trans*-4-(methyloxy)cyclohexyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

10 *N*-({1-[1,1'-Bi(cyclohexyl)-4-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[6-Hydroxy-2,4-dioxo-1,3-bis(1-propylbutyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

15 *N*-[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-phenylcyclohexyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({1-Cyclohexyl-3-[(3,4-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

20 *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[3-(2-Cyclopropylethyl)-6-hydroxy-1-(3-nitrophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-2,4-dioxo-1-[4-(2-thienyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

25 *N*-[1,3-Bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

30 *N*-[(1,3-Dibutyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[1,3-Bis(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[6-Hydroxy-1,3-bis(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

35 *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl)glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

5 *N*-({3-(2-Cyclopropylethyl)-1-[4-(2-furanyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl)glycine;

N-{[1,3-Bis(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

10 *N*-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(1- {[(phenylmethyl)oxy]carbonyl}-3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-(1-Acetyl-3-piperidinyl)-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

15 *N*-[(1-Cyclohexyl-3- {4-fluoro-2-(trifluoromethyl)phenyl}methyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine;

N-({3-[(2-Bromophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl)glycine;

20 *N*-({1-Cyclohexyl-3-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl)glycine;

N-[(3- {2-Bromo-5-(methyloxy)phenyl}methyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine;

N-[(3- {2,4-Bis(trifluoromethyl)phenyl}methyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine;

25 *N*-({3-[(2-Bromo-5-fluorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl)glycine;

N-[(3- {2-Bromo-4-(1,1-dimethylethyl)phenyl}methyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine;


30 *N*-({1-Cyclohexyl-6-hydroxy-3-[(2-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl} carbonyl)glycine;

N-{[1-Cyclohexyl-3-(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine; and


N-{[1,3-Bis(2,6-dichlorophenyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine.

35

Processes for preparing the compound of formula (I) are also within the ambit of this invention. To illustrate, a process for preparing a compound of formula (I)




- 5 wherein X, Y, R¹, R², R³ and R⁴ are the same as defined above for formula (I), the process comprising treating a compound of formula A:




- 10 wherein R¹ and R⁴ are the same as for those groups in formula (I) with glycine and an appropriate base, such as 1,8-diazabicyclo[5.4.0]undec-7-ene, in an appropriate solvent, such as ethanol, under either conventional thermal conditions or by microwave irradiation, to form a compound of formula (I) where Y is O, R² is -OH, and R³ is H;

or a process for preparing a compound of formula (I) wherein X, Y, R¹, R², R³ and R⁴ are the same as defined above for formula (I), the process comprising treating a compound of formula B:







- 15 wherein X, Y, R¹, R², R³ and R⁴ are the same as for those groups in formula (I) with an alkali such as sodium hydroxide, in an appropriate solvent, such as aqueous ethanol, at a suitable temperature such as room temperature, to form a compound of formula (I) where R² is -OH;

- 20 or a process for preparing a compound of formula (I) wherein X, Y, R¹, R², R³ are the same as defined above for formula (I) and R⁴ is piperidinyl, the process comprising treating a compound of formula C:



wherein X, Y, R¹, and R³ are the same as for those groups in formula (I) with an acylating agent such as acetic anhydride, in an appropriate solvent, such as acetic acid, at a suitable temperature such as 130 °C, to form a compound of formula (I) where R² is -OH, and R⁴ is acylpiperidinyl;

5 It will be appreciated by those skilled in the art that the compounds of formula (I) may exist in one or more tautomeric forms such as:



10 All tautomeric forms of the compounds described herein, including mixtures thereof, are intended to be encompassed within the scope of the invention. Generally, the compounds exemplified herein have been assigned names based on the structure of the tautomer of formula (IA). It should be understood that any reference to named compounds of this invention is intended to encompass all tautomers of the named compounds and any mixtures of tautomers of the named compounds.

15 The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be solvated, e.g. as the hydrate. This invention includes within its scope stoichiometric solvates (e.g. hydrates) as well as compounds containing variable amounts of solvent (e.g. water).

20 Certain of the compounds described herein may contain one or more chiral atoms, or may otherwise be capable of existing as two enantiomers. The compounds claimed below include

mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula (I), or claimed below, as well as any wholly or partially equilibrated mixtures thereof. The present invention also covers the individual isomers of the claimed
5 compounds as mixtures with isomers thereof in which one or more chiral centers are inverted.

Where there are different isomeric forms they may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

While it is possible that, for use in therapy, a compound of formula (I), as well as salts,
10 solvates and the like, may be administered as a neat preparation, i.e. no additional carrier, the more usual practice is to present the active ingredient confectioned with a carrier or diluent. Accordingly, the invention further provides pharmaceutical compositions, which includes a compound of formula (I) and salts, solvates and the like, and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compounds of formula (I) and salts, solvates, etc, are as described
15 above. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the invention there is also provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula (I), or salts, solvates etc, with one or more pharmaceutically acceptable carriers, diluents or excipients.

It will be appreciated by those skilled in the art that certain protected derivatives of
20 compounds of formula (I), which may be made prior to a final deprotection stage, may not possess pharmacological activity as such, but may, in certain instances, be administered orally or parenterally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Further, certain
25 compounds of the invention may act as prodrugs of other compounds of the invention. All protected derivatives and prodrugs of compounds of the invention are included within the scope of the invention. It will further be appreciated by those skilled in the art, that certain moieties, known to those skilled in the art as "pro-moieties" may be placed on appropriate functionalities when such functionalities are present within compounds of the invention. Preferred prodrugs for compounds of the invention
30 include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.

Pharmaceutical compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, more preferably 5 mg to 100 mg of a compound of the
35 formula (I), depending on the condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical compositions may be presented in unit dose

forms containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage compositions are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Furthermore, such pharmaceutical compositions may be prepared by any of the methods well known in the pharmacy art.

5 Pharmaceutical compositions may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such compositions may be prepared by any method known in the art of pharmacy, for example by bringing into association a compound of formal (I) with the
10 carrier(s) or excipient(s).

 Pharmaceutical compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

15 Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is
20 ingested.

 Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes
25 and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.

 Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is
30 prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginat, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by tablet forming dies by means of the addition of stearic acid, a stearate salt,
35 talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert carrier and compressed into

tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

5 Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit form so that a given quantity contains a predetermined amount of a compound of formula (I). Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated
10 isostearyl alcohols and polyoxy ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.

Where appropriate, dosage unit pharmaceutical compositions for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for
15 example by coating or embedding particulate material in polymers, wax or the like.

Pharmaceutical compositions adapted for rectal administration may be presented as suppositories or as enemas.

Pharmaceutical compositions adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

20 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The pharmaceutical compositions may be presented in unit-dose or multi-dose containers,
25 for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.

It should be understood that in addition to the ingredients particularly mentioned above,
30 the pharmaceutical compositions may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the intended recipient, the
35 precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant prescribing the

medication. However, an effective amount of a compound of formula (I) for the treatment of anemia will generally be in the range of 0.001 to 100 mg/kg body weight of recipient per day, suitably in the range of .01 to 10 mg/kg body weight per day. For a 70kg adult mammal, the actual amount per day would suitably be from 7 to 700 mg and this amount may be given in a single dose per day or in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate, etc., may be determined as a proportion of the effective amount of the compound of formula (I) *per se*. It is envisaged that similar dosages would be appropriate for treatment of the other conditions referred to above.

Definitions

CDI – carbonyl di-imidazole

DBU -1,8-diazabicyclo[5.4.0]undec-7-ene

DIAD – diisopropyl azodicarboxylate

DMA - *N,N*-dimethylacetamide

DMF – *N,N*-dimethylformamide

DMSO – dimethylsulfoxide

HPLC – high pressure liquid chromatography

LC/MS – liquid chromatography/mass spectrometry

NMR – nuclear magnetic resonance

rt – room temperature

TFA – Trifluoroacetic acid

THF - tetrahydrofuran

Chemical Background:


The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention as prepared are given in the examples.

Compounds of general formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent

to those skilled in the art. The selection of processes as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of formula (I). Those skilled in the art will recognize if a stereocenter exists in compounds of formula (I). Accordingly, the present invention includes both possible stereoisomers and includes not only racemic compounds but the individual enantiomers as well. When a compound is desired as a single enantiomer, it may be obtained by stereospecific synthesis or by resolution of the final product or any convenient intermediate. Resolution of the final product, an intermediate, or a starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Organic Compounds by E. L. Eliel, S. H. Wilen, and L. N. Mander (Wiley-Interscience, 1994).


Illustrated Methods of preparation

Scheme 1





- a) 1. NaH, THF, rt 2. R^1NCO , 60 °C; b) 1. NaH, THF or dioxane, rt 2. R^4NCX , heat; c) $\text{H}_2\text{NCH}_2\text{CO}_2\text{H}$, DBU, EtOH, 160 °C, microwave.

Scheme 2




- a) R^1NH_2 , CH_2Cl_2 or $\text{R}^1\text{NH}_2\cdot\text{HCl}$, base, CH_2Cl_2 ; b) $\text{CH}_2(\text{C}(\text{O})\text{Cl})_2$, CH_2Cl_2 , reflux or $\text{CH}_2(\text{CO}_2\text{Et})_2$, NaOEt, $\text{MeO}(\text{CH}_2)_2\text{OH}$, reflux or 1. $\text{EtO}_2\text{CCH}_2\text{COC}_2\text{H}_5$, CHCl_3 , 70 °C 2. DBU, CHCl_3 , 70 °C; c) 1. $\text{YCNCH}_2\text{CO}_2\text{Et}$, EtPr_2N , CHCl_3 or CH_2Cl_2 2. aq NaOH, EtOH, rt.

Scheme 3 (for $R^1 = R^4$)


a) CDI, DMF, 70 °C or , EtOAc, rt

5

Scheme 4


a) OCNCH₂CO₂Et, EtPrⁱ₂N, CHCl₃ or CH₂Cl₂; b) 1. R¹Hal, Na/K₂CO₃, DMF or DMA, 100 °C or R¹Hal, pol-BEMP, DMF, 120 °C, microwave 2. aq NaOH, MeOH or EtOH, rt.

10

Scheme 5

a) 1. CH₂(CO₂H)₂, THF, 0 °C – rt 2. EtOH, reflux; b) 1. OCNCH₂CO₂Et, EtPrⁱ₂N, CH₂Cl₂ 2. aq NaOH, EtOH, rt.


15

Scheme 6

a) 1. Phthalimide, DIAD, PPh₃, THF 2. (NH₂)₂, EtOH, reflux.

20


Scheme 7



a) Ac_2O , AcOH , $130\text{ }^\circ\text{C}$.

5 Experimentals

Example 1



N-{[1-(4-Chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

10

1a). Diethyl {[1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}propanedioate. A solution of diethyl malonate (1.52 mL, 10.0 mmoles) in dry tetrahydrofuran (20 mL) was added to a suspension of sodium hydride (60% suspension in mineral oil, 500 mg, 12.5 mmoles) under argon atmosphere at room temperature. After stirring for 15 minutes, a solution of benzyl isocyanate (1.33 mL, 10.0 mmoles) was added and the mixture was heated at 60°C for 3 hours. The mixture was cooled, carefully acidified with 1 molar hydrochloric acid and the tetrahydrofuran evaporated. The mixture was diluted with water and extracted twice with chloroform. The combined extracts were washed twice with brine, dried and evaporated. Crystallization from ether-hexane afforded the title compound as a white solid, 1.2 g, 40%. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.20 (t, $J=7.20$ Hz, 6 H) 4.11 - 4.20 (m, 4 H) 4.33 (d, $J=6.06$ Hz, 2 H) 4.56 (s, 1 H) 7.24 (s, 1 H) 7.25 - 7.36 (m, 5 H) 8.74 (t, $J=5.68$ Hz, 1 H).

20

1b) Ethyl 1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. Diethyl {[1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}propanedioate (293 mg, 1.0 mmoles) was added to a suspension of sodium hydride (60% suspension in mineral oil, 100 mg, 2.5 mmoles) in dry tetrahydrofuran (50 mL) and stirred for 10 minutes under argon. 4-Chlorophenyl isocyanate was added and the mixture was heated under reflux for 2 hours, cooled, acidified with 1 molar hydrochloric acid and extracted with ethyl acetate. Flash chromatography (hexane-ethyl


25

acetate) afforded the title compound (225 mg, 56%) ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.06 (t, $J=7.07$ Hz, 3 H) 3.45 (q, $J=7.07$ Hz, 2 H) 5.00 (s, 2 H) 7.25 - 7.28 (m, 1 H) 7.30 - 7.37 (m, 6 H) 7.53 (d, $J=8.59$ Hz, 2 H).

- 5 1c) *N*-{[1-(4-Chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of ethyl 1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (225 mg, 0.56 mmoles), DBU (200 mg, 1.31 mmoles) and glycine (100 mg, 1.33 mmoles) in ethanol (10 mL) was sealed in a flask and heated in a microwave reactor at 160°C for 1 hour. The reaction mixture was evaporated, dissolved
10 in chloroform and washed with 1 molar hydrochloric acid. Evaporation of the residue and separation by preparative HPLC (10-80% acetonitrile-water-0.1%TFA) afforded the title compound (25 mg, 10%) ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 4.13 (d, $J=5.81$ Hz, 2 H) 5.03 (s, 2 H) 7.24 - 7.29 (m, 1 H) 7.31 - 7.38 (m, 4 H) 7.42 (d, $J=8.34$ Hz, 2 H) 7.52 - 7.58 (m, 2 H) 10.07 (s, 1 H) 13.11 (s, 1 H)

15

Example 2



N-{[1-{[2,4-Bis(methoxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine


- 20 2a) Ethyl 1-{[2,4-bis(methoxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. Diethyl {[(phenylmethyl)amino]carbonyl}propanedioate (820 mg, 2.8 mmoles) was added to a suspension of sodium hydride (60% suspension in mineral oil, 280 mg, 7.0 mmoles) in dry tetrahydrofuran (50 mL) and stirred for 10 minutes under argon. 2,4-dimethoxybenzyl isocyanate (1.0 mL, 6.0
25 mmoles) was added and the mixture heated under reflux for 3 hours, cooled, acidified with 1 molar hydrochloric acid and extracted with ethyl acetate. Flash chromatography (30% methanol in dichloromethane) afforded the title compound (480 mg, 39%) ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 1.15 (t, $J=6.69$ Hz, 3 H) 3.71 (s, 3 H) 3.78 (s, 3 H) 4.09 (q, $J=5.05$ Hz, 1 H) 4.81 (s, 2 H) 4.92 (s, 2 H) 6.40 - 6.59 (m, 3 H) 6.62 - 7.26 (m, 5 H).

30

- 2b) *N*-{[1-{[2,4-bis(methoxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of ethyl 1-{[2,4-

bis(methyloxy)phenyl)methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (110 mg, 0.25 mmol), DBU (76 mg, 0.5 mmol) and glycine (38 mg, 0.5 mmol) in ethanol (5 mL) was sealed in a flask and heated in a microwave reactor at 160°C for 1 hour. The reaction mixture was diluted with 1 molar hydrochloric acid and extracted with ethyl acetate. Purification by preparative HPLC (10-80% acetonitrile-water-0.1%TFA) afforded the title compound (50 mg, 42%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.71 - 3.81 (m, 6 H) 4.13 (d, *J*=5.31 Hz, 2 H) 4.92 (s, 2 H) 5.03 (s, 2 H) 6.39 - 6.49 (m, 1 H) 6.56 (s, 1 H) 6.81 (d, *J*=8.08 Hz, 1 H) 7.24 - 7.36 (m, 5 H) 10.10 (s, 1 H) 13.10 (s, 1 H)

Example 3




N-([1-(4-Chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

3a) Ethyl 1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. Diethyl {[1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate]propanedioate} (400 mg, 1.36 mmol) was added to a suspension of sodium hydride (60% suspension in mineral oil, 200 mg, 5.0 mmol) in dry dioxan (15 mL) and stirred for 10 minutes under argon. 4-Chlorophenyl isothiocyanate (340 mg, 2.0 mmol) was added and the mixture sealed in a pressure flask heated in a microwave reactor at 100°C for 1 hour. The mixture was taken up in dichloromethane, washed with 1 molar hydrochloric acid and dried. Flash chromatography (hexane-ethyl acetate) afforded the title compound (85 mg, 20%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.18 (t, *J*=7.20 Hz, 3 H) 4.01 - 4.06 (q, *J*=7.20 Hz, 2 H) 4.89 (s, 2 H) 7.10 (d, *J*=8.59 Hz, 2 H) 7.26 - 7.31 (m, 5H) 7.39 (d, *J*=8.59 Hz, 2 H).

3b) N-([1-(4-Chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine. A mixture of ethyl 1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (85 mg, 0.21 mmol), DBU (90 mg, 0.6 mmol) and glycine (60 mg, 0.8 mmol) in ethanol (5 mL) was sealed in a flask and heated in a microwave reactor at 160°C for 1 hour. The reaction mixture was diluted with 1 molar hydrochloric acid and extracted twice with ethyl acetate. The combined extracts were washed with 1 molar hydrochloric acid, dried and evaporated. Purification by preparative HPLC (10-80% acetonitrile-water-0.1%TFA) afforded the title compound (23 mg, 24%) ¹H NMR (400 MHz,

DMSO-*d*₆) δ ppm 4.14 (d, *J*=5.81 Hz, 2 H) 5.67 (s, 2 H) 7.24 (t, *J*=6.95 Hz, 1 H) 7.29 - 7.40 (m, 7 H) 7.54 (d, *J*=8.59 Hz, 2 H) 10.10 (s, 1 H) 13.11 (s, 1 H)

Example 4




5

N-({6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

4a) Ethyl 6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. Diethyl {[(phenylmethyl)amino]carbonyl}propanedioate (200 mg, 0.68 mmoles) was added to a suspension of sodium hydride (60% suspension in mineral oil, 100 mg, 2.5 mmoles) in dry dioxane (5 mL) and stirred for 10 minutes under argon. 3-Trifluorophenyl isocyanate (140 μ L, 1.02 mmoles) was added and the mixture sealed in a pressure flask heated in a microwave reactor at 100°C for 40 minutes. The mixture was taken up in dichloromethane, washed with 1 molar hydrochloric acid and dried. The mixture was evaporated and azeotroped with ethanol. The residue was slurried in diethyl ether to give the title compound (110 mg, 37%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.10 (t, *J*=6.95 Hz, 3 H) 3.39 (q, *J*=6.99 Hz, 2 H) 4.89 - 4.94 (m, 2 H) 7.18 - 7.23 (m, 2 H) 7.24 - 7.31 (m, 3 H) 7.44 - 7.55 (m, 2 H) 7.59 - 7.69 (m, 2 H).

4b) *N*-({6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture of ethyl 6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (110 mg, 0.25 mmoles), DBU (100 mg, 0.6 mmoles) and glycine (40 mg, 0.5 mmoles) in ethanol (5 mL) was sealed in a flask and heated in a microwave reactor at 160°C for 1 hour. The reaction mixture was diluted with 1 molar hydrochloric acid and extracted twice with dichloromethane. Purification by preparative HPLC (10-80% acetonitrile-water-0.1%TFA) afforded the title compound (15 mg, 13%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.79 (d, *J*=5.05 Hz, 2 H) 4.97 (s, 2 H) 7.19 - 7.30 (m, 5 H) 7.46 - 7.57 (m, 2 H) 7.60 - 7.71 (m, 2 H) 8.27 (s, 1 H) 9.60 (s, 1 H)

Example 5



N-([6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine


5a) Ethyl 6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate.

- 5 Ethyl 1-([2,4-bis(methoxy)phenyl]methyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (260 mg, 0.59mmoles) was stirred in a mixture of sulfuric acid (5.0 mL) and water (1.0 mL) for 3 hours. The mixture was poured onto ice and the solid collected. The aqueous was adjusted to pH3 and extracted three times with ethyl acetate. The extracts were dried, evaporated and combined with the collected solid. Purification by preparative HPLC
- 10 (acetonitrile-water-0.1% TFA) gave the title compound (106 mg, 62%) ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.28 (t, *J*=7.07 Hz, 3 H) 4.14 (q, *J*=7.16 Hz, 2 H) 5.09 (s, 1 H) 5.14 (s, 1 H) 7.25 - 7.37 (m, 3 H) 7.42 - 7.52 (m, 2 H) 10.22 (s, 1 H) 15.53 (s, 1 H).

5b) N-([6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-

- 15 pyrimidinyl]carbonyl]glycine. A mixture of ethyl 6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (100 mg, 0.34 mmoles), DBU (106 mg, 0.7 mmoles) and glycine (52 mg, 0.7 mmoles) in ethanol (5 mL) was sealed in a flask and heated in a microwave reactor at 160°C for 1 hour. The reaction mixture was taken up in ethyl acetate and washed with 1 molar hydrochloric acid. Purification by preparative HPLC (10-80% acetonitrile-water-0.1%TFA)
- 20 afforded the title compound (15 mg, 14%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.11 (s, 2 H) 4.95 (s, 2 H) 7.23 - 7.35 (m, 5 H) 9.84 (s, 1 H) 12.09 (s, 1 H)

Example 6




25 N-([6-Hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-
pyrimidinyl]carbonyl]glycine

- 6a) Ethyl 6-hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-
pyrimidinecarboxylate. Diethyl {[(phenylmethyl)amino]carbonyl}propanedioate (420 mg, 1.43

mmoles) was added to a suspension of sodium hydride (60% suspension in mineral oil, 220 mg, 5.5 mmoles) in dry dioxan (10 mL) and stirred for 10 minutes under argon. Phenyl isocyanate (240 uL, 2.21 mmoles) was added and the mixture sealed in a pressure flask heated in a microwave reactor at 110°C for 1 hour. The mixture was taken up in dichloromethane, washed with 1 molar hydrochloric acid and evaporated onto silica gel. Flash chromatography (ethyl acetate) gave the title compound (300 mg, 57%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.15 (t, *J*=7.07 Hz, 3 H) 3.99 - 4.07 (q, *J*=7.07 Hz, 2 H) 4.94 (s, 1 H) 7.08 - 7.13 (m, 2 H) 7.21 (ddd, *J*=8.46, 4.42, 4.29 Hz, 1 H) 7.26 - 7.33 (m, 5 H) 7.37 (t, *J*=7.45 Hz, 2 H).

6b) *N*-{[6-Hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of ethyl 6-hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (300 mg, 0.82 mmoles), DBU (150 mg, 1.0 mmoles) and glycine (120 mg, 1.6 mmoles) in ethanol (15 mL) was sealed in a flask and heated in a microwave reactor at 160°C for 1 hour. The reaction mixture was filtered and the filtrate diluted with dichloromethane and washed with 1 molar hydrochloric acid. The aqueous was extracted with dichloromethane and the combined extracts dried and evaporated to give the title compound (50 mg, 15%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.81 (s, 2 H) 4.99 (s, 2 H) 7.14 (d, *J*=7.33 Hz, 2 H) 7.19 - 7.23 (m, 1 H) 7.25 - 7.34 (m, 5 H) 7.39 (t, *J*=7.45 Hz, 2 H) 9.84 (s, 1 H)

Example 7



N-[(1-(1,1-Dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine


7a) 1-(1,1-Dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of *t*-butyl isocyanate (571 uL, 5.0 mmoles) and 4-*t*-butylbenzylamine (880 uL, 5.0 mmoles) in dry dichloromethane was stirred for 1 hour. Dichloromalonate (486 uL, 5.0 mmoles) was added and the mixture was heated under reflux for 1 hour. The mixture was washed with 1N hydrochloric acid and evaporated onto silica gel. Flash chromatography (10-35% ethyl acetate-hexane) gave the title compound (1.3 g, 79%) ¹H NMR (400 MHz,

CHLOROFORM-*d*) δ ppm 1.32 (s, 9 H) 1.63 (s, 9 H) 3.60 (s, 2 H) 4.99 (s, 2 H) 7.37 (d, $J=2.78$ Hz, 4 H).

7b) Ethyl *N*-[(1-(1,1-dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate. 1-(1,1-Dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.3 g, 3.93 mmoles) and diisopropylethylamine (1.36 mL, 7.86 mmoles) were stirred together in dry chloroform (25 mL) and treated with ethyl isocyanatoacetate (335 μ L, 3.93 mmoles). The mixture was stirred for 3 hours, washed twice with 1 molar hydrochloric acid, dried and evaporated to give the title compound (1.8 g, quant.) ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.32 (t, $J=7.07$ Hz, 3 H) 1.71 (s, 9 H) 1.73 (s, 9 H) 4.28 - 4.34 (m, 2 H) 5.03 - 5.07 (m, 2 H) 7.33 - 7.39 (m, 4 H) 10.21 - 10.30 (m, 1 H).

7c) *N*-[(1-(1,1-Dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. A mixture of ethyl *N*-[(1-(1,1-dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (1.8 g, 3.9 mmoles) and 1 molar sodium hydroxide solution (6.0 mL) in ethanol (5.0 mL) was stirred overnight. The reaction was incomplete; therefore 6 molar sodium hydroxide was added. After 2 hours, the mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and evaporated. The title compound was obtained by crystallization from cold hexane (700 mg, 41%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.25 (s, 9 H) 1.65 (s, 9 H) 4.11 (d, $J=5.81$ Hz, 2 H) 4.93 (s, 2 H) 7.20 (d, $J=8.59$ Hz, 2 H) 7.34 (d, $J=8.34$ Hz, 2 H) 10.06 (t, $J=5.56$ Hz, 1 H) 13.06 (s, 1 H).

Example 8



N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine


8a) 2-Isocyanatopyridine. 2-Picolinic acid (1.0 g, 8.0 mmoles) was stirred in toluene (25mL) and treated with diphenylphosphoryl azide (2.0 mL, 9.3 mmoles) at room temperature under argon. Triethylamine (1.34 mL, 9.6 mmoles) was added dropwise, stirred for 30 minutes then heated to

80°C for 2 hours. The mixture was cooled, the solid collected, washed with a little ethyl acetate, hexane and vacuum dried to give the title compound (750 mg, 78%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.62 (dd, *J*=4.93, 1.14 Hz, 1 H), 8.44 (d, *J*=6.32 Hz, 1 H), 8.04 (td, *J*=7.71, 2.02 Hz, 1 H), 7.91 (ddd, *J*=8.84, 6.95, 1.64 Hz, 1 H), 7.55 (s, 1 H), 7.51 - 7.55 (m, 1 H), 7.17 (d, *J*=8.84 Hz, 1 H), 7.00 (td, *J*=6.95, 1.26 Hz, 1 H).

8b) Ethyl 6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. 2-Isocyanatopyridine (265 mg, 2.2 mmoles) was added to a suspension of sodium hydride (200 mg, 5 mmoles) and diethyl {[(phenylmethyl)amino]carbonyl}propanedioate (example 1a, 425 mg, 1.45 mmoles) in anhydrous dioxane (10 mL). The mixture was heated in a microwave reactor at 110°C for 1 hour, cooled, dissolved in dichloromethane, washed with 1 molar hydrochloric acid and purified by flash chromatography (ethyl acetate – 10% methanol in ethyl acetate) to give the title compound (90 mg, 12%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.93 (dd, *J*=7.20, 1.39 Hz, 1 H), 8.11 - 8.26 (m, 1 H), 7.19 - 7.45 (m, 7 H), 4.78 - 5.01 (m, 2 H), 4.15 (q, *J*=7.24 Hz, 2 H), 1.24 (t, *J*=7.07 Hz, 3 H).

8c) *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine (90 mg, 0.24 mmoles), glycine (90 mg, 1.2 mg) and DBU (150 mg, 1.0 mmoles) in ethanol (5 mL) was heated at 170°C for 1 hour in a microwave reactor. Purification by preparative HPLC (acetonitrile – 0.1% TFA in water, 20-100%) gave the title compound (17 mg, 18%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.13 (s, 1 H), 10.07 (s, 1 H), 8.58 (dd, *J*=4.93, 1.14 Hz, 1 H), 8.01 (td, *J*=7.71, 1.77 Hz, 1 H), 7.49 - 7.58 (m, 2 H), 7.26 - 7.36 (m, 6 H), 5.02 (s, 2 H), 4.15 (d, *J*=5.81 Hz, 2 H).

Example 9




N-{[6-Hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

9a) Ethyl 6-hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate. Diethyl {[(phenylmethyl)amino]carbonyl}propanedioate (420 mg, 1.43

mmoles) was added to a suspension of sodium hydride (60% suspension in mineral oil, 220 mg, 5.5 mmoles) in dry dioxan (10 mL) and stirred for 10 minutes under argon. 2-Nitrophenyl isocyanate (360 mg, 2.20 mmoles) was added and the mixture sealed in a pressure flask heated in a microwave reactor at 110°C for 1 hour. The mixture was taken up in dichloromethane, washed with 1 molar hydrochloric acid and evaporated onto silica gel. Flash chromatography (hexane to 0.5% formic acid in ethyl acetate) gave the title compound (59 mg, 7%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.16 (s, 1 H), 7.81 (s, 1 H), 7.68 (s, 1 H), 7.47 (s, 1 H), 7.08 - 7.38 (m, 5 H), 4.77 - 5.16 (m, 2 H), 4.12 (q, *J*=5.31 Hz, 2 H), 0.97 - 1.31 (m, 3 H)

9b) *N*-{[6-Hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine. A mixture of ethyl 6-hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate (59 mg, 0.14 mmoles), DBU (80 mg, 0.52 mmoles) and glycine (40 mg, 0.53 mmoles) in ethanol (3 mL) was sealed in a flask and heated in a microwave reactor at 170°C for 1 hour. The reaction mixture was poured into 1 molar hydrochloric acid and extracted with dichloromethane (x2) and washed with 1 molar hydrochloric acid. The title compound was obtained by purification by preparative HPLC (10-80% acetonitrile-water-0.1%TFA)(17 mg, 28%) ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.14 (br. s., 1 H), 10.04 (br. s., 1 H), 8.25 (dd, *J*=8.21, 1.14 Hz, 1 H), 7.93 (dt, *J*=7.71, 1.26 Hz, 1 H), 7.71 - 7.81 (m, 2 H), 5.06 (s, 2 H), 4.14 (d, *J*=5.56 Hz, 2 H)

Example 10




N-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

A microwave tube containing sodium hydride (60% suspension in oil, 46 mg, 1.15 mmoles) in dioxan (3 mL) was treated with diethyl {[phenylmethyl]amino}carbonyl}-propanedioate (example 1a, 100 mg, 0.34 mmoles) and stirred under argon until evolution ceased. Cyclohexyl isocyanate (90 uL, 0.7 mmoles) was added and the mixture was heated at 100°C for 30 minutes in a microwave reactor. Glycine (48 mg, 0.65 mmoles) and DBU (4 drops) was added, the flask re-sealed and heated at 160°C for 1 hour in a microwave reactor. The mixture was poured into 1 molar hydrochloric acid and extracted with dichloromethane (x3). The combined

extracts were washed with 1 molar hydrochloric acid and brine, dried and evaporated to give the crude product. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) gave the title compound (10 mg, 7%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.12 (t, *J*=5.18 Hz, 1 H), 7.23 - 7.34 (m, 6 H), 4.99 (s, 2 H), 4.65 (t, *J*=11.62 Hz, 1 H), 4.10 (d, *J*=5.81 Hz, 2 H), 2.21 - 2.32 (m, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.62 (s, 3 H), 1.22 - 1.33 (m, 3 H), 1.06 - 1.17 (m, 1 H)

Example 11




N-{[1-[(3-Cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

11a) Ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycinate. Ethyl isocyanatoacetate (2.24 mL, 20 mmoles) was added dropwise to a solution of 1-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (4.4 g, 20 mmoles) and ethyl diisopropylamine (6.9 mL, 40 mmoles) in dichloromethane (120 mL) and stirred overnight under argon. The mixture was washed with 1 molar hydrochloric acid, water and brine, dried and evaporated. The solid was slurried in diethyl ether, collected, washed with diethyl ether and hexane, dried to give the title compound (5.1 g, 73 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.13 (br. s., 1 H), 9.84 (br. s., 1 H), 7.13 - 7.48 (m, 5 H), 4.95 (s, 2 H), 4.17 (d, 2 H), 4.15 (q, 2 H), 1.21 (t, *J*=7.20 Hz, 3 H)

11b) Ethyl *N*-{[1-[(3-cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycinate. A mixture of ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycinate (350 mg, 1.0 mmoles), 3-cyanobenzyl bromide (250 mg, 1.22 mmoles) and sodium carbonate (300 mg, 2.9 mmoles) in dimethylformamide (5.0 mL) was stirred under argon at 100°C for 2 hours. The mixture was cooled, poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined extracts were washed with water and brine. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) gave the title compound (300 mg, 65%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.12 (t, *J*=5.81 Hz, 1 H), 7.79 (s, 1 H), 7.71 - 7.76 (m, 1 H), 7.66 (d, *J*=8.34 Hz, 1 H), 7.54 (t, *J*=7.83 Hz, 1 H), 7.32 (d, *J*=4.29 Hz, 4 H), 7.23 - 7.29 (m, 1 H), 5.07 (s, 2 H), 5.03 (s, 2 H), 4.22 (d, *J*=6.06 Hz, 2 H), 4.15 (q, *J*=7.07 Hz, 2 H), 1.21 (t, *J*=7.20 Hz, 3 H)

11c) *N*-{[1-[(3-Cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine. Ethyl *N*-{[1-[(3-cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycinate (280 mg, 0.6 mmol) was dissolved in methanol (5 mL) and treated with 1 molar sodium hydroxide solution (4 mL) and stirred for 3 hours. The mixture was acidified and extracted into ethyl acetate. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) and crystallization from ethanol – water gave the title compound (50 mg, 20%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (s, 1 H), 10.11 (s, 1 H), 7.79 (s, 1 H), 7.74 (d, *J*=7.58 Hz, 1 H), 7.66 (d, *J*=8.34 Hz, 1 H), 7.55 (t, *J*=7.71 Hz, 1 H), 7.29 - 7.35 (m, 4 H), 7.23 - 7.29 (m, 1 H), 5.07 (s, 2 H), 5.03 (s, 2 H), 4.14 (d, *J*=5.81 Hz, 2 H).


Example 12



N-[(6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[(4-(trifluoromethyl)phenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine

A mixture of ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycinate (example 11a, 356 mg, 1.03 mmol), 4-trifluoromethylbenzyl bromide (175 μ L, 1.13 mmol) and sodium carbonate (330 mg, 3.1 mmol) in dimethylformamide (6.0 mL) was stirred under argon at 100°C for 2.5 hours. The mixture was cooled, poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The ester was hydrolysed by stirring in a mixture of ethanol (3 mL) and 1 molar sodium hydroxide solution (3 mL) for 3 hours. The mixture was acidified and extracted with ethyl acetate. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) and crystallization from ethanol – water gave the title compound (150 mg, 30%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.12 (s, 1 H), 10.12 (t, *J*=5.56 Hz, 1 H), 7.69 (d, *J*=8.08 Hz, 2 H), 7.53 (d, *J*=8.08 Hz, 2 H), 7.24 - 7.35 (m, 5 H), 5.11 (s, 2 H), 5.03 (s, 2 H), 4.14 (d, *J*=5.81 Hz, 2 H).


Example 13



N-{[1-[(3,4-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 5 A mixture of ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycinate (example 11a, 357 mg, 1.03 mmol), 3,4-dichlorobenzyl bromide (193 μ L, 1.13 mmol) and sodium carbonate (330 mg, 3.1 mmol) in dimethylformamide (6.0 mL) was stirred under argon at 100°C for 2.5 hours. The mixture was cooled, poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The ester was hydrolysed by stirring in a
- 10 mixture of ethanol (3 mL) and 1 molar sodium hydroxide solution (3 mL) for 3 hours. The mixture was acidified and extracted with ethyl acetate. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) and crystallization from ethanol – water gave the title compound (50 mg, 10%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.13 (s, 1 H), 10.11 (t, *J*=5.68 Hz, 1 H), 7.59 (dd, *J*=5.18, 3.16 Hz, 2 H), 7.24 - 7.34 (m, 6 H), 5.01 (s, 2 H), 5.02 (s, 2 H), 4.14 (d, *J*=5.81 Hz, 2
- 15 H).

Example 14




N-{[6-Hydroxy-1-[[3-(methoxy)phenyl]methyl]-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 20 A mixture of ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycinate (example 11a, 369 mg, 1.06 mmol), 3-methoxybenzyl bromide (163 μ L, 1.17 mmol) and sodium carbonate (330 mg, 3.1 mmol) in dimethylformamide (6.0 mL) was stirred under argon at 100°C for 2.5 hours. The mixture was cooled, poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The ester was hydrolysed by stirring in a
- 25 mixture of ethanol (3 mL) and 1 molar sodium hydroxide solution (3 mL) for 3 hours. The mixture was acidified and extracted with ethyl acetate. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) and crystallization from ethanol – water gave the title compound (50

mg, 11%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.12 (t, 1 H), 7.14 - 7.47 (m, 6 H), 6.69 - 6.97 (m, 3 H), 5.00 (s, 2 H), 5.03 (s, 2 H), 4.13 (d, *J*=5.56 Hz, 2 H), 3.71 (s, 3 H).


Example 15



N-{[1-[(2,6-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

A mixture of ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycinate (example 11a, 388 mg, 1.12 mmol), 2,6-dichlorobenzyl bromide (295 μL, 1.23 mmol) and sodium carbonate (330 mg, 3.1 mmol) in dimethylformamide (6.0 mL) was stirred under argon at 100°C for 2.5 hours. The mixture was cooled, poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The ester was hydrolysed by stirring in a mixture of ethanol (3 mL) and 1 molar sodium hydroxide solution (3 mL) for 3 hours. The mixture was acidified and extracted with ethyl acetate. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) and crystallization from ethanol – water gave the title compound (60 mg, 11%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.12 (br. s., 1 H), 10.02 (br. s., 1 H), 7.42 (d, 2 H), 7.22 - 7.35 (m, 6 H), 5.30 (s, 2 H), 5.01 (s, 2 H), 4.12 (d, *J*=5.81 Hz, 2 H).

Example 16




N-{[6-Hydroxy-1-methyl-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

A mixture of ethyl *N*-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycinate (295 mg, 0.85 mmol), methyl iodide (62 μL, 1.0 mmol) and sodium carbonate (320 mg, 3.0 mmol) in dimethylformamide (5.0 mL) was stirred under argon at 100°C for 2.5 hours. The mixture was cooled, poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The ester was hydrolysed by stirring in a mixture of ethanol (5 mL) and 1

molar sodium hydroxide solution (4 mL) for 4 hours. The mixture was acidified and extracted with ethyl acetate. Purification by preparative HPLC (acetonitrile – water - 0.1% TFA, 20-100%) and crystallization from ether-hexane gave the title compound (80 mg, 28%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 10.09 (br. s., 1 H), 7.28 - 7.36 (m, 4 H), 7.19 - 7.29 (m, 1 H),
 5 5.01 (s, 2 H), 4.14 (d, *J*=5.81 Hz, 2 H), 3.21 (s, 3 H).

Example 17



N-{[1-Cyclohexyl-3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

17a) *N*-Cyclohexyl-*N'*-(2-cyclopropylethyl)urea. Cyclohexyl isocyanate (564 uL, 4.7 mmoles) was added to a solution of cyclopropylethylamine hydrochloride (537 mg, 4.4 mmoles) and triethylamine (615 uL, 4.4 mmoles) in chloroform (10 mL) under argon at room temperature. The mixture was stirred for 1 hour, washed with 1 molar hydrochloric acid, dried and evaporated.

Trituration with hexane gave a solid (550 mg, 59%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.55 (br. s., 1 H), 3.47 - 3.59 (m, 1 H), 3.27 (t, *J*=6.95 Hz, 2 H), 1.95 (dd, *J*=12.63, 3.54 Hz, 2 H), 1.67 - 1.79 (m, 2 H), 1.58 - 1.67 (m, 1 H), 1.43 (q, *J*=6.99 Hz, 2 H), 1.30 - 1.40 (m, 2 H), 1.07 - 1.24 (m, 3 H), 0.63 - 0.77 (m, 1 H), 0.44 - 0.51 (m, 2 H), 0.05 - 0.12 (m, 2 H)


17b) 1-Cyclohexyl-3-(2-cyclopropylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (250 uL, 2.57 mmoles) was added dropwise to a solution of *N*-cyclohexyl-*N'*-(2-cyclopropylethyl)urea (500 mg, 2.38 mmoles) in dichloromethane under argon. The mixture was stirred overnight then heated under reflux for 2 hours. Flash chromatography (hexane to 20% ethyl acetate – hexane) gave the title compound (230 mg, 35%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.57 - 4.71 (m, 1 H), 3.94 - 4.04 (m, 2 H), 3.60 - 3.68 (m, 2 H), 2.20 - 2.36 (m, 2 H), 1.86 (d, *J*=13.39 Hz, 2 H), 1.60 - 1.73 (m, 3 H), 1.45 - 1.60 (m, 2 H), 1.29 - 1.44 (m, 2 H), 1.15 - 1.29 (m, 1 H), 0.62 - 0.77 (m, 1 H), 0.40 - 0.51 (m, 2 H), -0.00 - 0.12 (m, 2 H).

17c) *N*-{[1-cyclohexyl-3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine. A solution of 1-cyclohexyl-3-(2-cyclopropylethyl)-

2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (225 mg, 0.8 mmoles) and diisopropylethylamine (280 uL, 1.6

mmoles) in chloroform (10 mL) was treated with ethyl 2-isocyanatoacetate (91 μ L, 0.81 mmoles) and stirred for 1 hour. The mixture was washed with hydrochloric acid (x2) and evaporated. The residue was dissolved in ethanol (3 mL) and treated with 1 molar sodium hydroxide solution and stirred for 3 hours. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, separated and the organic solution washed with brine, dried and evaporated. The solid residue was reprecipitated from ether-hexane to give the title compound (190 mg, 63%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 13.07 (br. s, 1 H), 10.14 (t, $J=5.81$ Hz, 1 H), 4.64 (s, 1 H), 4.12 (d, $J=5.81$ Hz, 2 H), 3.87 - 3.92 (m, 2 H), 2.22 - 2.34 (m, 2 H), 1.79 (d, $J=13.14$ Hz, 2 H), 1.61 (t, $J=12.13$ Hz, 3 H), 1.45 (q, $J=7.16$ Hz, 2 H), 1.23 - 1.33 (m, 2 H), 1.08 - 1.18 (m, 1 H), 0.62 - 0.70 (m, 1 H), 0.35 - 0.40 (m, 2 H), -0.04 - 0.00 (m, 2 H)

Example 18



N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Method 1

18.1a) 1,3-Dicyclohexyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Dicyclohexylurea (3.0 g, 13.39 mmoles) was stirred in chloroform (80 mL) and treated with a solution of malonyl dichloride (1.3 mL, 13.39 mmoles) in chloroform (20 mL), added dropwise under argon. The mixture was heated at 50°C for 4 hours, washed with 1 molar hydrochloric acid and evaporated onto silica gel. Flash chromatography (10-30% ethyl acetate in hexane) to give the title compound (2.13 g, 55%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 4.46 (tt, $J=12.13$, 3.54 Hz, 2 H), 3.69 (s, 2 H), 2.15 (qd, $J=12.46$, 3.28 Hz, 4 H), 1.77 (d, $J=13.14$ Hz, 4 H), 1.59 (t, $J=12.76$ Hz, 6 H), 1.26 (q, $J=12.97$ Hz, 4 H), 1.04 - 1.16 (m, 2 H)

18.1b) N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. Ethyl isocyanatoacetate (802 μ L, 7.15 mmoles) was added to a mixture of 1,3-dicyclohexyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (2.1 g, 7.15 mmoles) and diisopropylethylamine (2.47 mL, 14.3 mmoles) in dichloromethane (100 mL) and stirred overnight. The reaction mixture was washed with 1 molar hydrochloric acid (x2) and evaporated. The residue was dissolved in ethanol (10 mL) and treated with 1.0 molar sodium hydroxide (5 mL). The mixture was stirred for 72 hours, acidified and extracted into ethyl acetate. Some ester remained,

therefore the solution was evaporated and the residue was dissolved in 1 molar sodium hydroxide solution with warming and stirred for 2 hours. The mixture was acidified with 1M HCl and extracted with ethyl acetate (x2). The combined extracts were washed with 1 molar hydrochloric acid, dried and evaporated to a solid which was slurried in a mixture of diethyl ether and hexane, collected, washed with the same solvent mixture and dried to give the title compound (1.86 g, 66%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.07 (br. s., 1 H), 10.19 (t, *J*=5.31 Hz, 1 H), 4.63 (t, *J*=10.99 Hz, 2 H), 4.12 (d, *J*=5.56 Hz, 2 H), 2.27 (q, *J*=11.71 Hz, 4 H), 1.79 (d, *J*=12.88 Hz, 4 H), 1.50 - 1.69 (m, 6 H), 1.28 (q, *J*=12.97 Hz, 4 H), 1.12 (q, *J*=12.72 Hz, 2 H)

10 Method 2

18.2a) 1,3-Dicyclohexyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A solution of N,N-dicyclohexylcarbodiimide (254 g; 1.23 mol.) in anhydrous THF (700 mL) was added dropwise to a cold (0 °C) solution of malonic acid (64.1 g; 0.616 mol.) in anhydrous THF (300 mL) over a period of ~ 30 minutes. The mixture was stirred and allowed to warm to room temperature over 2 h.

15 (After 1 h, the mixture became very thick with precipitate so further anhydrous THF (500 mL) was added to facilitate agitation.). The mixture was filtered and the filtrate evaporated to afford a yellow solid which was immediately slurried in ethanol (1 L) and heated to reflux temperature. The mixture was then allowed to cool to room temperature then filtered and the solid washed with cold ethanol (250 mL) to afford the title compound (129.4 g; 72%) as a colorless solid. ¹H NMR (400
20 MHz, DMSO-*d*₆) δ ppm 1.03 - 1.18 (m, 2 H) 1.18 - 1.34 (m, 4 H) 1.59 (t, *J*=13.14 Hz, 6 H) 1.76 (d, *J*=12.88 Hz, 4 H) 2.04 - 2.24 (m, 4 H) 3.69 (s, 2 H) 4.35 - 4.54 (m, 2 H).


18.2b) Ethyl N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate. A solution of 1,3-dicyclohexyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (120.0 g; 0.41 mol.) and diisopropylethylamine (105.8 g; 0.82 mol.) in dichloromethane (1 L) was stirred and treated dropwise with a solution of ethyl isocyanatoacetate (53.0 g; 0.41 mol.) in dichloromethane (500 mL) and the mixture was then stirred at room temperature overnight. The mixture was then treated dropwise with 6M aq. hydrochloric acid (500 mL) and the separated organic layer was dried and evaporated. The resulting solid was slurried in hexanes (500 mL) and heated to reflux temperature. The mixture was then allowed to cool and filtered to afford ethyl N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (159.1 g; 92%) as a cream powder. ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 1.24 (s, 2 H) 1.37 (s, 7 H) 1.52 - 1.76 (m, 6 H) 1.78 - 1.94 (m, 4 H) 2.25 - 2.48 (m, 4 H) 4.17 (d, *J*=5.81 Hz, 2 H) 4.28 (q, *J*=7.24 Hz, 2 H) 4.74 (s, 2 H) 10.37 (t, *J*=4.67 Hz, 1 H).

35

18.2c) N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-

pyrimidinyl)carbonyl]glycine. A stirred suspension of ethyl N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (159.0 g; 0.377 mol.) in ethanol (1.5 L) was treated dropwise with 6M aq. Sodium hydroxide (250 mL) and stirred at room temperature for 3 h. The solution was then acidified by the dropwise addition of 6M aq. hydrochloric acid (300 mL), diluted with water (1L) and then filtered. The crude solid was slurried in water (2 L) then stirred vigorously and heated at 35 °C for 1 h and filtered and dried. The solid material (~ 138 g) was then crystallized from glacial acetic acid (1.5 L) (with hot filtration to remove a small amount of insoluble material). The solid, which crystallized upon cooling, was collected and washed with cold glacial acetic acid (3 x 100 mL) to afford N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine (116.2 g; 78%) as a colorless solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.11 (d, *J*=12.88 Hz, 2 H) 1.27 (q, *J*=12.80 Hz, 4 H) 1.62 (s, 6 H) 1.70 - 1.90 (m, *J*=12.88 Hz, 4 H) 2.11 - 2.44 (m, 4 H) 4.11 (d, *J*=5.81 Hz, 2 H) 4.45 - 4.77 (m, 2 H) 10.19 (t, *J*=5.81 Hz, 1 H) 13.08 (s, 1 H).

Example 19



N-[(1-Hexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-
pyrimidinyl)carbonyl]glycine

19a) N-Hexyl-N'-(phenylmethyl)urea. *n*-Hexyl isocyanate (620 uL, 4.24 mmoles) was added to a solution of benzylamine hydrochloride (610 mg, 4.24 mmoles) and diisopropylethylamine (735 uL, 4.24 mmoles) in chloroform (10 mL). The mixture was stirred for 1 hour, washed with 1 molar hydrochloric acid (x2), dried and evaporated to give the title compound (993 mg, 91%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.18 - 7.45 (m, 5 H), 4.37 (s, 2 H), 3.15 (t, *J*=7.20 Hz, 2 H), 1.42 - 1.53 (m, 2 H), 1.23 - 1.36 (m, 6 H), 0.84 - 0.94 (m, 3 H).

19b) 1-Hexyl-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (411 uL, 4.2 mmoles) was added to a solution of *N*-hexyl-*N'*-(phenylmethyl)urea (900 mg, 3.8 mmoles) in dichloromethane (25 mL) and the mixture was heated under reflux for 3 hours. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-15% ethyl acetate in hexane) gave the title compound (480 mg, 42%). ¹H NMR (400 MHz,


CHLOROFORM-*d*) δ ppm 7.46 (dd, $J=7.83$, 1.52 Hz, 2 H), 7.28 - 7.41 (m, 3 H), 5.07 (s, 2 H), 3.82 - 3.91 (m, 2 H), 3.70 (s, 2 H), 1.52 - 1.66 (m, 2 H), 1.19 - 1.38 (m, 6 H), 0.79 - 0.97 (m, 3 H).

19c) *N*-{[1-Hexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-

pyrimidinyl]carbonyl} glycine. A mixture of 1-hexyl-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (470 mg, 1.55 mmol), diisopropylethylamine (280 μ L, 1.6 mmol) and ethyl 2-isocyanatoacetate (132 μ L, 1.55 mmol) was stirred in chloroform (10 mL) for 3 hours. The mixture was washed with hydrochloric acid (x2) and evaporated. The residue was dissolved in ethanol (15 mL), treated with 1 molar sodium hydroxide solution and stirred for 4 hours.

The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid. The aqueous was extracted with ethyl acetate and the combined extracts washed with 1 molar hydrochloric acid and brine, dried and evaporated. A solid was obtained from diethyl ether – hexane and recrystallized from toluene-hexane to give the title compound (280 mg, 46%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (s, 1 H), 10.10 (s, 1 H), 7.24 - 7.34 (m, 5 H), 5.01 (s, 2 H), 4.13 (d, $J=5.81$ Hz, 2 H), 3.77 - 3.86 (m, 2 H), 1.54 (d, $J=6.82$ Hz, 2 H), 1.26 (s, 6 H), 0.81 - 0.89 (m, 3 H).

Example 20



N-{[1-Ethyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-
pyrimidinyl]carbonyl} glycine


20a) 1-Ethyl-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (411 μ L, 4.2 mmol) was added to a solution of *N*-ethyl-*N'*-(phenylmethyl)urea (685 mg, 3.84 mmol) in dichloromethane (25 mL) and the mixture was heated under reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-30% ethyl acetate in hexane) gave the title compound (390 mg, 42%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.41 - 7.49 (m, 2 H), 7.25 - 7.34 (m, 3 H), 5.03 (s, 2 H), 3.92 (q, $J=7.07$ Hz, 2 H), 3.64 (s, 2 H), 1.20 (t, $J=7.07$ Hz, 3 H).

20b) *N*-{[1-Ethyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-
pyrimidinyl]carbonyl} glycine. A solution of 1-ethyl-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-

pyrimidinetrione (390 mg, 1.58 mmol) and diisopropylethylamine (546 μ L, 3.16 mmol) in chloroform (10 mL) was treated with ethyl isocyanatoacetate (135 μ L, 1.58 mmol) and stirred for 2 hours under argon. The mixture was washed with 1 molar hydrochloric acid (x2), dried and

evaporated. The residue was dissolved in ethanol (10 mL), treated with 1 molar sodium hydroxide solution (5 mL) and stirred overnight. The mixture was acidified and extracted into ethyl acetate and the organic solution dried and evaporated. Crystallization from methanol – water gave the title compound (350 mg, 64%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.12 (br. s, 1 H), 10.10 (s, 1 H), 7.24 - 7.35 (m, 5 H), 5.01 (s, 2 H), 4.14 (d, *J*=5.56 Hz, 2 H), 3.87 (q, *J*=6.99 Hz, 2 H), 1.14 (t, *J*=6.95 Hz, 3 H).

Example 21




N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

21a) 1-(Phenylmethyl)-3-propyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (427 uL, 4.4 mmoles) was added to a solution of *N*-(phenylmethyl)-*N*-propylurea (778 mg, 4.04 mmoles) in dichloromethane (25 mL) and the mixture was heated under reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-20% ethyl acetate in hexane) gave the title compound (730 mg, 70%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.46 (dd, *J*=8.08, 1.52 Hz, 2 H), 7.29 - 7.38 (m, 3 H), 5.07 (s, 2 H), 3.79 - 3.87 (m, 2 H), 3.69 (s, 2 H), 1.57 - 1.69 (m, 2 H), 0.94 (t, *J*=7.45 Hz, 3 H)

21b) *N*-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A solution of 1-(phenylmethyl)-3-propyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (730 mg, 2.8 mmoles) and diisopropylethylamine (970 uL, 5.6 mmoles) in chloroform (12 mL) was treated with ethyl isocyanatoacetate (239 uL, 2.8 mmoles) and stirred for 2 hours under argon. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (10 mL), treated with 1 molar sodium hydroxide solution (5 mL) and stirred overnight. The mixture was acidified and extracted into ethyl acetate and the organic solution dried and evaporated. Crystallization from ethanol – water gave the title compound (800 mg, 71%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (s, 1 H), 10.11 (s, 1 H), 7.24 - 7.34 (m, 5 H), 5.01 (s, 2 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.75 - 3.84 (m, 2 H), 1.52 - 1.63 (m, 2 H), 0.86 (t, *J*=7.45 Hz, 3 H)

Example 22




N-{[1-Butyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 22a) 1-Butyl-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (497 uL, 5.1 mmoles) was added to a solution of *N*-butyl-*N'*-(phenylmethyl)urea (959 mg, 4.65 mmoles) in dichloromethane (25 mL) and the mixture was heated under reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (0-15% ethyl acetate in hexane) gave the title compound (676 mg, 53%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.29 - 7.35 (m, 4 H), 7.20 - 7.28 (m, 1 H), 4.92 (s, 2 H), 3.82 (s, 2 H), 3.71 (t, 2 H), 1.48 (tt, 2 H), 1.28 (tq, *J*=7.49, 7.33 Hz, 2 H), 0.88 (t, *J*=7.33 Hz, 3 H).

- 22b) *N*-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A solution of 1-butyl-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (676 mg, 2.46 mmoles) and diisopropylethylamine (826 uL, 4.93 mmoles) in chloroform (12 mL) was treated with ethyl isocyanatoacetate (211 uL, 2.46 mmoles) and stirred for 3 hours under argon. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (10 mL), treated with 1 molar sodium hydroxide solution (7 mL) and stirred overnight. The mixture was acidified and extracted into ethyl acetate and the organic solution dried and evaporated. Crystallization from ethanol – water gave the title compound (580 mg, 63%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (s, 1 H), 10.11 (s, 1 H), 7.24 - 7.35 (m, 5 H), 5.01 (s, 2 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.79 - 3.87 (m, 2 H), 1.54 (dq, *J*=7.58, 7.41 Hz, 2 H), 1.29 (dq, *J*=14.97, 7.39 Hz, 2 H), 0.89 (t, *J*=7.45 Hz, 3 H).

Example 23




N-{[6-Hydroxy-2,4-dioxo-1-(2-phenylethyl)-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

23a) *N*-(2-Phenylethyl)-*N'*-(phenylmethyl)urea. Phenethyl isocyanate (612 uL, 4.42 mmoles) was added to a stirred solution of benzylamine hydrochloride (635 mg, 4.42 mmoles) and diisopropylamine (766 uL, 4.42 mmoles) in chloroform under argon and stirred for 1 hour. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated to give the title compound (1.0 g, 89%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.20 - 7.41 (m, 8 H), 7.18 (d, *J*=6.82 Hz, 2 H), 4.34 (s, 1 H), 3.47 (t, *J*=6.82 Hz, 2 H), 2.82 (t, *J*=6.95 Hz, 2 H).

23b) 1-(2-Phenylethyl)-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (546 uL, 5.6 mmoles) was added to a solution of *N*-(2-phenylethyl)-*N'*-(phenylmethyl)urea (1.0 g, 3.93 mmoles) in dichloromethane (25 mL) and the mixture was heated under reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-25% ethyl acetate in hexane) gave the title compound (930 mg, 73%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.43 (dd, *J*=7.96, 1.64 Hz, 2 H), 7.14 - 7.40 (m, 8 H), 5.06 (s, 2 H), 4.08 - 4.17 (m, 2 H), 3.64 (s, 2 H), 2.87 - 2.97 (m, 2 H)

23c) *N*-{[6-Hydroxy-2,4-dioxo-1-(2-phenylethyl)-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A solution of 1-(2-phenylethyl)-3-(phenylmethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (930 mg, 2.89 mmoles) and diisopropylethylamine (1.0 mL, 5.78 mmoles) in chloroform (15 mL) was treated with ethyl isocyanatoacetate (250 uL, 2.89 mmoles) and stirred for 3 hours under argon. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (10 mL), treated with 1 molar sodium hydroxide solution (10 mL) and stirred overnight. The mixture was acidified and extracted into ethyl acetate and the organic solution dried and evaporated to a solid. The solid was slurried in diethyl ether, collected, washed with diethyl ether and hexane and dried to afford the title compound (580 mg, 47%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 10.10 (br. s., 1 H), 7.08 - 7.44 (m, 10 H), 5.00 (s, 2 H), 4.14 (d, *J*=5.81 Hz, 2 H), 3.98 - 4.10 (m, 2 H), 2.87 (t, 2 H)

Example 24



N-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-1-(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine


24a) 1-{[4-(1,1-Dimethylethyl)phenyl]methyl}-3-(1-methylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of 4-*t*-butylbenzylamine (704 μ L, 4.0 mmol) and isopropyl

isocyanate (392 μ L, 4.0 mmol) was stirred in chloroform (10 mL) for 1 hour. Malonyl dichloride (388 μ L, 4.0 mmol) was added and the mixture was heated at 45°C for 1 hour. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (10-25% ethyl acetate – hexane) to give the title compound (385 mg, 30%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.34 - 7.43 (m, 4 H), 5.03 - 5.09 (m, 1 H), 5.03 (s, 2 H), 3.66 (s, 2 H), 1.45 (d, *J*=7.07 Hz, 6 H), 1.32 (s, 9 H).

24b) *N*-{[3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-1-(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A solution of 1-{[4-(1,1-

dimethylethyl)phenyl]methyl}-3-(1-methylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (385 mg, 1.21 mmol) and diisopropylethylamine (418 μ L, 2.42 mmol) in chloroform (10 mL) was treated with ethyl isocyanatoacetate (103 μ L, 1.21 mmol) and stirred for 3 hours under argon. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (5 mL), treated with 1 molar sodium hydroxide solution (8 mL) and stirred for 3 hours. The mixture was acidified and extracted into ethyl acetate and the organic solution dried and evaporated. A solid was obtained by trituration in hexane plus a little diethyl ether, collected, washed with hexane to give the title compound (338 mg, 67%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.09 (br.s, 1 H), 10.12 (br.s, 1 H), 7.34 (d, *J*=8.34 Hz, 2 H), 7.22 (d, *J*=8.59 Hz, 2 H), 5.06 (ddd, *J*=13.52, 6.69, 6.57 Hz, 1 H), 4.96 (s, 2 H), 4.13 (d, *J*=5.81 Hz, 2 H), 1.41 (d, *J*=7.07 Hz, 6 H), 1.25 (s, 9 H)

Example 25




N-[(1-cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

25a) 1-Cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of 4-*t*-butylbenzylamine (880 μ L, 5.0 mmol) and cyclohexyl

isocyanate (638 uL, 5.0 mmoles) was stirred in dichloromethane (40 mL) for 1 hour. Malonyl dichloride (388 uL, 4.0 mmoles) was added and the mixture was heated under gentle reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (10-25% ethyl acetate – hexane) to give the title compound (1.23 g, 69%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.33 - 7.43 (m, 4 H), 5.02 (s, 2 H), 4.56 - 4.70 (m, 1 H), 3.65 (s, 2 H), 2.20 - 2.35 (m, 2 H), 1.85 (d, *J*=13.39 Hz, 2 H), 1.65 (t, *J*=16.42 Hz, 3 H), 1.20 - 1.43 (m, 11 H)

25b) *N*-[(1-Cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. A solution 1-cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.23 g, 3.45 mmoles) and diisopropylethylamine (1.2 mL, 6.9 mmoles) in chloroform (20 mL) was treated with ethyl isocyanatoacetate (295 uL, 3.45 mmoles) and stirred overnight under argon. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (8 mL), treated with 1 molar sodium hydroxide solution (8 mL) and stirred for 3 hours. The mixture was diluted with ethyl acetate, washed with 1 molar hydrochloric acid (x2), dried and evaporated. A solid was obtained from ethanol - water to give the title compound (1.3 g, 82%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.14 (br. s., 1 H), 7.34 (d, *J*=8.34 Hz, 2 H), 7.22 (d, *J*=8.34 Hz, 2 H), 4.95 (s, 2 H), 4.65 (t, *J*=11.75 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.14 - 2.37 (m, 2 H), 1.79 (d, *J*=12.63 Hz, 2 H), 1.62 (d, *J*=11.62 Hz, 3 H), 1.19 - 1.37 (m, 11 H), 1.04 - 1.19 (m, 1 H)

Example 26



25 *N*-{[6-Hydroxy-1,3-bis(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine


26a) 1,3-Bis(1-methylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A solution of isopropylamine (520 uL, 6.11 mmoles) was stirred in dichloromethane (25 mL) under nitrogen, treated with isopropyl isocyanate (600 uL, 6.11 mmoles) in dichloromethane (25 mL) and stirred for 1 hour. Malonyl dichloride (593 uL, 6.11 mmoles) was added and the mixture was heated under gentle reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (10-30% ethyl acetate – hexane) to give the title compound (900 mg, 69%). ¹H

NMR (400 MHz, CHLOROFORM-*d*) δ ppm 5.04 (dt, $J=13.89, 6.95$ Hz, 2 H), 3.61 (s, 2 H), 1.45 (d, $J=7.07$ Hz, 12 H).

26b) *N*-{[6-Hydroxy-1,3-bis(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-

5 pyrimidinyl]carbonyl} glycine. A solution 1,3-bis(1-methylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (900 mg, 4.24 mmol) and diisopropylethylamine (1.47 mL, 8.48 mmol) in chloroform (15 mL) was treated with ethyl isocyanatoacetate (362 μ L, 4.24 mmol) and stirred for 4 hours under nitrogen. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (6 mL), treated with 1 molar sodium hydroxide solution (8 mL) and stirred overnight. The mixture was diluted with ethyl acetate, washed with 1 molar hydrochloric acid (x2), dried and evaporated to a solid that crystallized from diethyl ether - hexane to give the title compound (925 mg, 69%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.06 (s, 1 H), 10.14 (t, $J=5.81$ Hz, 1 H), 4.98 - 5.09 (m, 2 H), 4.12 (d, $J=5.81$ Hz, 2 H), 1.39 (d, $J=6.82$ Hz, 12 H)

Example 27



N-{[3-[(2-Bromophenyl)methyl]-1-(1,1-dimethylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-

pyrimidinyl]carbonyl} glycine


20 27a) 1-[(2-Bromophenyl)methyl]-3-(1,1-dimethylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. *t*-Butyl isocyanate (571 μ L, 5.0 mmol) was added to a solution of 2-bromobenzylamine hydrochloride (1.112 g, 5.0 mmol) and diisopropylethylamine (864 μ L, 5.0 mmol) in chloroform (50 mL) and the mixture stirred for 1 hour. Malonyl dichloride (486 μ L, 5.0 mmol) was added and the mixture was stirred at 50°C for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-35% ethyl acetate – hexane)

25 afforded the title compound (500 mg, 28%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.59 (dd, $J=8.08, 1.26$ Hz, 1 H), 7.26 - 7.32 (m, 1 H), 7.12 - 7.19 (m, 1 H), 6.99 (dd, $J=7.58, 1.52$ Hz, 1 H), 5.12 (s, 2 H), 3.72 (s, 2 H), 1.63 (s, 9 H)

30 27b) *N*-{[3-[(2-Bromophenyl)methyl]-1-(1,1-dimethylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine. 1-[(2-Bromophenyl)methyl]-3-(1,1-dimethylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (500 mg, 1.41 mmol) and diisopropylethylamine (490 μ L,

2.82 mmols) were stirred together in dry chloroform (15 mL) and treated with ethyl isocyanatoacetate (121 μ L, 1.41 mmols). The mixture was stirred for 3 hours, washed twice with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (5.0 mL) and treated with 1 molar sodium hydroxide solution (6.0 mL) and stirred overnight. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and evaporated. The title compound was obtained by crystallization from ethanol-water (390 mg, 61%). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 13.08 (s, 1 H), 10.05 (s, 1 H), 7.65 (dd, $J=8.08$, 1.01 Hz, 1 H), 7.34 (t, $J=6.95$ Hz, 1 H), 7.22 (td, $J=7.71$, 1.52 Hz, 1 H), 7.03 (d, $J=6.57$ Hz, 1 H), 4.96 (s, 2 H), 4.12 (d, $J=5.81$ Hz, 2 H), 1.66 (s, 9 H).

Example 28




N-[(1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

28a) 1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1H,3H,5H)-pyrimidinetrione. A mixture of 2,6-dichlorophenylisocyanate (1.47 g, 7.82 mmols) and 4-*t*-butylbenzylamine (1.38 g, 7.82 mmols) in dichloromethane (100 mL) was stirred under argon for 1 hour. Malonyl dichloride (760 μ L, 7.82 mmols) was added and the mixture was heated at 40°C for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-25% ethyl acetate – hexane) afforded the title compound (2.2 g, 67%). ^1H NMR (400 MHz, CHLOROFORM- d) δ ppm 7.50 (d, $J=1.26$ Hz, 1 H), 7.48 (d, $J=0.51$ Hz, 2 H), 7.35 - 7.41 (m, 5 H), 5.11 (s, 2 H), 3.92 (s, 2 H), 1.33 (s, 9 H).

28b) N-[(1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. 1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1H,3H,5H)-pyrimidinetrione (2.3 g, 5.48 mmols) and diisopropylethylamine (1.9 mL, 10.97 mmols) were stirred together in dry chloroform (50 mL) and treated with ethyl isocyanatoacetate (469 μ L, 5.48 mmols). The mixture was stirred overnight, washed twice with 1 molar hydrochloric acid, dried and evaporated. Flash chromatography (dichloromethane) gave pure ester which was dissolved in ethanol (10 mL) and treated with 6 molar sodium hydroxide solution (5.0 mL) and stirred overnight. The mixture was

partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and evaporated. The title compound was obtained by crystallization from ethanol-water (1.8 g, 63%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.20 (s, 1 H), 10.08 (s, 1 H), 7.67 - 7.74 (m, 2 H), 7.54 - 7.61 (m, 1 H), 7.37 (d, *J*=8.34 Hz, 2 H), 7.22 (d, *J*=8.59 Hz, 2 H), 5.06 (s, 2 H), 4.15 (d, *J*=5.56 Hz, 2 H), 1.26 (s, 9 H).

Example 29




N-[(1-(2,4-dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

29a) 1-(2,4-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of 2,4-dichlorophenylisocyanate (1.43 g, 7.6 mmol) and 4-*t*-butylbenzylamine (1.34 mL, 7.6 mmol) in dichloromethane (100 mL) was stirred under argon for 1 hour. Malonyl dichloride (739 μL, 7.6 mmol) was added and the mixture was heated at 40°C for 1 hour. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-25% ethyl acetate – hexane) afforded the title compound (2.6 g, 82%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.58 (d, *J*=2.27 Hz, 1 H), 7.35 - 7.43 (m, 5 H), 7.21 (d, *J*=8.59 Hz, 1 H), 5.10 - 5.17 (m, 1 H), 5.01 - 5.07 (m, 1 H), 3.89 (d, *J*=5.81 Hz, 2 H), 1.33 (s, 9 H)

29b) *N*-[(1-(2,4-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. 1-(2,4-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (2.57 g, 6.13 mmol) and diisopropylethylamine (2.12 mL, 12.26 mmol) were stirred together in dry chloroform (50 mL) and treated with ethyl isocyanatoacetate (524 μL, 6.13 mmol). The mixture was stirred overnight, washed twice with 1 molar hydrochloric acid, dried and evaporated. Flash chromatography (dichloromethane) gave pure ester which was dissolved in ethanol (10 mL) and treated with 6 molar sodium hydroxide solution (5.0 mL) and stirred overnight. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and evaporated. The title compound was obtained as a solid by trituration with hexane (680 mg, 51%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.87 (d, *J*=2.27

Hz, 1 H), 7.56 - 7.68 (m, 2 H), 7.62 (none, 2 H), 7.36 (d, 2 H), 7.26 (d, $J=8.59$ Hz, 2 H), 5.02 (d, $J=2.27$ Hz, 2 H), 4.15 (d, $J=5.81$ Hz, 2 H), 1.26 (s, 9 H).

Example 30



5

N-[(1-(2-Bromophenyl)-3-([4-(1,1-dimethylethyl)phenyl]methyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

30a) 1-(2-Bromophenyl)-3-([4-(1,1-dimethylethyl)phenyl]methyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of 2-bromophenylisocyanate (1.11 g, 5.6 mmol) and 4-*t*-


10 butylbenzylamine (1.0 mL, 5.6 mmol) in dichloromethane (100 mL) was stirred under argon for 2 hours. Malonyl dichloride (739 μ L, 7.6 mmol) was added and the mixture was heated at 40°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-35% ethyl acetate – hexane) afforded the title compound (1.75 g, 72%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.74 (dd, $J=7.96$, 1.39 Hz, 1 H), 7.47 (td, $J=7.71$, 1.52 Hz, 1 H), 7.41 - 7.44 (m, 2 H), 7.35 - 7.40 (m, 3 H), 7.28 (dd, $J=7.83$, 1.77 Hz, 1 H), 5.11 - 5.18 (m, 1 H), 5.02 - 5.09 (m, 1 H), 3.90 (d, $J=6.57$ Hz, 2 H), 1.33 (s, 9 H)

30b) *N*-[(1-(2-Bromophenyl)-3-([4-(1,1-dimethylethyl)phenyl]methyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. 1-(2-Bromophenyl)-3-([4-(1,1-

20 dimethylethyl)phenyl]methyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.7 g, 3.96 mmol) and diisopropylethylamine (1.37 mL, 7.92 mmol) were stirred together in dry dichloromethane (20 mL) and treated with ethyl isocyanatoacetate (338 μ L, 3.96 mmol). The mixture was stirred for 4 hours, washed twice with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (10 mL) and treated with 1 molar sodium hydroxide solution (6.0 mL) and stirred overnight. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and evaporated to a foam. The title compound was obtained as a solid by trituration with hexane and standing overnight (1.3 mg, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.14 (s, 1 H), 10.09 (s, 1 H), 7.80 (dd, $J=8.08$, 1.26 Hz, 1 H), 7.55 - 7.61 (m, 1 H), 7.53 (td, $J=7.58$, 1.26 Hz, 1 H), 7.43 (td, $J=7.58$, 1.77 Hz, 1 H), 7.33 - 7.40 (m, 2 H), 7.24 - 7.31 (m, 2 H), 4.98 - 5.08 (m, 2 H), 4.15 (d, $J=5.81$ Hz, 2 H), 1.26 (s, 9 H).

30

Example 31




N-[(1-(2-Biphenyl)-3-([4-(1,1-dimethylethyl)phenyl]methyl)-6-hydroxy-2,4-dioxo-1,2,3,4-
tetrahydro-5-pyrimidinyl)carbonyl]glycine

31a) 1-(2-Biphenyl)-3-([4-(1,1-dimethylethyl)phenyl]methyl)-2,4,6(1H,3H,5H)-
pyrimidinetrione. A mixture of 2-biphenylisocyanate (858 uL, 5.0 mmoles) and 4-*t*-
 butylbenzylamine (881 uL, 5.0 mmoles) in dichloromethane (50 mL) was stirred under argon
 overnight. Malonyl dichloride (486 uL, 5.0 mmoles) was added and the mixture was heated at
 40°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash
 chromatography (10-35% ethyl acetate – hexane) afforded the title compound as a gum (1.86 g,
 87%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.48 - 7.57 (m, 2 H), 7.44 (dd, *J*=7.07, 2.02 Hz, 1
 H), 7.30 - 7.41 (m, 4 H), 7.26 (d, *J*=8.34 Hz, 2 H), 7.13 (d, *J*=6.82 Hz, 2 H), 6.89 (d, *J*=8.08 Hz, 2
 H), 4.74 - 4.85 (m, 2 H), 3.92 (s, 2 H), 1.28 (s, 9 H).

31b) N-[(1-(2-Biphenyl)-3-([4-(1,1-dimethylethyl)phenyl]methyl)-6-hydroxy-2,4-dioxo-
1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. 1-(2-Biphenyl)-3-([4-(1,1-
 dimethylethyl)phenyl]methyl)-2,4,6(1H,3H,5H)-pyrimidinetrione (1.8 g, 4.22 mmoles) and
 diisopropylethylamine (730 uL, 4.22 mmoles) were stirred together in dry dichloromethane (50
 mL) and treated with ethyl isocyanatoacetate (474 uL, 4.22 mmoles). The mixture was stirred for
 under argon overnight, washed twice with 1 molar hydrochloric acid, dried and evaporated. The
 residue was dissolved in ethanol (10 mL) and treated with 1 molar sodium hydroxide solution (1.0
 mL) and 6 molar sodium hydroxide solution (2.0 mL) and stirred for 24 hours. The mixture was
 partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with
 1 molar hydrochloric acid, dried and evaporated. The title compound was obtained as a solid by
 trituration with a small amount of dichloromethane in hexane (1.3 mg, 58%). ¹H NMR (400
 MHz, DMSO-*d*₆) δ ppm 13.09 (br. s, 1 H), 10.01 (t, *J*=5.68 Hz, 1 H), 7.49 - 7.58 (m, 2 H), 7.41 -
 7.47 (m, 1 H), 7.26 - 7.37 (m, 5 H), 7.15 (d, *J*=6.57 Hz, 2 H), 6.89 (d, *J*=8.08 Hz, 2 H), 4.89 (s, 2
 H), 4.11 (d, *J*=5.81 Hz, 2 H), 1.28 (s, 9 H).


Example 32



N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 5 32a) 1-(Phenylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,4,6(1H,3H,5H) pyrimidinetrione. A mixture of tetrahydro-2H-pyran-4-ylamine (400 mg, 3.96 mmol) and benzyl isocyanate (490 μ L, 3.96 mmol) in chloroform (40 mL) was stirred under inert atmosphere for 4 hours. Malonyl dichloride (388 μ L, 4.0 mmol) was added and the mixture was heated at 50°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-40% ethyl acetate – hexane) afforded the title (980 mg, 82%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.23 - 7.35 (m, 5 H), 4.91 (s, 2 H), 4.69 - 4.79 (m, *J*=12.06, 12.06, 3.92, 3.79 Hz, 1 H), 3.91 (dd, *J*=11.12, 4.29 Hz, 2 H), 3.82 (s, 2 H), 3.33 (t, *J*=11.12 Hz, 2 H), 2.41 (qd, *J*=12.38, 4.55 Hz, 2 H), 1.49 (dd, *J*=12.00, 2.15 Hz, 2 H).
- 15 32b) N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. 1-(Phenylmethyl)-3-(tetrahydro-2H-pyran-4-yl)-2,4,6(1H,3H,5H) pyrimidinetrione (970 mg, 3.21 mmol) and diisopropylethylamine (1.11 mL, 6.42 mmol) were stirred together in dry dichloromethane (50 mL) and treated with ethyl isocyanatoacetate (360 μ L, 3.21 mmol). The mixture was stirred for under argon overnight, washed twice with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (15 mL) and treated with 1 molar sodium hydroxide solution (2.0 mL) and 6 molar sodium hydroxide solution (2.0 mL) and stirred for 4 hours. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and evaporated to a solid. The solid was triturated with diethyl ether, collected, washed with a small amount of diethyl ether and hexane to afford the title compound (1.05 g, 81 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s, 1 H), 10.15 (t, *J*=4.93 Hz, 1 H), 7.24 - 7.35 (m, 5 H), 5.00 (s, 2 H), 4.86 - 4.96 (m, *J*=11.91, 11.91, 3.85, 3.66 Hz, 1 H), 4.14 (d, *J*=5.81 Hz, 2 H), 3.93 (dd, *J*=11.12, 4.04 Hz, 2 H), 3.37 (d, *J*=11.37 Hz, 2 H), 3.32 (s, 1 H), 2.53 - 2.59 (m, 1 H), 1.55 (d, *J*=10.36 Hz, 2 H).


Example 33



N-([3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

- 5 33a) 1-Cyclohexyl-3-(tetrahydro-2H-pyran-4-yl)-2,4,6(1H,3H,5H)-pyrimidinetrione. A mixture of tetrahydro-2H-pyran-4-ylamine (400 mg, 3.96 mmol) and cyclohexyl isocyanate (505 μ L, 3.96 mmol) in chloroform (40 mL) was stirred under inert atmosphere for 4 hours. Malonyl dichloride (388 μ L, 4.0 mmol) was added and the mixture was heated at 50°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-35% ethyl acetate – hexane) afforded the title (900 mg, 77%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.72 (tt, *J*=12.09, 3.95 Hz, 1 H), 4.42 - 4.51 (m, *J*=12.16, 12.16, 3.60, 3.41 Hz, 1 H), 3.91 (dd, *J*=11.12, 4.29 Hz, 2 H), 3.70 (s, 2 H), 3.33 (t, *J*=10.99 Hz, 3 H), 2.42 (qd, *J*=12.38, 4.80 Hz, 2 H), 2.15 (qd, *J*=12.51, 3.41 Hz, 2 H), 1.77 (d, *J*=13.14 Hz, 2 H), 1.55 - 1.65 (m, 3 H), 1.48 (dd, *J*=11.87, 2.27 Hz, 2 H), 1.21 - 1.32 (m, 2 H), 1.12 (tt, *J*=12.85, 3.06 Hz, 1 H).
- 15 33b) N-([3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine. 1-Cyclohexyl-3-(tetrahydro-2H-pyran-4-yl)-2,4,6(1H,3H,5H)-pyrimidinetrione (900 mg, 3.06 mmol) and diisopropylethylamine (1.06 mL, 6.12 mmol) were stirred together in dry dichloromethane (50 mL) and treated with ethyl isocyanatoacetate (360 μ L, 3.21 mmol). The mixture was stirred for under argon overnight, washed twice with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (15 mL) and treated with 1 molar sodium hydroxide solution (2.0 mL) and 6 molar sodium hydroxide solution (2.0 mL) and stirred for 4 hours. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid, dried and
- 25 evaporated to a solid. The solid was triturated with diethyl ether, collected, washed with a small amount of diethyl ether and hexane to afford the title compound (570 mg, 47%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s, 1 H), 10.19 (t, *J*=5.56 Hz, 1 H), 4.83 - 4.94 (m, 1 H), 4.63 (t, *J*=11.49 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.93 (dd, *J*=11.12, 4.04 Hz, 2 H), 3.30 - 3.37 (m, 2 H), 2.56 (m, 2 H), 2.21 - 2.33 (m, 2 H), 1.79 (d, *J*=12.88 Hz, 2 H), 1.61 (s, 3 H), 1.52 (d, *J*=10.61 Hz, 2 H), 1.28 (q, *J*=12.97 Hz, 2 H), 1.11 - 1.18 (m, 1 H).
- 30


Example 34



N-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(2-thienyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 5 34a) 1-{[4-(1,1-Dimethylethyl)phenyl]methyl}-3-(2-thienyl)-2,4,6(1H,3H,5H)-pyrimidinetrione. A mixture of 2-thienyl isocyanate (970 mg, 7.76 mmol) and 4-*t*-butylbenzylamine (1.38 mL, 7.76 mmol) in dichloromethane (100 mL) was stirred under inert atmosphere for 2 hours. Malonyl dichloride (754 μ L, 7.76 mmol) was added (became dark on addition) and the mixture was heated under reflux for 1.5 hours. The mixture was washed with 1 molar hydrochloric acid and evaporated. Flash chromatography (10-35% ethyl acetate – hexane) afforded the title (274 mg, 10%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.57 (dd, *J*=5.56, 1.52 Hz, 1 H), 7.27 - 7.36 (m, 4 H), 7.04 (dd, *J*=5.43, 3.66 Hz, 1 H), 6.96 (dd, *J*=3.66, 1.39 Hz, 1 H), 4.90 (s, 2 H), 3.94 (s, 2 H), 1.26 (s, 9 H).
- 15 34b) N-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(2-thienyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. 1-{[4-(1,1-Dimethylethyl)phenyl]methyl}-3-(2-thienyl)-2,4,6(1H,3H,5H)-pyrimidinetrione (270 mg, 0.66 mmol) and diisopropylethylamine (228 μ L, 1.32 mmol) were stirred together in dry chloroform (5 mL) and treated with ethyl isocyanatoacetate (56.4 μ L, 0.66 mmol). The mixture was stirred under argon overnight, washed twice with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 6 molar sodium hydroxide solution (1.5 mL) and stirred overnight. The mixture was partitioned between ethyl acetate and 1 molar hydrochloric acid, the organic solution washed with 1 molar hydrochloric acid and evaporated, taken up in diethyl ether and warmed with decolorizing charcoal. The mixture was filtered and evaporated to a foam. The solid was triturated with hexane and collected. Preparative HPLC (10-100% acetonitrile – water -0.1% TFA) gave the title compound (120 mg, 40%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.15 (br. s, 1 H), 10.09 (br. s, 1 H), 7.60 (dd, *J*=5.05, 1.77 Hz, 1 H), 7.32 - 7.38 (m, 2 H), 7.26 - 7.31 (m, 2 H), 7.04 - 7.10 (m, 2 H), 4.98 (s, 2 H), 4.12 - 4.19 (m, 2 H), 1.26 (s, 9 H).
- 20
- 25

Example 35




N-({1-Cyclohexyl-6-hydroxy-3-[3-(4-morpholinyl)propyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

5 35a) 1-Cyclohexyl-3-[3-(4-morpholinyl)propyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of cyclohexyl isocyanate (638 mg, 5.0 mmoles) and 3-morpholinopropylamine (730 mL, 5.0 mmoles) in dichloromethane (50 mL) was stirred under inert atmosphere for 3 hours. Malonyl dichloride (486 uL, 5.0 mmoles) was added and the mixture was heated under reflux for 3 hours. The mixture was washed with water, sodium bicarbonate solution and evaporated. Flash
10 chromatography (0-5% methanol - dichloromethane) afforded the title (785 mg, 47%).

35b) *N-({1-Cyclohexyl-6-hydroxy-3-[3-(4-morpholinyl)propyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine*. 1-Cyclohexyl-3-[3-(4-morpholinyl)propyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (785 mg, 2.32 mmoles) and diisopropylethylamine (805 uL, 4.65 mmoles) were
15 stirred together in dry dichloromethane (50 mL) and treated with ethyl isocyanatoacetate (260 uL, 2.32 mmoles). The mixture was stirred under argon overnight, washed with water and brine, dried and evaporated. The residue was dissolved in ethanol (10 mL) and treated with 1 molar sodium hydroxide solution (2.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) and stirred for 2 hours. The mixture was diluted with 1 molar hydrochloric acid and extracted with ethyl acetate
20 (x3), the organic solution washed with brine and evaporated. The residue was purified by preparative HPLC (10-70% acetonitrile – water – 0.1%TFA) to give the title compound (90 mg, 9%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.16 (br. s., 1 H), 10.15 (br. s., 1 H), 4.64 (t, *J*=11.62 Hz, 1 H), 4.15 (d, *J*=3.28 Hz, 2 H), 3.88 (t, *J*=6.44 Hz, 6 H), 2.86 - 3.31 (br. m, 6 H), 2.18 - 2.39 (m, 2 H), 1.90 - 2.05 (m, 2 H), 1.88 - 2.05 (m, 2 H), 1.80 (d, *J*=12.88 Hz, 2 H), 1.63 (s, 3 H),
25 1.21 - 1.38 (m, 2 H), 1.03 - 1.20 (m, 1 H)

Example 36



N-([3-([4-(1,1-Dimethylethyl)phenyl]methyl)-6-hydroxy-2,4-dioxo-1-(3-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine


5 36a) 1-([4-(1,1-Dimethylethyl)phenyl]methyl)-3-(3-pyridinyl)-2,4,6(1H,3H,5H)-pyrimidinetrione. A mixture of pyridine 3-isocyanate (622 mg, 5.18 mmoles) and 4-*t*-butylbenzylamine (912 uL, 5.18 mmoles) in dichloromethane (50 mL) was stirred overnight. The urea was purified by flash chromatography (ethyl acetate), taken up in methoxyethanol (10 mL), treated with diethyl malonate (1.0 mL, 6.58 mmoles) and sodium ethoxide (1.0 mL of a 21 molar solution in ethanol) and heated under reflux for 24 hours in an inert atmosphere.

10 The mixture was cooled, diluted with ethyl acetate and washed with brine. The organic solution was evaporated and purified by flash chromatography (10-100% ethyl acetate in hexane) to give the title compound (340 mg, 19%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.62 (dd, *J*=4.80, 1.52 Hz, 1 H), 8.48 (d, *J*=2.02 Hz, 1 H), 7.75 (d, *J*=8.08 Hz, 1 H), 7.57 (dd, *J*=8.21, 4.93 Hz, 1 H), 7.29 - 7.36 (m, 4 H), 3.55 (s, 2 H), 1.26 (s, 9 H).

15 36b) N-([3-([4-(1,1-Dimethylethyl)phenyl]methyl)-6-hydroxy-2,4-dioxo-1-(3-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine. 1-([4-(1,1-Dimethylethyl)phenyl]methyl)-3-(3-pyridinyl)-2,4,6(1H,3H,5H)-pyrimidinetrione (340 mg, 0.96 mmoles) and diisopropylethylamine (334 uL, 1.93 mmoles) were stirred together in dry chloroform (25 mL) and treated with ethyl isocyanatoacetate (108 uL, 0.96 mmoles). The mixture was stirred under argon overnight, washed with 1 molar hydrochloric acid and brine, dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 1 molar sodium hydroxide solution (2.0 mL) and 6 molar sodium hydroxide solution (2.0 mL) and stirred overnight. The mixture was diluted with 1 molar hydrochloric acid and extracted with ethyl acetate (x2), the organic solution washed with

20 brine and evaporated. The solid residue was slurried in hot ethanol, collected and recrystallized from ethanol – water to give the title compound (100 mg, 23%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (s, 1 H), 10.09 (s, 1 H), 8.62 (dd, *J*=4.67, 1.39 Hz, 1 H), 8.58 (s, 1 H), 7.86 (d, *J*=7.83 Hz, 1 H), 7.55 (dd, *J*=8.08, 4.80 Hz, 1 H), 7.28 - 7.37 (m, 4 H), 5.00 (s, 2 H), 4.11 - 4.19 (m, 2 H), 1.26 (s, 9 H).

Example 37




N-({1-Cyclohexyl-3-[(2-fluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

5 37a) Ethyl N-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate. Ethyl isocyanatoacetate (9.7 mL, 86.32 mmoles) in dichloromethane (80 mL) was added dropwise to a stirred solution of 1-cyclohexylpyrimidinetrione (16.5 g, 78.5 mmoles) and diisopropylethylamine (27.2 mL, 157 mmoles) in dichloromethane (120 mL). The mixture was stirred for 3 hours, 1 molar hydrochloric acid was added, causing the title compound to precipitate. The solid was collected and washed with 1 molar hydrochloric acid. The solid was slurried in diethyl ether, collected, washed with diethyl ether and hexane then dried to give the title compound (23 g, 86%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 11.92 (br. s., 1 H), 9.91 (br. s., 1 H), 4.57 (s, 1 H), 4.15 (q, *J*=6.99 Hz, 4 H), 2.26 (d, *J*=11.62 Hz, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.50 - 1.68 (m, 3 H), 1.17 - 1.36 (m, 5 H), 1.11 (q, *J*=13.05 Hz, 1 H)

37b) N-({1-Cyclohexyl-3-[(2-fluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* Potassium carbonate (740 mg, 5.35 mmoles) and 2-fluorobenzyl bromide (380 mg, 2.0 mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (163 mg, 39 %). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.09 (br. s, 1 H), 10.13 (br. s, 1 H), 7.28 - 7.34 (m, 1 H), 7.12 - 7.22 (m, 3 H), 5.05 (s, 2 H), 4.64 (t, *J*=12.13 Hz, 1 H), 4.10 - 4.16 (m, 2 H), 2.26 (qd, *J*=12.38, 2.78 Hz, 2 H), 1.78 (d, *J*=12.88 Hz, 2 H), 1.63 (s, 3 H), 1.28 (q, *J*=12.88 Hz, 2 H), 1.06 - 1.17 (m, 1 H).

Example 38




N-((3-((2-Chlorophenyl)methyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl)glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* Potassium carbonate (740 mg, 5.35 mmoles) and 2-chlorobenzyl bromide (300 mg, 1.5 mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (193 mg, 44%).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s, 1 H), 10.13 (br. s, 1 H), 7.45 - 7.50 (m, 1 H), 7.26 - 7.32 (m, 2 H), 7.05 - 7.09 (m, 1 H), 5.05 (s, 2 H), 4.65 (t, *J*=11.87 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.20 - 2.30 (m, 2 H), 1.79 (d, *J*=13.14 Hz, 2 H), 1.59 - 1.69 (m, 3 H), 1.28 (q, *J*=12.97 Hz, 2 H), 1.06 - 1.16 (m, 1 H).

Example 39




N-((1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-((5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl)glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* Potassium carbonate (740 mg, 5.35 mmoles) and 6-(bromomethyl)-1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphthalene (250 mg, 0.89

mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (156 mg, 35%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.07 (br. s., 1 H), 7.24 (dd, *J*=4.80, 3.28 Hz, 2 H), 6.98 (dd, *J*=8.21, 1.39 Hz, 1 H), 4.93 (s, 2 H), 4.66 (t, *J*=11.87 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.19 - 2.36 (m, 2 H), 1.79 (d, *J*=12.63 Hz, 2 H), 1.62 (s, 7 H), 1.01 - 1.37 (m, 15 H).


Example 40



N-((1-Cyclohexyl-3-[(2,4-dimethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl)glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* Potassium carbonate (740 mg, 5.35 mmoles) and 2,4-dimethylbenzyl bromide (400 mg, 2.0 mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (173 mg, 40%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.15 (br. s., 1 H), 2.31 (s, 3 H), 2.18 - 2.29 (m, 5 H), 1.78 (d, *J*=13.14 Hz, 2 H), 1.62 (d, *J*=10.36 Hz, 3 H), 1.28 (q, *J*=12.72 Hz, 2 H), 1.12 (t, *J*=12.88 Hz, 1 H).

Example 41




N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trifluorophenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

5 A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* Potassium carbonate (740 mg, 5.35 mmoles) and 2,4,6-trifluorobenzyl bromide (337 mg, 1.5 mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (240 mg, 53%).

10 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.06 (br. s, 1 H), 10.08 (br. s, 1 H), 7.11 - 7.19 (m, 2 H), 5.06 (s, 2 H), 4.61 (t, *J*=12.00 Hz, 1 H), 4.12 (d, *J*=5.81 Hz, 2 H), 2.19 - 2.30 (m, *J*=12.25, 12.25, 12.13, 2.53 Hz, 2 H), 1.78 (d, *J*=12.88 Hz, 2 H), 1.59 (t, *J*=13.01 Hz, 3 H), 1.28 (q, *J*=12.88 Hz, 2 H), 1.06 - 1.17 (m, 1 H).

Example 42




N-[(1-Cyclohexyl-6-hydroxy-3-{[4-(1-methylethyl)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

25 A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* Potassium carbonate (1.0 g, 7.24

mmoles) and 4-isopropylbenzyl chloride (250 mg, 1.5 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in
 5 hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (161 mg, 36%).
 1H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (s, 1 H), 10.14 (s, 1 H), 7.16 - 7.24 (m, 4 H), 4.95 (s,
 10 2 H), 4.64 (t, *J*=11.37 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.79 - 2.90 (m, *J*=6.86, 6.86, 6.86, 6.86, 6.86 Hz, 1 H), 2.20 - 2.32 (m, 2 H), 1.78 (d, *J*=12.88 Hz, 2 H), 1.62 (d, *J*=11.12 Hz, 3 H), 1.22 - 1.34 (m, 2 H), 1.09 - 1.20 (m, 7 H).

Example 43




N-({1-Cyclohexyl-3-[(2-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (680 mg, 2.0 mmoles), *pulv.* potassium carbonate (2.0 g, 14.46
 20 mmoles) and a mixture of both 2- and 4-ethylbenzyl chloride (464 mg, 3.0 mmoles) in dimethylacetamide (8.0 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was separated by preparative HPLC
 25 (80% acetonitrile-water-0.1%TFA), to give a) ethyl *N*-({1-cyclohexyl-3-[(2-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycinate (100 mg, 11%) and b) ethyl *N*-({1-cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycinate (300 mg, 33%). Product a) was dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added.
 30 The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound

(58 mg, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.00 (br. s., 1 H), 10.15 (br. s., 1 H), 7.14 - 7.23 (m, 2 H), 7.07 - 7.15 (m, 1 H), 6.88 (d, *J*=7.58 Hz, 1 H), 5.03 (s, 2 H), 4.65 (t, *J*=11.75 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.72 (q, *J*=7.49 Hz, 2 H), 2.17 - 2.35 (m, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.56 - 1.69 (m, 3 H), 1.23 - 1.35 (m, 2 H), 1.20 (t, *J*=7.58 Hz, 3 H), 1.04 - 1.17 (m, 1 H).

5

Example 44




N-({1-Cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

10

Ethyl *N*-({1-cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycinate (product b from example 43) was dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (195 mg, 69%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.13 (br. s., 1 H), 10.15 (s, 1 H), 7.18 - 7.24 (m, 2 H), 7.13 - 7.18 (m, 2 H), 4.95 (s, 2 H), 4.64 (t, *J*=11.62 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.56 (q, *J*=7.58 Hz, 2 H), 2.20 - 2.31 (m, 2 H), 1.78 (d, *J*=12.13 Hz, 2 H), 1.61 (d, *J*=10.36 Hz, 3 H), 1.28 (q, *J*=12.72 Hz, 2 H), 1.06 - 1.17 (m, 4 H).

20

Example 45




N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trimethylphenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

25

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (1.0 g, 7.24

mmoles) and 2,4,6-trimethylbenzyl chloride (339 mg, 1.5 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (61 mg, 13%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.07 (s, 1 H), 10.07 (s, 1 H), 6.77 (s, 2 H), 4.99 (s, 2 H), 4.59 (t, *J*=12.00 Hz, 1 H), 4.08 - 4.14 (m, 2 H), 2.21 - 2.29 (m, 8 H), 2.14 - 2.20 (m, 4 H), 1.77 (d, *J*=12.63 Hz, 2 H), 1.52 - 1.64 (m, 3 H), 1.27 (q, *J*=12.88 Hz, 2 H), 1.05 - 1.17 (m, 1 H).


Example 46



N-{[1-Cyclohexyl-3-(2-cyclohexylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (1.0 g, 7.24 mmoles) and 2-cyclohexylethyl bromide (287 mg, 1.5 mmoles) in dimethylacetamide (8 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from toluene gave the title compound (180 mg, 42%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.15 (br. s., *J*=5.43, 5.43 Hz, 1 H), 4.63 (t, *J*=11.62 Hz, 1 H), 4.07 - 4.19 (m, 2 H), 3.72 - 3.88 (m, 2 H), 2.18 - 2.36 (m, 2 H), 1.50 - 1.87 (m, 10 H), 1.35 - 1.47 (m, 2 H), 1.04 - 1.35 (m, 7 H), 0.91 (q, *J*=11.62 Hz, 2 H).

Example 47




N-[(3-{[3,5-Bis(methoxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

- 5 A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (1.5 g, 11 mmoles) and 3,5-dimethoxybenzyl bromide (300 mg, 1.3 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and extracted with ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide solution (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from toluene gave the title
- 15 compound (190 mg, 41%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (s, 1 H), 10.15 (s, 1 H), 6.40 (s, 3 H), 4.92 (s, 2 H), 4.64 (t, *J*=11.87 Hz, 1 H), 4.09 - 4.17 (m, 2 H), 3.70 (s, 6 H), 2.26 (s, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.62 (d, *J*=11.62 Hz, 3 H), 1.28 (q, *J*=13.05 Hz, 2 H), 1.06 - 1.17 (m, 1 H).

20


Example 48



N-{[1-Cyclohexyl-6-hydroxy-3-(2-naphthalenylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 25 A mixture of ethyl *N*-[(3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (100 mg, 0.29 mmoles), 2-bromomethylnaphthalene (195 mg, 0.88 mmoles) and polymer-bound 2-*tert*-butylimino-2-diethylamine-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine(pol-BEMP, 0.88 mmoles) in DMF (3 mL) was heated in a microwave

synthesiser at 120°C for 20 minutes. After cooling, the mixture was filtered, and the solids washed with dichloromethane (3 X 3 mL). The combined filtrate was evaporated and purified by flash chromatography (ethyl acetate-hexane) to obtain the desired intermediate ester. The crude ester was dissolved in ethanol (4 mL) and 1M aqueous NaOH (1 mL) and the solution stirred for 2 hours, then neutralized by addition of 1M aqueous HCl. The solid was collected, washed with water (3 X 4 mL) and dried under vacuum overnight to give the title compound (77 mg, 29%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.13 - 1.42 (m, 4 H) 1.56 - 1.72 (m, 3 H) 1.77 - 1.90 (m, 2 H) 2.26-2.44 (m, 2 H) 4.24 (dd, *J*=2.2, 5.7 Hz, 2 H) 4.64 - 4.84 (m, 1 H) 5.24 (s, 2 H) 7.40 - 7.50 (m, 2 H) 7.55 (dt, *J*=2.1, 8.3 Hz, 1 H) 7.75 - 7.90 (m, 4 H) 10.21 - 10.34 (m, 1 H)




Example 49

N-({1-Cyclohexyl-6-hydroxy-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

Using 4-methylbenzyl bromide in place of 2-bromomethylnaphthylene, the title compound was prepared in 27% yield (67 mg) following the procedures described in example 48. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.10 - 1.43 (m, 4 H) 1.52 - 1.72 (m, 3 H) 1.76 - 1.93 (m, 2 H) 2.20 - 2.43 (m, 5 H) 4.22 (dd, *J*=3.4, 5.7 Hz, 2 H) 4.64 - 4.82 (m, 1 H) 5.04 (s, 2 H) 7.06 - 7.16 (m, 2 H) 7.29 - 7.36 (m, 2 H) 10.15 - 10.36 (m, 1 H)

Example 50




N-([3-(4-Biphenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl glycine

Using 4-bromomethylbiphenyl in place of 2-bromomethylnaphthylene, the title compound was prepared in 17% yield (48 mg) following the procedures described in example 48. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.13 - 1.45 (m, 3 H) 1.55 -1.75 (m, 3 H) 1.76 - 1.91 (m, 2 H) 2.24 - 2.46

(m, 2 H) 4.23 (dd, $J=3.4, 5.7$ Hz, 2 H) 4.62 - 4.92 (m, 1 H) 5.12 (s, 2 H) 5.42 - 5.97 (m, 2 H) 7.29 - 7.38 (m, 1 H) 7.38 - 7.46 (m, 2 H) 7.46 - 7.61 (m, 6 H) 10.14 - 10.42 (m, 1 H)

Example 51




5

N-[(3-{[4-(1,3-Benzoxazol-2-yl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using 2-[4-(bromomethyl)phenyl]-1,3-benzoxazole in place of 2-bromomethylnaphthylene, the title compound was prepared in 10% yield (30 mg) following the procedures described in example 48. ^1H NMR (400 MHz, CDCl_3) δ ppm 1.11 - 1.42 (m, 3 H) 1.57 - 1.72 (m, 3 H) 1.74 - 1.91 (m, 2 H) 2.27 - 2.43 (m, 2 H) 4.16 (dd, $J=3.4, 5.7$ Hz, 2 H) 4.67-4.95 (m, 3 H) 5.09-5.23 (m, 2 H) 7.32-7.42 (m, 3 H) 7.53-7.62 (m, 3 H) 7.74-7.79 (m, 1 H) 8.18-8.27 (m, 1 H) 10.22-10.42 (m, 1 H)

15

Example 52




N-({3-[2-(4-Biphenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

Using 2-bromo-4'-phenylacetophenone in place of 2-bromomethylnaphthylene, the title compound was prepared in 8% yield (24 mg) following the procedures described in example 48. ^1H NMR (400 MHz, CDCl_3) δ ppm 1.11 - 1.27 (m, 1 H) 1.27 - 1.43 (m, 2 H) 1.59 - 1.78 (m, 3 H) 1.78 - 1.20 (m, 2 H) 2.25 - 2.43 (m, 2 H) 4.15 - 4.31 (m, 2 H) 4.62 - 4.87 (m, 1 H) 5.36 - 5.42 (m, 2 H) 7.39 - 7.45 (m, 1 H) 7.45 - 7.53 (m, 2 H) 7.61 - 7.67 (m, 2 H) 7.69 - 7.76 (m, 2 H) 8.08 (d, $J=8.3$ Hz, 2 H) 10.07 - 10.42 (m, 1 H)

20

Example 53



N-[(1,3-Bis{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

53a) N,N'-Bis{[4-(1,1-dimethylethyl)phenyl]methyl}urea. Diphosgene (725 uL, 6.0 mmoles) was added to a solution of 4-*t*-butylbenzylamine (880 uL, 5.0mmoles) in ethyl acetate (20 mL) under nitrogen atmosphere at room temperature. A solid precipitated and the mixture was then heated to 70°C until the solid dissolved. After stirring for 1 hour, 4-*t*-butylbenzylamine (880 uL, 5.0mmoles) was added and the mixture was stirred for 2 hours. Diisopropylethylamine (1.0 mL, 5.75 uL) was added and the mixture was stirred for 1 hour, washed with 1 molar hydrochloric acid, dried and evaporated to an oil which solidified on standing overnight to give the title compound (710 mg, 40%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.30 - 7.38 (m, 4 H), 7.17 (d, *J*=8.34 Hz, 4 H), 6.34 (t, *J*=5.94 Hz, 2 H), 4.18 (d, *J*=5.81 Hz, 4 H), 1.27 (s, 18 H).


53b) 1,3-Bis{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (195 uL, 2.0 mmoles) was added to a stirred solution of *N,N*-bis{[4-(1,1-dimethylethyl)phenyl]methyl}urea in dichloromethane (80 mL) and the mixture was heated under reflux for 2 hours. The mixture was washed with 1 molar hydrochloric acid, and purified by flash chromatography (0-30% ethyl acetate in hexane) to give the title compound (700 mg, 84%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.29 - 7.35 (m, 4 H), 7.21 - 7.29 (m, 4 H), 4.87 (s, 4 H), 3.86 - 3.93 (s, 2 H), 1.25 (s, 18 H).

53c) N-[(1,3-Bis{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. A mixture of 1,3-bis{[4-(1,1-dimethylethyl)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (700 mg, 1.66 mmoles) and diisopropylethylamine (574 uL, 3.32 mmoles) was stirred in dichloromethane (50 mL) and treated with ethyl isocyanatoacetate (202 uL, 1.8 mmoles). The mixture was stirred for 5 hours, then warmed to complete reaction. The mixture was washed with 1 molar hydrochloric acid, evaporated, taken up in ethanol - 6 molar sodium hydroxide solution, stirred and gently warmed to complete hydrolysis. The mixture was acidified and extracted into ethyl acetate. The extracts were

evaporated and a solid obtained from aqueous ethanol to give the title compound (700 mg, 81%).
¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.67 (s, 1 H), 7.24 - 7.30 (m, 4 H), 7.16 (d, *J*=8.59 Hz, 4 H), 4.94 (s, 4 H), 3.42 (d, *J*=4.04 Hz, 2 H), 1.25 (s, 18 H).


5

Example 54



N-{[1-Cyclohexyl-6-hydroxy-3-(4-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

A solution of cyclohexylisocyanate (1252 mg, 10 mmoles) in dichloromethane (20mL)
 10 was added dropwise to a solution of 4-methylcyclohexylamine (1132 mg, 10 mmoles) in dichloromethane (100 mL). The solution was allowed to stir at room temperature for 2 hours, then the solvent evaporated and the residue dissolved in dichloromethane (10 mL) along with malonyl chloride (10 mmol). The mixture was heated in a microwave synthesiser (80°C/20 min). All volatiles were evaporated and the residue dissolved in of chloroform (10 mL) along with ethyl
 15 isocyanatoacetate (10 mmol), then the mixture was stirred at room temperature for 2 hours. Solvent was evaporated and the residue was purified by flash chromatography (ethyl acetate-hexane) to obtain the intermediate ester. The ester was dissolved in a mixture of of ethanol (4 mL) and 1M aqueous NaOH (1 mL). The solution was stirred for 2 hours and neutralized by addition of 1M aqueous HCl. The solid was collected, washed with water (3 X 4 mL) and dried under vacuum
 20 overnight to give the title compound (443 mg, 11%). ¹H NMR (400 MHz, CDCl₃) δ ppm 0.85 - 0.96 (m, 2 H) 1.10 - 1.13 (m, 3 H) 1.16 - 1.50 (m, 6 H), 1.53 - 1.72 (m, 6 H) 1.73 - 1.89 (m, 3 H) 2.25 - 2.47 (m, 3 H) 2.50 - 2.66 (m, 1 H) 4.01 - 4.08 (m, 1 H) 4.23 (d, *J*=5.8 Hz, 1 H) 4.60 - 4.82 (m, 2 H) 10.25 - 10.36 (m, 1 H)



25


Example 55

N-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)cyclohexyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

Using 4-*tert*-butylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 21% yield (931 mg) following the procedures described in example 54.

¹H NMR (400 MHz, CDCl₃) δ ppm 0.77 - 0.94 (m, 13 H) 1.03 - 1.45 (m, 6 H) 1.45 - 1.77 (m, 5 H) 1.77 - 1.97 (m, 3 H) 2.18 - 2.48 (m, 3 H) 4.01 - 4.10 (m, 1 H) 4.24 (d, *J*=5.6 Hz, 1 H) 4.58 - 4.82 (m, 2 H) 10.26 - 10.36 (m, 1 H)

Example 56




N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using aniline in place of 4-methylcyclohexylamine, the title compound was prepared in 5% yield (198 mg) following the procedures described in example 54. ¹H NMR (400 MHz,

CDCl₃) δ ppm 1.02 - 1.46 (m, 5 H) 1.54 - 1.78 (m, 3 H) 1.78 - 1.98 (m, 2 H) 2.26 - 2.47 (m, 2 H) 4.21 (dd, *J*=5.8, 19 Hz, 2 H) 4.69 - 4.87 (m, 1 H) 7.16 - 7.31 (m, 2 H) 7.40 - 7.46 (m, 3 H) 10.06 - 10.42 (m, 1 H)


Example 57



N-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

Using 4-*tert*-butylaniline in place of 4-methylcyclohexylamine, the title compound was prepared in 7% yield (321 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.09 - 1.24 (m, 1 H) 1.26 - 1.43 (m, 13 H) 1.58 - 1.77 (m, 3 H) 1.78 - 1.91 (m, 2 H) 2.27 - 2.49 (m, 2 H) 4.22 (dd, *J*=14.7, 20.2 Hz, 2 H) 4.68 - 4.88 (m, 1 H) 7.16 (dd, *J*=8.6, 14.4 Hz, 2 H) 7.51 (dd, *J*=14.4 Hz, 2 H) 10.10 - 10.42 (m, 1 H)

Example 58




N-([1-Cyclohexyl-3-(cyclohexylmethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

5

Using cyclohexylmethylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 22% yield (442 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.85 - 1.11 (m, 2 H) 1.11 - 1.28 (m, 5 H) 1.28 - 1.48 (m, 2 H) 1.55 - 1.79 (m, 10 H) 1.79 - 1.91 (m, 2 H) 2.35 (dq, *J*=3.0, 12.4 Hz, 2 H) 3.76 (d, *J*=1.4, 7.2 Hz, 2 H) 4.24 (dd, *J*=3.0, 7.2 Hz, 2 H) 4.65 - 4.83 (m, 1 H) 10.17 - 10.33 (m, 1 H)

10

Example 59




N-[(3-Cycloheptyl-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

15

Using cycloheptylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 29% yield (583 mg) following the procedures described in example 54. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 1.03 - 1.19 (m, 2 H) 1.19 - 1.34 (m, 3 H) 1.34 - 1.84 (m, 14 H) 2.14 - 2.36 (m, 4 H) 3.17 (s, 1 H) 4.06 (d, *J*=5.6 Hz, 2 H) 4.56 - 4.71 (m, 1 H) 4.73 - 4.89 (m, 1 H) 10.11 - 10.23 (m, 1 H)

20

Example 60




N-[(3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using 1-admantanamine hydrochloride in place of 4-methylcyclohexylamine, the title compound was prepared in 3% yield (66 mg) following the procedures described in example 54.

- 5 ¹H NMR (400 MHz, CDCl₃) δ ppm 1.12 - 1.43 (m, 4 H) 1.54 - 1.88 (m, 12 H) 2.03 - 2.20 (m, 3 H) 2.23 - 2.28 (m, 2 H) 2.45 - 2.57 (m, 6 H) 4.21 (d, *J*=5.8 Hz, 2 H) 4.50 - 4.70 (m, 1 H) 10.16 - 10.31 (m, 1 H)

Example 61




N-({1-[(1*R*,2*R*,4*S*)-Bicyclo[2.2.1]hept-2-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

Using exo-2-aminonorbornane in place of 4-methylcyclohexylamine, the title compound was prepared in 30% yield (604 mg) following the procedures described in example 54.

- 15 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.96 - 1.34 (m, 9 H) 1.35 - 1.67 (m, 6 H) 1.67 - 1.84 (m, 3 H) 2.20 - 2.36 (m, 4 H) 4.01 (d, *J*=5.6 Hz, 2 H) 4.55 - 4.72 (m, 2 H) 10.11 - 10.20 (m, 1 H)

Example 62




N-([1-Cyclohexyl-6-hydroxy-3-(3-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

Using 3-methylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 41% yield (836 mg) following the procedures described in example 54.

- 25 ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 0.89 (d, *J*=6.6 Hz, 3 H) 0.97 - 1.48 (m, 8 H) 1.49 - 1.67 (m, 6 H) 1.69 - 1.86 (m, 3 H) 2.08 - 2.37 (m, 4 H) 4.06 (d, *J*=5.6 Hz, 2 H) 4.55 - 4.76 (m, 2 H) 10.12 - 10.26 (m, 1 H)

Example 63




N-[(3-Cyclohexyl-1-cyclopropyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

5 Using cyclopropylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 20% yield (351 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.95 – 1.08 (m, 1 H), 1.12 – 1.28 (m, 4H), 1.29 – 1.42 (m, 1 H), 1.57 – 1.80 (m, 6 H), 1.80 – 1.89(m, 1 H), 2.28 – 2.42 (m, 2 H), 3.76 (d, *J*=7.1 Hz, 2 H), 4.24 (dd, *J*=5.6, 3.5 Hz, 2 H), 4.66 – 4.82 (m, 1 H), 10.21 – 10.31 (m, 1 H).

10

Example 64




N-[(1-Cyclobutyl-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

15 Using cyclobutylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 23% yield (424 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.14-1.46 (m, 4 H) 1.56 - 1.98 (m, 7 H) 2.14 - 2.46 (m, 4 H) 2.80 - 3.00 (m, 2 H) 4.24 (d, *J*=5.6 Hz, 2 H) 4.58 - 4.83 (m, 1 H) 5.08 - 5.33 (m, 2 H) 10.22 - 10.32 (m, 1 H)

20

Example 65



N-[(3-Cyclohexyl-1-cyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Method 1


65.1 Using cyclopentylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 19% yield (357 mg) generally following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.14 - 1.45 (m, 4 H) 1.52 - 1.73 (m, 5 H) 1.75 - 2.00 (m, 7 H) 2.00 - 2.16 (m, 2 H) 2.24 - 2.43 (m, 2 H) 4.24 (dd, *J*=1.3, 5.8 Hz, 2 H) 4.64 - 4.82 (m, 1 H) 5.11 - 5.38 (m, 1 H) 10.23 - 10.35 (m, 1 H)

Method 2

65.2a) 1-Cyclohexyl-3-cyclopentyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Cyclohexyl isocyanate (14.7 g, 117.34 mmol) in dichloromethane (500 mL) under argon was treated with a solution of cyclopentylamine (11.58 mL, 117.34 mmol) in dichloromethane (300 mL) and stirred overnight to leave a thick suspension of the urea. Malonyl dichloride (12.55 mL, 129 mmol) in dichloromethane (200 mL) was added and the mixture was heated under gentle reflux for 3.5 hours. The mixture was washed with 1 molar hydrochloric acid (x2) dried and evaporated. Crystallization from ethanol and flash chromatography of the liquors (hexane to ethyl acetate) gave the title compound (18.9 g, 58%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 4.96 - 5.12 (m, 1 H), 4.46 (tt, *J*=12.13, 3.54 Hz, 1 H), 3.69 (s, 2 H), 2.15 (ddd, 2 H), 1.67 - 2.00 (m, 8 H), 1.41 - 1.66 (m, 5 H), 1.27 (m, 2 H), 1.11 (m, 1 H).

65.2b) N-[(1-Cyclohexyl-3-cyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. Ethyl isocyanatoacetate (8.33 mL, 74.3 mmol) was added to a mixture of 1-cyclohexyl-3-cyclopentyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (18.8 g, 67.54 mmol) and diisopropylethylamine (23.53 mL, 135.08 mmol) in dichloromethane (800 mL) and stirred for 2 hours. Reaction mixture from a prior run (approx 25% scale) was added. The combined reaction mixture was washed with 2 molar hydrochloric acid (2 x 1.0 L) and evaporated. The residue was dissolved in ethanol (200 mL) and treated with 3.0 molar sodium hydroxide (100 mL). The mixture was stirred for 2 hours. Ethyl acetate (500 mL) was added and the mixture acidified with 6 molar hydrochloric acid (200 mL), water (500 mL) was added and the layers separated. The aqueous layer was extracted with ethyl acetate (500 mL) and the organic solution was washed with 1 molar hydrochloric acid. The organic solution was dried and evaporated to a solid residue which recrystallized from acetic acid (300 mL) to afford the title compound (15.5 g, 49%). Mp 222-224°C. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.08 (s, 1 H), 10.17 (t, *J*=5.43 Hz, 1 H), 5.08 - 5.33 (m, 1 H), 4.63 (t, *J*=12.25 Hz, 1 H), 4.12 (d, *J*=5.81 Hz, 2 H), 2.18 - 2.36 (m, 2 H), 1.93 - 2.06 (m, 2 H), 1.69 - 1.91 (m, 6 H), 1.46 - 1.68 (m, 5 H), 1.28 (q, *J*=12.88 Hz, 2 H), 1.12 (q, *J*=13.05 Hz, 1 H).

Example 66




N-{[6-Hydroxy-1,3-bis(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

5 66a) N,N'-Bis(3-methylbutyl)urea. Isoamylamine (1.4 mL, 12 mmoles) was added to a solution of [1,3]oxathiolo[4,5-*b*]pyridin-2-one (765 mg, 5.0 mmoles) in ethyl acetate (15 mL). The mixture was stirred for 2 hours, the solid collected, washed with ethyl acetate and dried to give the title compound (1.1g, 91%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.86 (br. s, 2 H), 3.20 (td, *J*=7.33, 5.81 Hz, 4 H), 1.61 - 1.72 (m, *J*=13.39, 6.69, 6.69, 6.69 Hz, 2 H), 1.40 - 1.48 (m, 4 H), 0.93 (d, *J*=6.57 Hz, 12 H).

66b) 3-Bis(3-methylbutyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Ethyl malonyl chloride (768 uL, 6.0 mmoles) was added to a solution of *N,N'*-bis(3-methylbutyl)urea (1.1 g, 5.5 mmoles) in chloroform (70 mL) and the mixture was stirred at 70°C for 2 hours. The mixture was washed with 1 molar hydrochloric acid, dried and evaporated to give ethyl 3-((3-methylbutyl){[(3-methylbutyl)amino]carbonyl}amino)-3-oxopropanoate. The intermediate was dissolved in ethanol (30 mL), DBU (900 uL, 6 mmoles) and heated to 70°C for 5 minutes. The mixture was cooled, diluted with ethyl acetate and washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (1.2 g, 81%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.65 - 3.78 (m, 3 H), 1.56 (dt, *J*=20.02, 13.33, 6.57 Hz, 1 H), 1.32 - 1.44 (m, 2 H), 0.90 (d, *J*=6.57 Hz, 6 H).

66c) -{[6-Hydroxy-1,3-bis(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of 1,3-bis(3-methylbutyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.2 g, 4.47 mmoles) and diisopropylethylamine (1.56 mL, 8.94 mmoles) was stirred in dichloromethane (30 mL) and treated with ethyl isocyanatoacetate (501 uL, 4.47 mmoles). The mixture was stirred for 5 hours, washed with 1 molar hydrochloric acid (x2), evaporated, taken up in ethanol - 6 molar sodium hydroxide and stirred overnight. The mixture was acidified and extracted into ethyl acetate (x2). The extracts were washed with 1 molar hydrochloric acid evaporated, dried and evaporated. The title compound was recrystallized from acetic acid (430 mg, 26%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.09 (br. s, 1 H), 10.11 (s, 1 H), 4.09 - 4.16 (m, 2 H), 3.77 - 3.86 (m, 4 H), 1.51 - 1.62 (dt, *J*=13.29, 6.59, 6.59, 6.59 Hz, 2 H), 1.42 (q, *J*=7.07 Hz, 4 H), 0.91 (d, *J*=6.57 Hz, 12 H).

Example 67



N-[(6-Hydroxy-1,3-bis{[2-(methyloxy)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

5

67a) 1,3-Bis{[2-(methyloxy)phenyl]methyl}-2,4,6(1H,3H,5H)-pyrimidinetrione. 2-

Methoxybenzyl isocyanate (923 uL, 6.0 mmoles) was added to a solution of 2-methoxybenzylamine (775 uL, 6.0 mmoles) in chloroform (100 mL) and the mixture stirred for 1 hour. Ethyl malonyl chloride (768 uL, 6.0 mmoles) was added and the mixture was heated to 70°C for 2 hours. DBU (1.0 mL) was added and the mixture was heated for a further 1 hour. The mixture was cooled and washed with 1 molar hydrochloric acid (x2), dried and evaporated. The title compound was obtained as a solid by trituration in diethyl ether (1.65 g, 75 1H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.22 (t, 2 H), 7.15 (d, *J*=7.58 Hz, 2 H), 6.98 (d, *J*=7.58 Hz, 2 H), 6.86 (t, 2 H), 4.88 (s, 4 H), 3.81 (s, 6 H), 3.79 - 3.80 (s, 2 H).


15

67b) N-[(6-hydroxy-1,3-bis{[2-(methyloxy)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine. A mixture of 1,3-bis{[2-(methyloxy)phenyl]methyl}-

2,4,6(1H,3H,5H)-pyrimidinetrione (1.64 g, 4.45 mmoles) and diisopropylethylamine (1.56 mL, 8.94 mmoles) was stirred in dichloromethane (30 mL) and treated with ethyl isocyanatoacetate (500 uL, 4.45 mmoles). The mixture was stirred for 5 hours, washed with 1 molar hydrochloric acid (x2), evaporated, taken up in ethanol – 6 molar sodium hydroxide and stirred overnight. The mixture was acidified and extracted into ethyl acetate (x2). The extracts were washed with 1 molar hydrochloric acid evaporated, dried and evaporated. The title compound was recrystallized from acetic acid (1.0 g, 48%). 1H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.51 (br. s., 1 H), 10.11 (t, *J*=4.93 Hz, 1 H), 7.20 - 7.28 (m, 2 H), 7.00 (d, *J*=7.83 Hz, 2 H), 6.86 - 6.96 (m, 4 H), 5.00 (s, 4 H), 4.10 - 4.18 (m, 2 H), 3.82 (s, 6 H).

25

Example 68




N-({1,3-Bis[(2-chlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

5 68a) 1,3-Bis[(2-chlorophenyl)methyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. 2-Chlorobenzyl isocyanate (875 uL, 6.0 mmoles) was added to a solution of 2-chlorobenzylamine (725 uL, 6.0 mmoles) in chloroform (100 mL) and the mixture stirred for 1 hour. Ethyl malonyl chloride (768 uL, 6.0 mmoles) was added and the mixture was heated to 70°C for 2 hours. DBU (1.0 mL) was added and the mixture was heated for a further 1 hour. The mixture was cooled and washed with 10 molar hydrochloric acid (x2), dried and evaporated to an oil (2.0 g, 88%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.45 - 7.49 (m, 2 H), 7.40 - 7.45 (m, 2 H), 7.28 - 7.32 (m, 4 H), 4.98 (s, 4 H), 4.02 (s, 2 H).

68b) *N*-({1,3-Bis[(2-chlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture of 1,3-bis[(2-chlorophenyl)methyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (2.0 g, 5.3 mmoles) and diisopropylethylamine (1.85 mL, 10.6 mmoles) was stirred in dichloromethane (35 mL) and treated with ethyl isocyanatoacetate (594 uL, 5.3 mmoles). The mixture was stirred for 5 hours, washed with 1 molar hydrochloric acid (x2), evaporated, taken up in ethanol – 6 molar sodium hydroxide and stirred overnight. The mixture was acidified and 20 extracted into ethyl acetate (x2). The extracts were washed with 1 molar hydrochloric acid evaporated, dried and evaporated. The title compound was recrystallized from acetic acid (1.59 g, 62%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.06 (br. s., 1 H), 10.13 (s, 1 H), 7.41 - 7.60 (m, 2 H), 7.30 (dd, *J*=5.81, 3.28 Hz, 4 H), 7.21 (dd, *J*=5.31, 3.79 Hz, 2 H), 5.09 (s, 4 H), 4.15 (s, 2 H).


Example 69



N-[(1,3-Dihexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Hexyl isocyanate (728 μ L, 5.0 mmol) was added to a solution of *n*-hexylamine (660 μ L, 5.0 mmol) in dichloromethane (100 mL) and the mixture stirred for 1 hour. Malonyl dichloride (486 μ L, 5.0 mmol) was added and the mixture was heated to gentle reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was redissolved in dichloromethane (50 mL) and diisopropylethylamine (1.73 mL, 10 mmol) and the mixture was treated with ethyl isocyanatoacetate (561 μ L, 5.0 mmol). After stirring overnight the mixture was washed with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 6 molar sodium hydroxide (2.0 mL). The mixture was stirred for 1 hour, acidified and extracted into ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid, dried and evaporated. The crude product was slurried in hexane to afford the title compound (890 mg, 45%). ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 13.10 (br. s, 1 H), 10.10 (t, $J=4.80$ Hz, 1 H), 4.13 (d, $J=5.81$ Hz, 2 H), 3.75 - 3.84 (m, 4 H), 1.53 (s, 4 H), 1.26 (s, 12 H), 0.82 - 0.90 (m, 6 H).

Example 70




N-[(1-Cyclohexyl-6-hydroxy-3-(2-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using 2-methylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 19% yield (390 mg) following the procedures described in example 54. ^1H NMR (400 MHz, CDCl_3) δ ppm 0.68 - 0.84 (m, 3 H) 1.14 - 1.43 (m, 8 H) 1.53 - 1.76 (m, 5 H) 1.76 - 1.90

(m, 4 H) 2.14 - 2.43 (m, 3 H) 4.18 - 4.27 (m, 2 H) 4.38 - 4.54 (m, 1 H) 4.62 - 4.87 (m, 2 H) 10.21 - 10.43 (m, 1 H)


Example 71



N-[(1-Cyclohexyl-6-hydroxy-3-(2-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using 2-aminonaphthalene in place of 4-methylcyclohexylamine, the title compound was prepared in 0.6% yield (12.9 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.04 - 1.19 (m, 1 H) 1.27 - 1.46 (m, 2 H) 1.57 - 1.93 (m, 6 H) 2.26 - 2.48 (m, 2 H) 4.06 - 4.21 (m, 1 H) 4.23 (d, *J*=5.6 Hz, 1 H) 4.72 - 4.91 (m, 1 H) 7.39 (dd, *J*=1.0, 7.3 Hz, 1 H) 7.47 - 7.65 (m, 4 H) 7.84 - 8.03 (m, 2 H) 10.21 (t, *J*=5.6 Hz, 1 H)

Example 72




N-[(1-Cyclohexyl-3-hexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Cyclohexyl isocyanate (635 uL, 5.0 mmoles) was added to a solution of *n*-hexylamine (660 uL, 5.0 mmoles) in dichloromethane (100 mL) and the mixture stirred for 1 hour. Malonyl dichloride (486 uL, 5.0 mmoles) was added and the mixture was heated to gentle reflux for 1 hour. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was redissolved in dichloromethane (50 mL) and diisopropylethylamine (1.73 mL, 10 mmoles) and the mixture was treated with ethyl isocyanatoacetate (561 uL, 5.0 mmoles). After stirring overnight the mixture was washed with 1 molar hydrochloric acid, dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 6 molar sodium hydroxide (2.0 mL). The mixture was stirred for 1 hour, acidified and extracted into ethyl acetate. The organic solution was washed with

1 molar hydrochloric acid, dried and evaporated to a brown oil. The crude material was stood in a freezer overnight in hexane to afford some solid. The liquors were concentrated and purified by preparative HPLC (acetonitrile-water-0.1% TFA) to give additional material which was combined with the previously obtained solid and recrystallized from ethanol-water to give the title compound (480 mg, 24%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.09 (br. s., 1 H), 10.15 (t, *J*=5.56 Hz, 1 H), 4.53 - 4.73 (m, 1 H), 4.05 - 4.18 (m, 2 H), 3.78 (t, 2 H), 2.16 - 2.36 (m, 2 H), 1.79 (d, *J*=12.38 Hz, 2 H), 1.42 - 1.71 (m, 5 H), 1.26 (s, 8 H), 1.03 - 1.19 (m, 1 H), 0.79 - 0.92 (m, 3 H).


Example 73



N-[(1,3-Dicycloheptyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using cycloheptylamine in place of 4-methylcyclohexylamine and cycloheptylisocyanate in place of cyclohexylisocyanate, the title compound was prepared in 7% yield (142.6 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.19 - 1.36 (m, 2 H) 1.37 - 1.92 (m, 17 H) 2.20 - 2.42 (m, 6 H) 4.15 (d, *J*=5.8 Hz, 2 H) 4.69 - 5.03 (m, 3 H) 10.20 - 10.46 (m, 1 H)

Example 74




N-[(1,3-Dicyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Method 1

Using cyclopentylamine in place of 4-methylcyclohexylamine and cyclopentylisocyanate in place of cyclohexylisocyanate, the title compound was prepared in 14% yield (263 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.50 - 1.66

(m, 4 H) 1.75 - 1.88 (m, 4 H) 1.88 - 2.00 (m, 4 H) 2.01 - 2.16 (m, 4 H) 2.56 - 2.71 (m, 1 H) 3.06 - 3.27 (m, 1 H) 4.14 (d, $J=5.6$ Hz, 2 H) 5.12 - 5.40 (m, 2 H) 10.28 - 10.41 (m, 1 H)

Example 75




5

N-{[1-Cyclohexyl-3-(2,3-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

Using 2,3-dimethylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 5% yield (85 mg) following the procedures described in example 54. LC/MS m/z 422 ($M+H^+$).

10

Example 76




15

4-[5-([(Carboxymethyl)amino]carbonyl)-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]cyclohexanecarboxylic acid

Using 4-aminocyclohexanecarboxylic acid in place of 4-methylcyclohexylamine, the title compound was prepared in 16% yield (151 mg) following the procedures described in example 54. LC/MS m/z 438 ($M+H^+$).

20


Example 77



N-{[1-Cyclohexyl-3-(4-ethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

Using 4-ethylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 20% yield (185 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.85 - 0.96 (m, 3 H) 1.10 - 1.40 (m, 8 H) 1.53 - 1.72 (m, 6 H) 1.73 - 1.89 (m, 3 H) 2.19 - 2.61 (m, 3 H) 3.85 - 4.04 (m, 1 H) 4.09 - 4.34 (m, 2 H) 4.59 - 4.85 (m, 2 H) 5.07 - 5.32 (m, 2 H) 10.30 - 10.426 (m, 1 H).


Example 78



cis-4-[3-Cyclohexyl-5-({[2-(ethyloxy)-2-oxoethyl]amino}carbonyl)-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid

Using *cis*-4-aminocyclohexanecarboxylic acid in place of 4-methylcyclohexylamine, the title compound was prepared in 9% yield (114 mg) following the procedures described in example 54. LC/MS *m/z* 466 (M+H⁺).

Example 79




N-{[1-Cyclohexyl-6-hydroxy-3-(1-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

Using 1-amino-1-methylcyclohexane in place of 4-methylcyclohexylamine, the title compound was prepared in 18% yield (595 mg) following the procedures described in example 54.

5 ¹H NMR (400 MHz, CDCl₃) δ ppm 0.97 - 1.18 (m, 3 H) 1.19 - 1.44 (m, 9 H) 1.46 - 1.74 (m, 5 H) 1.77 - 1.99 (m, 4 H) 2.22 - 2.40 (m, 2 H) 3.11 - 3.30 (m, 2 H) 4.07 - 4.37 (m, 2 H) 4.50 - 4.78 (m, 1 H) 10.15 - 10.35 (m, 1 H)

Example 80




10 3-[5-[[[(Carboxymethyl)amino]carbonyl]-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]cyclohexanecarboxylic acid

Using 3-aminocyclohexanecarboxylic acid in place of 4-methylcyclohexylamine, the title compound was prepared in 18% yield (184 mg) following the procedures described in example 54.

15 LC/MS m/z 438 (M+H⁺).

Example 81




20 *N*-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

A mixture of ethyl *N*-[(3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (300 mg, 0.88 mmoles), 2-bromoacetophenone (350 mg, 1.76 mmoles) and potassium carbonate (243 mg, 1.76 mmoles) in DMF (4 mL) was heated in a microwave synthesiser at 100°C for 15 minutes, then cooled and filtered. The residue was washed with dichloromethane (3 X 3 mL) and the combined filtrate was evaporated and purified by flash chromatography (ethyl acetate-hexane) to obtain the desired crude ester. The ester was dissolved

in ethanol (3 mL) and 1M aqueous NaOH (1 mL) and the solution stirred for 2 hours, then neutralized by addition of 1M aqueous HCl. The solid was collected, washed with water (3 X 4 mL) and dried under vacuum overnight to give the title compound (51 mg, 20%). ¹H NMR (400 MHz, CDCl₃) δ ppm 1.10 - 1.27 (m, 1 H) 1.27 - 1.45 (m, 2 H) 1.58 - 1.77 (m, 3 H) 1.77 - 1.91 (m, 2 H) 2.24 - 2.43 (m, 2 H) 3.56 - 5.09 (br s, 2 H), 4.19 - 4.26 (m, 2 H) 4.62 - 4.85 (m, 1 H) 5.31 - 5.41 (m, 2 H) 7.45 - 7.55 (m, 2 H) 7.58 - 7.66 (m, 1 H) 7.97 - 8.03 (m, 2 H) 10.04 - 10.42 (m, 1 H)


Example 82



N-[(1-Cyclohexyl-6-hydroxy-3-{2-[4-(methoxy)phenyl]-2-oxoethyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Using 2-bromo-4'-methoxyacetophenone in place of 2-bromoacetophenone, the title compound was prepared in 48% yield (196 mg) following the procedures described in example 81. LC/MS *m/z* 460 (M+H⁺).


Example 83



N-({1-Cyclohexyl-6-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

Using 2-bromo-4'-methylacetophenone in place of 2-bromoacetophenone, the title compound was prepared in 61% yield (241 mg) following the procedures described in example 81. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.10 - 1.43 (m, 4 H) 1.57 - 1.75 (m, 4 H) 1.77 - 1.90 (m, 2 H) 2.21 - 2.52 (m, 5 H) 4.11 - 4.29 (m, 2 H) 4.64 - 4.85 (m, 1 H) 5.26 - 5.39 (m, 2 H) 7.20 - 7.35 (m, 2 H) 7.89 (d, *J*=8.3 Hz, 2 H) 10.02 - 10.41 (m, 1 H)


Example 84



N-{[1-Cyclohexyl-3-(3,3-dimethyl-2-oxobutyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

Using 1-bromopinacolone in place of 2-bromoacetophenone, the title compound was prepared in 31% yield (114 mg) following the procedures described in example 81. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.01 - 1.45 (m, 5 H) 1.26 (s, 9 H) 1.57 - 1.76 (m, 3 H) 1.76 - 1.91 (m, 2 H) 2.22 - 2.43 (m, 2 H) 4.15 - 4.30 (m, 2 H) 4.62 - 4.79 (m, 1 H) 4.82 - 4.97 (m, 2 H) 9.97 - 10.39 (m, 1 H)


Example 85



N-([1-Cyclohexyl-3-[2-(4-fluorophenyl)-2-oxoethyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

Using 2-bromo-4'-fluoroacetophenone in place of 2-bromoacetophenone, the title compound was prepared in 69% yield (275 mg) following the procedures described in example 81. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.06 - 1.43 (m, 5 H) 1.55 - 1.76 (m, 3 H) 1.76 - 1.93 (m, 2 H) 2.23 - 2.43 (m, 2 H) 4.09 - 4.33 (m, 2 H) 4.65 - 4.84 (m, 1 H) 5.28 - 5.38 (m, 2 H) 7.13 - 7.23 (m, 2 H) 7.99 - 8.08 (m, 2 H) 10.01 - 10.52 (m, 1 H)

Example 86




N-({3-[2-(4-Cyanophenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

- 5 Using 2-bromo-4'-cyanoacetophenone in place of 2-bromoacetophenone, the title compound was prepared in 65% yield (259 mg) following the procedures described in example 81. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.05 - 1.45 (m, 5 H) 1.59 - 1.77 (m, 3 H) 1.77 - 1.91 (m, 2 H) 2.21 - 2.40 (m, 2 H) 4.18 - 4.29 (m, 2 H) 4.64 - 4.83 (m, 1 H) 5.29 - 5.41 (m, 2 H) 7.79 - 7.85 (m, 2 H) 8.09 (d, *J*=8.6 Hz, 2 H) 9.99 - 10.45 (m, 1 H)

10

Example 87




N-({3-[2-(1-Benzofuran-2-yl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

- 15 Using 1-(1-benzofuran-2-yl)-2-bromoethan-1-one in place of 2-bromoacetophenone, the title compound was prepared in 44% yield (183 mg) following the procedures described in example 81. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.04 - 1.44 (m, 5 H) 1.59 - 1.77 (m, 3 H) 1.77 - 1.91 (m, 2 H) 2.25 - 2.43 (m, 2 H) 4.16 - 4.28 (m, 2 H) 4.65 - 4.84 (m, 1 H) 5.30 - 5.40 (m, 2 H) 7.30 - 7.38 (m, 1 H) 7.46 - 7.56 (m, 1 H) 7.56 - 7.67 (m, 2 H) 7.69 - 7.78 (m, 1 H) 10.02 - 10.45 (m, 1 H)

20


Example 88



N-{[3-Cyclohexyl-6-hydroxy-1-(1-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

Using 1-aminonaphthalene in place of 4-methylcyclohexylamine, the title compound was prepared in 20% yield (257 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.07 - 1.43 (m, 4 H) 1.56 - 1.90 (m, 5 H) 2.27 - 2.48 (m, 2 H) 4.05 - 4.19 (m, 2 H) 4.23 (d, *J*=5.8 Hz, 1 H) 4.71 - 4.92 (m, 1 H) 7.37 - 7.46 (m, 1 H) 7.48 - 7.61 (m, 4H) 7.87 - 8.00 (m, 2 H) 9.99 - 10.46 (m, 1 H)


Example 89



N-{[3-Cyclohexyl-1-(4,4-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine

Using 4,4-dimethylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound was prepared in 3% yield (45 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.93 (s, 3 H) 1.02 (s, 3 H) 1.14 - 1.53 (m, 11 H) 1.56 - 1.72 (m, 3 H) 1.77 - 1.89 (m, 2 H) 2.26 - 2.43 (m, 2 H) 2.45 - 2.65 (m, 2 H) 4.15 - 4.32 (m, 2 H) 4.57 - 4.84 (m, 2 H) 10.20 - 10.40 (m, 1 H)


Example 90



N-[(1-Cyclohexyl-3-[(2,3-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 2,3-difluorobenzyl bromide (255 uL, 2.0 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from ethanol-water gave the title compound (140 mg, 32%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.11 (br. s., 1 H), 7.25 - 7.43 (m, 1 H), 7.08 - 7.23 (m, 1 H), 7.03 (t, *J*=7.07 Hz, 1 H), 5.08 (s, 2 H), 4.55 - 4.73 (m, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.12 - 2.35 (m, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.63 (s, 3 H), 1.20 - 1.38 (m, 2 H), 1.02 - 1.18 (m, 1 H)


Example 91



Ethyl N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycinate


A mixture of 1,3-dicyclohexyl-2,4,6-(1*H*,3*H*,5*H*)-pyrimidinetrione (660 mg, 2.25 mmoles), diisopropylethylamine (780 uL, 4.5 mmoles) and ethyl isocyanatoacetate (340 uL, 2.75 mmoles) in chloroform (20 mL) was stirred for 6 hours. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The solid residue was purified by flash chromatography (0-20% ethyl acetate in hexane) and crystallization from ethanol to give the title compound (250 mg, 25%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.57 (t, *J*=5.18 Hz, 1 H), 4.69 (t, 2 H), 4.44 (d, *J*=5.31 Hz, 2 H), 4.17 (q, *J*=7.24 Hz, 2 H), 2.25 (q, 4 H), 1.79 (d, *J*=12.88 Hz, 4 H), 1.55 - 1.72 (m, 6 H), 1.24 - 1.38 (m, 4 H), 1.22 (t, *J*=7.07 Hz, 3 H), 1.12 (q, *J*=12.88 Hz, 2 H).

Example 92



N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycine

A mixture of 1,3-dicyclohexyl-2,4,6-(1*H*,3*H*,5*H*)-pyrimidinetrione (660 mg, 2.25 mmoles),
 5 diisopropylethylamine (780 uL, 4.5 mmoles) and ethyl isothiocyanatoacetate (340 uL, 2.75
 mmoles) in chloroform (20 mL) was stirred overnight. The mixture was washed with 1 molar
 hydrochloric acid (x2), dried and evaporated. The solid residue was purified by flash
 chromatography (dichloromethane) and the fractions evaporated, dissolved in ethanol (5 mL, some
 heating) and treated with 1 molar sodium hydroxide (3 mL). The mixture was stirred for 30
 10 minutes and acidified to give a solid which recrystallized from ethanol-water to give the title
 compound (135 mg, 15%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.16 (s, 1 H), 12.54 (t, *J*=4.80
 Hz, 1 H), 4.69 (t, *J*=12.00 Hz, 2 H), 4.35 (d, *J*=5.05 Hz, 2 H), 2.25 (q, 4 H), 1.79 (d, *J*=12.38 Hz, 4
 H), 1.63 (d, *J*=12.38 Hz, 6 H), 1.29 (q, 4 H), 1.13 (q, 2 H).




15 Example 93

6-[5-[[[(Carboxymethyl)amino]carbonyl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]hexanoic acid

93a) Ethyl 6-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2H)-pyrimidinyl)hexanoate. Ethyl
 isocyanatohexanoate (790 mg, 4.26 mmoles) and cyclohexylamine (490 uL, 4.26 mmoles) were
 20 stirred together in dichloromethane (100 mL) for 2 hours. Malonyl dichloride (414 uL, 4.26
 mmoles) was added and the mixture was heated under gentle reflux for 2 hours. The mixture was
 purified by flash chromatography (dichloromethane to 5% methanol in dichloromethane) to give
 the title compound (1.07 g, 71%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.56 - 4.67
 (m, 1 H), 4.62 (tt, *J*=12.25, 3.79 Hz, 1 H), 4.13 (q, *J*=7.24 Hz, 2 H), 3.85 (t, 2 H), 2.31 (t, 2 H),
 25 2.26 (dq, 2 H), 1.85 (d, *J*=13.39 Hz, 2 H), 1.57 - 1.73 (m, 7 H), 1.29 - 1.43 (m, 4 H), 1.26 (t, *J*=7.07
 Hz, 3 H), 1.06 - 1.24 (m, 2 H).

93b) 6-[5-{{[(Carboxymethyl)amino]carbonyl}}-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]hexanoic acid. A mixture of ethyl 6-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2H)-pyrimidinyl)hexanoate (330 mg, 0.936 mmoles) and diisopropylethylamine (324 uL, 1.87 mmoles) in chloroform (30mL) was treated with ethyl isocyanatoacetate (126 uL, 1.12 mmoles) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was taken up in ethanol and treated with 1 molar sodium hydroxide (2 mL) and stirred for 1 hour. The mixture was acidified and extracted into ethyl acetate. The organic solution was washed with 1 molar hydrochloric acid, dried and evaporated. Crystallization from acetic acid afforded the title compound (160 mg, 40%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.06 (br. s., 1 H), 12.08 (br. s., 1 H), 10.15 (t, *J*=5.81 Hz, 1 H), 4.63 (t, *J*=9.22 Hz, 1 H), 4.12 (d, *J*=5.81 Hz, 2 H), 3.66 - 3.87 (m, 2 H), 2.26 (d, *J*=11.37 Hz, 2 H), 2.20 (t, *J*=7.33 Hz, 2 H), 1.79 (d, *J*=12.88 Hz, 2 H), 1.57 - 1.68 (m, 3 H), 1.46 - 1.57 (m, 4 H), 1.21 - 1.35 (m, 4 H), 1.04 - 1.19 (m, 1 H).


Example 94



6-[5-{{[(Carboxymethyl)amino]carbonothioyl}}-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]hexanoic acid

A mixture of ethyl 6-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2H)-pyrimidinyl)hexanoate (330 mg, 0.94 mmoles), diisopropylethylamine (324 uL, 1.87 mmoles) and ethyl isothiocyanatoacetate (139 uL, 1.12 mmoles) in chloroform (20 mL) was stirred for 7 days. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was purified by flash chromatography (hexane – 20% ethyl acetate in hexane) to give the title compound as a clear oil (250 mg, 60%). The diester was dissolved in ethanol (3 mL) and treated with 1 molar sodium hydroxide (2 mL). The mixture was stirred overnight, taken up in ethyl acetate and washed with 1 molar hydrochloric acid (x2), dried and evaporated. Crystallization from acetic acid afforded the title compound (160 mg, 40%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.13 (br s, 1 H), 12.50 (s, 1 H), 12.03 (br s, 1 H), 4.71 (m, 1 H), 4.35 (d, *J*=5.05 Hz, 2 H), 3.84 (t, *J*=7.20 Hz, 2 H), 2.10 – 2.38 (m, 4 H), 1.80 (d, *J*=12.63 Hz, 2 H), 1.42 – 1.71 (m, 7 H), 1.21 – 1.42 (m, 4 H), 1.01 – 1.22 (m, 1 H).


Example 95



N-[(1-Cyclohexyl-3-[(3,4-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 3,4-dichlorobenzyl bromide (480 μ L, 2.0 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from ethanol-water gave the title compound (154 mg, 33%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 10.12 (br. s., 1 H), 7.58 (dd, *J*=5.05, 3.03 Hz, 2 H), 7.29 (dd, *J*=8.34, 2.02 Hz, 1 H), 4.97 (s, 2 H), 4.62 (t, *J*=12.00 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.24 (q, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.63 (s, 3 H), 1.27 (q, *J*=12.88 Hz, 2 H), 1.11 (q, 1 H)


Example 96



N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (270 mg, 0.80 mmol) was dissolved in ethanol (2 mL) and 1M aqueous NaOH solution was added. The solution was stirred one hour at room temperature, then neutralized by addition of 1M aqueous HCl. The resulting solid was collected, washed with water, and dried under vacuum overnight to give the title compound (208 mg, 84%). LC/MS *m/z* 312 (*M*+*H*⁺).


Example 97



N-(3-cyclohexyl-6-hydroxy-1-[(trans-4-(methyloxy)cyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

Using *trans*-4-(methyloxy)cyclohexylamine hydrochloride in place of 4-methylcyclohexylamine, the title compound was prepared in 11% yield (541.6 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.12 - 1.50 (m, 6 H) 1.56 - 1.77 (m, 6 H) 1.78 - 1.90 (m, 2 H) 2.09 - 2.22 (m, 2 H) 2.25 - 2.55 (m, 4 H) 3.18 - 3.31 (m, 1 H) 3.37 (s, 3 H) 4.22 (d, *J*=5.3 Hz, 2 H) 4.62- 4.89 (m, 2 H) 10.22 - 10.41 (m, 1 H)


Example 98



N-(1-[1,1'-Bi(cyclohexyl)-4-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl)glycine

Using 1,1'-bi(cyclohexyl)-4-amine hydrochloride in place of 4-methylcyclohexylamine, the title compound was prepared in 19% yield (84 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 0.88 - 1.43 (m, 13 H) 1.56 - 1.76 (m, 11 H) 1.76 - 1.91 (m, 4 H) 2.26 - 2.43 (m, 4 H) 4.24 (d, *J*=5.8 Hz, 2 H) 4.59 - 4.82 (m, 2 H) 10.24 - 10.38 (m, 1 H)

Example 99




N-([6-Hydroxy-2,4-dioxo-1,3-bis(1-propylbutyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

99a) N,N'-Bis(1-propylbutyl)urea. A mixture of carbonyldiimidazole (3.0 g, 18.5 mmoles) and
 5 4-heptylamine (6.0 mL, 40 mmoles) in dimethylformamide (25 mL) was heated at 70°C for 3
 hours. The mixture was cooled and partitioned between ethyl acetate and 1 molar hydrochloric
 acid. The aqueous was extracted with ethyl acetate and the combined extracts washed with 1 molar
 hydrochloric acid, dried and evaporated to a solid (4.18 g, 88%). ¹H NMR (400 MHz, DMSO-*d*₆)
 δ ppm 5.34 (d, *J*=8.59 Hz, 2 H), 1.12 - 1.38 (m, 16 H), 0.85 (t, *J*=6.19 Hz, 12 H).

99b) 1,3-Bis(1-propylbutyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. *N,N*-bis(1-propylbutyl)urea
 (1.87 g, 7.29 mmoles) in chloroform (70 mL) was treated with malonyl dichloride (851 uL, 8.75
 mmoles) and heated at 70°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid
 (x2), dried and evaporated. Flash chromatography (hexane – 50% ethyl acetate in hexane) gave the
 15 title compound (660 mg, 28%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.78 (s, 2 H), 3.61
 (s, 2 H), 1.94 - 2.04 (m, 4 H), 1.58 - 1.67 (m, 4 H), 1.17 - 1.28 (m, 8 H), 0.90 (t, *J*=7.33 Hz, 12 H)

99c) N-([1,3-Bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine. A mixture of 1,3-bis(1-ethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-

20 pyrimidinetrione (660 mg, 2.0 mmoles) and diisopropylethylamine (690 uL, 4.0 mmoles) in
 dichloromethane (50 mL) was treated with ethyl isocyanatoacetate (270 uL, 2.4 mmoles) and
 stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and
 evaporated. The residue was dissolved in ethanol (6 mL) and treated with 6 molar sodium
 hydroxide (4.0 mL). The mixture was stirred for 72 hour, acidified and extracted with ethyl acetate
 25 (x2), dried and evaporated. The residue was stored at -10°C overnight to crystallize. The solid
 produced was slurried in hexane, collected and washed with hexane to give the title compound
 (310, 36%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.09 (s, 1 H), 10.19 (d, *J*=21.47 Hz, 1 H),
 4.82 (s, 2 H), 4.12 (d, *J*=3.54 Hz, 2 H), 2.02 (s, 4 H), 1.58 (s, 4 H), 1.16 (s, 8 H), 0.84 (t, *J*=7.33
 Hz, 12 H)



N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(methoxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

100a) 1-(2-Cyclopropylethyl)-3-{[3-(methoxy)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-

5 pyrimidinetrione. Cyclopropylethylamine hydrochloride (2.0 g, 16.44 mmoles) in dichloromethane (60 mL) was treated with diisopropylethylamine (2.84 mL, 16.44 mmoles) followed by 3-methoxyphenyl isocyanate (2.12 mL, 16.44 mmoles). The mixture was stirred for 1 hour, malonyl dichloride (1.92 mL, 19.73 mmoles) was added and the mixture heated under gentle reflux for 4 hours. The mixture was washed with 1 molar hydrochloric acid and purified by flash


10 chromatography (hexane to 30% ethyl acetate in hexane) to give the title compound which was obtained as a solid from hexane-diethyl ether (2.12 g, 42%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.37 (t, *J*=8.21 Hz, 1 H), 6.94 - 7.12 (m, 1 H), 6.69 - 6.88 (m, 2 H), 3.86 (s, 2 H), 3.78 - 3.85 (m, 2 H), 3.76 (s, 3 H), 1.43 (q, *J*=7.07 Hz, 2 H), 0.69 (dt, 1 H), 0.29 - 0.47 (m, 2 H), -0.09 - 0.12 (m, 2 H)

100b) *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(methoxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture 1-(2-cyclopropylethyl)-3-{[3-

(methoxy)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (2.12 g, 7.0 mmole) and diisopropylethylamine (2.42 mL, 14.0 mmoles) in dichloromethane (80 mL) was treated with ethyl isocyanatoacetate (942 uL, 8.4 mmoles) and stirred for 72 hours. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (10 mL) and treated with 6 molar sodium hydroxide (6.0 mL). The mixture was stirred for 2 hours, acidified and extracted with ethyl acetate (x2), dried and evaporated. The residue was purified by flash chromatography (1.0% methanol-0.1% acetic acid in dichloromethane to 3.0% methanol-

25 0.1% acetic acid in dichloromethane) to give the title compound (1.4 g, 50%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.12 (br. s, 1 H), 10.04 (s, 1 H), 8.35 (s, 1 H), 8.32 (d, *J*=8.08 Hz, 1 H), 7.76 - 7.87 (m, 2 H), 4.14 (d, *J*=5.56 Hz, 2 H), 3.87 - 3.97 (m, 2 H), 2.50 (s, 3 H), 1.50 (q, *J*=7.16 Hz, 2 H), 0.66 - 0.76 (m, 1 H), 0.37 - 0.46 (m, 2 H), 0.05 (q, *J*=4.80 Hz, 2 H)

Example 101




N-([3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-phenylcyclohexyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

Using 4-phenylcyclohexylamine in place of 4-methylcyclohexylamine, the title compound
 5 was prepared in 29% yield (173 mg) following the procedures described in example 54. ¹H NMR (400 MHz, CDCl₃) δ ppm 1.16 - 1.44 (m, 4 H) 1.56 - 1.91 (m, 8 H) 1.95 - 2.07 (m, 3 H) 2.27 - 2.43 (m, 2 H) 2.51 - 2.68 (m, 4 H) 4.26 (d, *J*=5.6 Hz, 2 H) 4.65 - 4.96 (m, 2 H) 7.15 - 7.25 (m, 3 H) 7.27 - 7.35 (m, 2 H) 10.27 - 10.38 (m, 1 H)

10

Example 102




N-([1-Cyclohexyl-3-[(3,4-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35
 15 mmoles) and 3,4-difluorobenzyl bromide (256 uL, 2.0 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50%
 20 ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from ethanol-water gave the title compound (138 mg, 32%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 10.12 (br. s., 1 H), 7.28 - 7.52 (m, 2 H), 7.05 - 7.23 (m, *J*=5.43, 3.16 Hz, 1 H), 4.96 (s, 2 H), 4.63 (t, *J*=12.00 Hz, 1 H), 4.13 (d,
 25 (m, 2 H), 7.05 - 7.23 (m, *J*=5.43, 3.16 Hz, 1 H), 4.96 (s, 2 H), 4.63 (t, *J*=12.00 Hz, 1 H), 4.13 (d,

$J=5.81$ Hz, 2 H), 2.25 (q, 2 H), 1.78 (d, $J=12.88$ Hz, 2 H), 1.63 (s, 3 H), 1.28 (q, $J=12.97$ Hz, 2 H), 1.11 (q, 1 H)

Example 103



N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

103a) 1-(2-Cyclopropylethyl)-3-{[4-(methyloxy)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-


pyrimidinetrione. Cyclopropylethylamine hydrochloride (1.62 g, 13.32 mmoles) in chloroform (80 mL) was treated with diisopropylethylamine (2.3 mL, 13.32 mmoles) followed by 4-methoxyphenyl isocyanate (1.73 mL, 13.32 mmoles). The mixture was stirred for 2 hours, malonyl dichloride (1.55 mL, 16.0 mmoles) was added and the mixture heated at 43°C for 4 hours. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (hexane to 35% ethyl acetate in hexane) to give the title compound which was obtained as a solid from hexane-diethyl ether (2.2 g, 54%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.13 (d, 2 H), 7.00 (d, $J=9.09$ Hz, 2 H), 3.85 (s, 2 H), 3.80 - 3.84 (m, 2 H), 3.79 (s, 3 H), 1.42 (q, $J=7.07$ Hz, 2 H), 0.62 - 0.77 (m, 1 H), 0.36 - 0.44 (m, 2 H), -0.00 - 0.06 (m, 2 H)

103b) *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-

tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture 1-(2-cyclopropylethyl)-3-{[4-(methyloxy)phenyl]methyl}-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (2.2 g, 7.27 mmole) and diisopropylethylamine (2.50 mL, 14.5 mmoles) in dichloromethane (80 mL) was treated with ethyl isocyanatoacetate (979 μ L, 8.7 mmoles) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (6 mL) and treated with 6 molar sodium hydroxide (5.0 mL). The mixture was stirred for 2 hours, acidified and extracted with ethyl acetate (x2), dried and evaporated. The residue was purified by flash chromatography (1.0% methanol-0.1% acetic acid in dichloromethane to 3.0% methanol-0.1% acetic acid in dichloromethane) to give the title compound (1.3 g, 44%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (s, 1 H), 10.08 (s, 1 H), 7.21 (d, $J=5.31$ Hz, 2 H), 6.97 - 7.04 (m, 2 H), 4.13 (d, $J=5.81$ Hz, 2 H), 3.89 - 3.97 (m, 2 H), 3.80 (s, 3 H), 1.48 (q, $J=6.91$ Hz, 2 H), 0.64 -

0.74 (m, $J=15.22, 12.25, 7.39, 5.05$ Hz, 1 H), 0.41 (ddd, $J=7.96, 5.68, 4.04$ Hz, 2 H), 0.02 (td, $J=5.18, 4.29$ Hz, 2 H)

Example 104



5


N-{[3-(2-Cyclopropylethyl)-6-hydroxy-1-(3-nitrophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

104a) 1-(2-Cyclopropylethyl)-3-(3-nitrophenyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione.

Cyclopropylethylamine hydrochloride (1.62 g, 13.32 mmoles) in chloroform (80 mL) was treated with diisopropylethylamine (2.3 mL, 13.32 mmoles) followed by 3-nitrophenyl isocyanate (2.19 g, 13.32 mmoles). The mixture was stirred for 2 hours, malonyl dichloride (1.55 mL, 16.0 mmoles) was added and the mixture heated at 43°C for 4 hours. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (hexane to 50% ethyl acetate in hexane) to give the title compound (1.66 g, 40%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.27 - 8.36 (m, 1 H), 8.22 (t, $J=2.02$ Hz, 1 H), 7.80 (d, $J=8.08$ Hz, 1 H), 7.71 - 7.77 (m, 1 H), 3.90 (s, 2 H), 3.84 (t, 2 H), 1.44 (q, $J=7.16$ Hz, 2 H), 0.62 - 0.80 (m, 1 H), 0.31 - 0.47 (m, 2 H), 0.05 (q, $J=4.80$ Hz, 2 H)

104b) *N*-{[1-(2-Cyclopropylethyl)-6-hydroxy-3-(3-nitrophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture 1-(2-cyclopropylethyl)-3-(3-nitrophenyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.66 g, 5.23 mmole) and diisopropylethylamine (1.80 mL, 10.5 mmoles) in dichloromethane (80 mL) was treated with ethyl isocyanatoacetate (704 uL, 6.27 mmoles) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (6 mL) and treated with 6 molar sodium hydroxide (5.0 mL). The mixture was stirred for 1 hour, acidified and extracted with ethyl acetate (x2), dried and evaporated. A solid was obtained from acetic acid-water, which was purified by trituration in boiling chloroform to give the title compound (800 mg, 37%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.12 (br. s, 1 H), 10.03 (s, 1 H), 8.35 (s, 1 H), 8.32 (ddd, $J=8.40, 1.64, 1.33$ Hz, 1 H), 7.82 - 7.88 (m, 1 H), 7.79 (t, $J=8.08$ Hz, 1 H), 4.14 (d, $J=5.81$ Hz, 2 H), 3.88 - 3.97 (m, 2 H), 1.50 (q, $J=7.16$ Hz, 2 H), 0.66 - 0.76 (m, 1 H), 0.42 (ddd, $J=7.96, 5.68, 4.04$ Hz, 2 H), 0.05 (td, $J=5.18, 4.29$ Hz, 2 H).

Example 105



N-({3-(2-Cyclopropylethyl)-6-hydroxy-2,4-dioxo-1-[4-(2-thienyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

105a) 1-(2-Cyclopropylethyl)-3-[4-(2-thienyl)phenyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione.

Cyclopropylethylamine hydrochloride (608 mg, 4.96 mmol) in chloroform (50 mL) was treated with diisopropylethylamine (2.1 mL, 12.0 mmol) followed by 2-(4-isocyanatophenyl) thiophene (1.0 g, 4.96 mmol). The mixture was stirred for 2 hours, malonyl dichloride (583 μ L, 6.0

mmol) was added and the mixture heated at 63°C for 2 hours. The mixture was washed with 1

molar hydrochloric acid and purified by flash chromatography (0-4.0% methanol in

dichloromethane) to give the title compound (630 mg, 36%) ¹H NMR (400 MHz, DMSO-*d*₆) δ

ppm 7.75 (d, *J*=8.59 Hz, 2 H), 7.61 (dd, *J*=5.05, 1.26 Hz, 1 H), 7.57 (dd, *J*=3.54, 1.01 Hz, 1 H),

7.27 (d, *J*=8.59 Hz, 2 H), 7.18 (dd, *J*=5.18, 3.66 Hz, 1 H), 3.89 (s, 2 H), 3.84 (t, 2 H), 1.44 (q, 2 H),

0.63 - 0.76 (m, 1 H), 0.37 - 0.46 (m, 2 H), 0.05 (q, *J*=4.80 Hz, 2 H)

105b) N-({3-(2-Cyclopropylethyl)-1-[4-(2-thienyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine.

A mixture of 1-(2-cyclopropylethyl)-3-[4-(2-thienyl)phenyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (630 mg, 1.78 mmol) and

diisopropylethylamine (616 μ L, 2.13 mmol) in dichloromethane (50 mL) was treated with ethyl

isocyanatoacetate (239 μ L, 2.13 mmol) and stirred overnight. The mixture was washed with 1

molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (5 mL)

and treated with 6 molar sodium hydroxide (2.0 mL). The mixture was stirred for 2 hour, acidified

and extracted with ethyl acetate (x2), dried and evaporated. Flash chromatography

(dichloromethane to 3.5% methanol-0.1% acetic acid) gave the title compound which was

recrystallized from dichloromethane (300 mg, 37%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm


13.11 (s, 1 H), 10.07 (s, 1 H), 7.75 (ddd, *J*=8.72, 2.53, 2.15 Hz, 2 H), 7.60 (ddd, *J*=9.79, 4.36, 1.01

Hz, 2 H), 7.36 (d, *J*=6.82 Hz, 2 H), 7.18 (dd, *J*=5.05, 3.54 Hz, 1 H), 4.14 (d, *J*=5.81 Hz, 2 H), 3.90

- 3.99 (m, 2 H), 1.50 (q, *J*=7.07 Hz, 2 H), 0.65 - 0.75 (m, 1 H), 0.42 (ddd, *J*=7.96, 5.68, 4.04 Hz, 2

H), 0.03 (td, *J*=5.18, 4.29 Hz, 2 H)

Example 106



N-[[1,3-Bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine


106a) *N,N*-Bis(1-ethylpropyl)urea. A mixture of carbonyldiimidazole (3.0 g, 18.5 mmoles) and
 5 3-aminopentane (4.66 mL, 40 mmoles) in dimethylformamide (25 mL) was heated at 70°C for 3
 hours. The mixture was cooled and partitioned between ethyl acetate and 1 molar hydrochloric
 acid. The aqueous was extracted with ethyl acetate and the combined extracts washed with 1 molar
 hydrochloric acid, dried and evaporated to a solid (3.6 g, 97%). ¹H NMR (400 MHz, DMSO-*d*₆) δ
 ppm 5.37 (s, 2 H), 1.55 (q, *J*=7.33 Hz, 4 H), 1.13 (s, 12 H), 0.76 (t, *J*=7.45 Hz, 6 H).

106b) 1,3-Bis(1-ethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. *N,N*-bis(1-ethylpropyl)urea
 (1.03 g, 5.15 mmoles) in chloroform (60 mL) was treated with malonyl dichloride (600 uL, 6.2
 mmoles) and heated at 70°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid
 (x2), dried and evaporated. Flash chromatography (hexane – 50% ethyl acetate in hexane) gave
 15 the title compound (540 mg, 39%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.45 - 4.76
 (m, 2 H), 3.66 (s, 2 H), 1.91 - 2.14 (m, 4 H), 1.55 - 1.87 (m, 4 H), 0.85 (t, *J*=7.45 Hz, 12 H)

106c) *N*-[[1,3-Bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl]glycine. A mixture of 1,3-bis(1-ethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-

20 pyrimidinetrione (540 mg, 2.0 mmoles) and diisopropylethylamine (690 uL, 4.0 mmoles) in
 dichloromethane (50 mL) was treated with ethyl isocyanatoacetate (270 uL, 2.4 mmoles) and
 stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and
 evaporated. The residue was dissolved in ethanol (6 mL) and treated with 6 molar sodium
 hydroxide (4.0 mL). The mixture was stirred for 72 hour, acidified and extracted with ethyl acetate
 25 (x2), dried and evaporated. The residue was stored at -10°C overnight, crystallized. The solid was
 slurried in hexane, collected, washed with hexane to give the title compound (300 mg, 40%). ¹H
 NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s, 1 H), 10.20 (br s, 1 H), 4.65 (br. s, 2 H), 4.13 (d,
J=5.81 Hz, 2 H), 2.02 (br. s, 4 H), 1.69 (br. s, 4 H), 0.77 (t, *J*=7.33 Hz, 12 H)


Example 107



N-[(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

Barbituric acid (512 mg, 4 mmol) was dissolved in a mixture of dichloromethane (3 mL) and DMF (5 mL). *N,N*-Diisopropylethylamine (2 mL) was added followed by ethyl isocyanatoacetate (645 mg, 5 mmol) and the solution was stirred overnight. After evaporation of all volatiles, the residue was re-dissolved in a mixture of ethanol (5 mL) and 1M aqueous NaOH (5 mL). After stirring at room temperature for one hour, this solution was neutralized by addition of 1M aqueous HCl. The resulting solid was collected, washed with water, and dried under vacuum overnight to give the title compound (202 mg, 22%). LC/MS *m/z* 230 (*M*+*H*⁺).

Example 108




N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 4-trifluoromethylbenzyl bromide (478 μ L, 2.0 mmoles) in dimethylacetamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from ethanol-water gave the title compound (176 mg, 37.5%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.13 (br. s., 1 H), 7.69 (d, *J*=8.08 Hz, 2 H), 7.51 (d, *J*=8.08 Hz, 2 H), 5.07 (s, 2 H), 4.64 (t, *J*=12.13 Hz, 1 H), 4.13 (d, *J*=5.81

Hz, 2 H), 2.13 - 2.32 (m, 2 H), 1.78 (d, $J=12.63$ Hz, 2 H), 1.50 - 1.72 (m, 3 H), 1.28 (q, 2 H), 1.11 (q, $J=13.22$ Hz, 1 H).

Example 109



5

N-[(1,3-Dibutyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

109a) 1,3-Dibutyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. 1-Butylisocyanate (2.25 mL, 20 mmol) and butylamine (1.98 mL, 20 mmol) were stirred together in dichloromethane (100 mL) for 2 hours. Malonyl dichloride (2.14 mL, 22 mmol) was added and the mixture was heated under gentle reflux for 2 hours. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. Flash chromatography (hexane – 25% ethyl acetate-hexane) gave the title compound (1.32 g, 27%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 3.65 - 3.77 (m, 6 H), 1.48 (tt, 4 H), 1.28 (tq, $J=7.49, 7.33$ Hz, 4 H), 0.89 (t, $J=7.33$ Hz, 6 H)

10


109b) *N*-[(1,3-Dibutyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine.

A mixture of 1,3-dibutyl-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.3 g, 5.5 mmol) and diisopropylethylamine (1.9 mL, 11.0 mmol) in dichloromethane (20 mL) was treated with ethyl isocyanatoacetate (673 μ L, 6.0 mmol) and stirred for 24 hours. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was taken up in ethanol (5 mL) and treated with 6 molar sodium hydroxide (3 mL) and stirred for 2 hours. The mixture was acidified with 1 molar hydrochloric acid and stirred for 30 minutes to give a solid which was recrystallized from acetic acid-water to afford the title compound (1.2 g, 64%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.11 (t, $J=6.19$ Hz, 1 H), 4.13 (d, $J=5.81$ Hz, 2 H), 3.81 (t, 4 H), 1.43 - 1.63 (m, 4 H), 1.14 - 1.41 (m, 4 H), 0.89 (t, $J=7.33$ Hz, 6 H).

20

25


Example 110



N-{[1,3-Bis(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 110a) *N,N'*-Bis(2-cyclopropylethyl)urea. A mixture of cyclopropylethylamine hydrochloride (5.15 g, 42.35 mmol), sodium carbonate (4.56 g, 43 mmol) and carbonyldiimidazole (2.99 g, 18.4 mmol) in dimethylformamide (30 mL) was sealed in a pressure flask and heated at 100°C for 2 hours. The mixture was acidified with 1 molar hydrochloric acid and extracted into ethyl acetate (x2). The combined extracts were washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (3.28 g, 79%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 5.77 (br. s., 2 H), 3.03 (t, *J*=6.95 Hz, 4 H), 1.25 (q, *J*=7.07 Hz, 4 H), 0.50 - 0.76 (m, 2 H), 0.26 - 0.48 (m, 4 H), -0.17 - 0.16 (m, 4 H)
- 110b) 1,3-Bis(2-cyclopropylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (2.02 mL, 20.8 mmol) was added to a solution of *N,N'*-bis(2-cyclopropylethyl)urea (3.26 g, 16.6 mmol) in dichloromethane (200 mL) and the mixture was heated under gentle reflux for 2 hours. The mixture was washed with 1 molar hydrochloric acid, evaporated and purified by flash chromatography (hexane – 25% ethyl acetate-hexane) gave the title compound (1.05 g, 24%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 3.94 (t, 4 H), 3.61 (s, 2 H), 1.46 (q, 4 H), 0.55 - 0.75 (m, 2 H), 0.33 - 0.49 (m, 4 H), -0.04 - 0.08 (m, 4 H)
- 110c) *N*-{[1,3-Bis(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of 1,3-bis(2-cyclopropylethyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.05 g, 3.97 mmol) and diisopropylethylamine (1.51 mL, 8.7 mmol) in dichloromethane (50 mL) was treated with ethyl isocyanatoacetate (980 μL, 8.7 mmol) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was taken up in ethanol (6 mL) and treated with 6 molar sodium hydroxide (4 mL) and stirred for 2 hours. The mixture was acidified with 1 molar hydrochloric acid and stirred for 30 minutes to give a solid which was recrystallized from acetic acid-water to afford the title compound (1.1 g, 76%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.09 (br. s, 1 H), 10.10 (t, *J*=5.81 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.86 - 3.95 (m, 4 H), 1.45 (q, *J*=7.07 Hz, 4 H), 0.62 - 0.72 (m, *J*=15.13, 12.28, 7.33, 4.93 Hz, 2 H), 0.38 (ddd, *J*=7.96, 5.68, 4.04 Hz, 4 H), -0.00 (q, *J*=4.80 Hz, 4 H)

Example 111




N-{[6-Hydroxy-1,3-bis(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

111a) *N,N'*-Bis(2-methylpropyl)urea. A mixture of isobutylamine (3.98 mL, 40 mmoles) and carbonyldiimidazole (3.0 g, 18.5 mmoles) in dimethylformamide (6 mL) was sealed in a pressure flask and heated at 75°C for 2 hours. The mixture was acidified with 1 molar hydrochloric acid and extracted into ethyl acetate (x2). The combined extracts were washed with 1 molar hydrochloric acid, dried and evaporated to give the title compound (3.2 g, 93%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 5.79 (br. s., 2 H), 2.81 (d, *J*=6.82 Hz, 4 H), 1.59 (dq, *J*=13.39, 6.69 Hz, 2 H), 0.82 (d, *J*=6.82 Hz, 12 H)

111b) 1,3-Bis(2-methylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Malonyl dichloride (2.2 mL, 22.3 mmoles) was added to a solution of *N,N'*-bis(2-methylpropyl)urea (3.2 g, 18.6 mmoles) in dichloromethane (175 mL) and the mixture was heated under gentle reflux for 2 hours. The mixture was washed with 1 molar hydrochloric acid, evaporated and purified by flash chromatography (hexane – 25% ethyl acetate-hexane) gave the title compound (3.38 g, 76%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 3.75 (d, *J*=7.33 Hz, 4 H), 3.70 (s, 2 H), 2.07 (dq, *J*=13.89, 7.07 Hz, 2 H), 0.92 (d, *J*=6.82 Hz, 12 H)

111c) *N*-{[6-Hydroxy-1,3-bis(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of 1,3-bis(2-methylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (3.3 g, 13.73 mmoles) and diisopropylethylamine (5.2 mL, 30 mmoles) in dichloromethane (100mL) was treated with ethyl isocyanatoacetate (3.36 mL, 30 mmoles) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated to a solid which was slurried in hexane and collected. The solid was taken up in ethanol (10 mL) and treated with 6 molar sodium hydroxide (6 mL) and stirred for 2 hours. The mixture was acidified with 6 molar hydrochloric acid and diluted with 6 molar hydrochloric acid stirred for 30 minutes to give a solid which was recrystallized from acetic acid-water to afford the title compound (3.15 g, 67%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s, 1 H), 10.13 (t, *J*=5.81 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.67 (d, *J*=7.33 Hz, 4 H), 2.02 (dq, *J*=13.80, 6.92 Hz, 2 H), 0.85 (d, *J*=6.82 Hz, 12 H)

Example 112




N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

112a) 1-(2-Cyclopropylethyl)-3-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4,6(1H,3H,5H)-pyrimidinetrione. Cyclopropylethylamine hydrochloride (588 mg, 4.84 mmol) in chloroform (50 mL) was treated with diisopropylethylamine (2.1 mL, 12.0 mmol) followed by 3-(3-isocyanatophenyl)-5-methyl-1,2,4-oxadiazole (973 mg, 4.84 mmol). The mixture was stirred for 2 hours, malonyl dichloride (583 μ L, 6.0 mmol) was added and the mixture heated at 63°C for 2 hours. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (0-4.0% methanol in dichloromethane) to give the title compound (425 mg, 25%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 8.19 (ddd, *J*=7.96, 1.39, 1.26 Hz, 1 H), 7.95 (t, *J*=1.77 Hz, 1 H), 7.64 (t, *J*=8.08 Hz, 1 H), 7.36 (ddd, *J*=7.96, 2.15, 1.01 Hz, 1 H), 4.03 - 4.09 (m, 2 H), 3.89 (s, 2 H), 2.68 (s, 3 H), 1.54 - 1.57 (m, 1 H), 0.67 - 0.77 (m, 1 H), 0.46 - 0.52 (m, 2 H), 0.10 (td, *J*=5.24, 4.42 Hz, 2 H).

112b) N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture of 1-(2-cyclopropylethyl)-3-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4,6(1H,3H,5H)-pyrimidinetrione (418 mg, 1.18 mmol) and diisopropylethylamine (408 μ L, 2.36 mmol) in dichloromethane (50 mL) was treated with ethyl isocyanatoacetate (160 μ L, 1.41 mmol) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 6 molar sodium hydroxide (2.0 mL). The mixture was stirred for 2 hours, acidified and extracted with ethyl acetate (x2), dried and evaporated. Flash chromatography (dichloromethane to 3.5% methanol-0.1% acetic acid) gave the title compound which was recrystallized from acetic acid - water (290 mg, 54%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s, 1 H), 10.06 (br. s, 1 H), 8.05 (d, *J*=7.83 Hz, 1 H), 7.98 (s, 1 H), 7.67 (t, *J*=7.83 Hz, 1 H), 7.55 (d, *J*=7.33 Hz, 1 H), 4.14 (d, *J*=5.81 Hz, 2 H), 3.88 - 3.98 (m, 2 H), 2.68 (s, 3 H), 1.50 (q, *J*=7.16 Hz, 2 H), 0.66 - 0.76 (m, 1 H), 0.42 (ddd, *J*=7.83, 5.68, 4.17 Hz, 2 H), -0.01 - 0.08 (m, 2 H).

Example 113




N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

- 5 113a) 1-(2-Cyclopropylethyl)-3-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. Cyclopropylethylamine hydrochloride (620 mg, 5.1 mmol) in chloroform (50 mL) was treated with diisopropylethylamine (2.1 mL, 12.0 mmol) followed by 4-(4-isocyanatophenyl)-2-methyl-1,3-thiazole (1.1 g, 5.1 mmol). The mixture was stirred for 2 hours, malonyl dichloride (583 μ L, 6.0 mmol) was added and the mixture heated at 63°C for 2 hours.
- 10 The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (0-7.0% methanol in dichloromethane) to give the title compound (620mg, 33%) ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 8.03 (d, *J*=8.59 Hz, 2 H), 7.39 (s, 1 H), 7.26 (d, *J*=8.84 Hz, 2 H), 4.01 - 4.10 (m, 2 H), 3.88 (s, 2 H), 2.81 (s, 3 H), 1.58 (q, 2 H), 0.67 - 0.78 (m, 1 H), 0.44 - 0.50 (m, 2 H), 0.06 - 0.13 (m, 2 H)

15 113b) *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine. A mixture of 1-(2-cyclopropylethyl)-3-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (618 mg, 1.67 mmol) and diisopropylethylamine (578 μ L, 3.34 mmol) in dichloromethane (50 mL) was treated with ethyl isocyanatoacetate (224 μ L, 2.0 mmol) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 6 molar sodium hydroxide (2.0 mL). The mixture was stirred for 2 hour, acidified and extracted with ethyl acetate (x2), dried and evaporated. Flash chromatography (dichloromethane to 3.5% methanol-0.1% acetic acid) gave the title compound which was obtained

20 as a solid from diethyl ether. (210 mg, 27%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s, 1 H), 10.08 (br. s, 1 H), 7.97 - 8.05 (m, 3 H), 7.37 (d, *J*=6.82 Hz, 2 H), 4.14 (d, *J*=5.56 Hz, 2 H), 3.88 - 3.98 (m, 2 H), 2.74 (s, 3 H), 1.50 (q, *J*=7.07 Hz, 2 H), 0.65 - 0.75 (m, 1 H), 0.37 - 0.46 (m, 2 H), 0.03 (q, *J*=4.72 Hz, 2 H).

Example 114



N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-piperidiny)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

114a) Phenylmethyl 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-piperidinecarboxylate. A mixture of benzyl 4-hydroxy-1-piperidine carboxylate (2.0 g, 8.5 mmoles), phthalimide (2.5 g, 17 mmoles), triphenylphosphine (4.46 g, 17 mmoles) and diisopropyl azodicarboxylate (3.345 mL, 17 mmoles) were stirred together in tetrahydrofuran (60 mL) for 5 hours. The mixture was evaporated onto silica gel and chromatographed (hexane to 60% ethyl acetate – hexane). The fractions afforded crystalline product on standing (1.5 g, 48%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.76 - 7.94 (m, 5 H), 7.37 - 7.41 (m, 3 H), 7.30 - 7.37 (m, 1 H), 4.71 - 4.83 (m, 1 H), 4.18 - 4.29 (m, 1 H), 4.14 (d, *J*=13.64 Hz, 2 H), 2.16 (dd, 2 H), 1.73 (d, *J*=10.36 Hz, 2 H), 1.18 (d, *J*=6.32 Hz, 2 H)

114b) Phenylmethyl 4-amino-1-piperidinecarboxylate. A mixture of phenylmethyl 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-piperidinecarboxylate (1.5 g, 4.11 mmoles) and 25% hydrazine hydrate (10.0 mL) in ethanol (20 mL) was heated under reflux for 30 minutes. The mixture was evaporated, re-diluted with ethanol and re-evaporated to a solid. The solid was slurried in diethyl ether, collected, washed with diethyl ether and the filtrate evaporated to give the title compound as an oil (quant.) ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 7.25 - 7.45 (m, 5 H), 5.14 (s, 2 H), 4.89 - 5.07 (m, 1 H), 3.18 - 3.42 (m, 2 H), 2.76 - 2.95 (m, 2 H), 1.74 - 1.94 (m, 2 H), 1.51 - 1.68 (m, 2 H), 1.28 (d, *J*=6.06 Hz, 2 H).


114c) Phenylmethyl 4-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2H)-pyrimidinyl)-1-piperidinecarboxylate. A mixture of phenylmethyl 4-amino-1-piperidinecarboxylate (700 mg, 2.98 mmoles) and cyclohexyl isocyanate (457 uL, 3.6 mmoles) was stirred in chloroform (60 mL) for 2 hours. Malonyl dichloride (350 uL, 3.6 mmoles) was added and the mixture was stirred at 50°C for 2 hours. The mixture was washed with 1 molar hydrochloric acid (x2) and evaporated onto silica gel. Flash chromatography (dichloromethane to 30% methanol in dichloromethane) gave the title compound (350 mg, 80%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.24 - 7.47 (m, 5 H), 5.10 (s, 2 H), 4.61 - 4.78 (m, 1 H), 4.35 - 4.52 (m, 1 H), 4.09 (d, *J*=10.86 Hz, 2 H), 3.70 (s, 2 H), 2.85 (d,

$J=26.02$ Hz, 2 H), 2.20 - 2.33 (m, 2 H), 2.14 (dd, 1 H), 1.78 (d, 2 H), 1.58 (d, $J=11.12$ Hz, 4 H), 1.00 - 1.34 (m, 5 H).

114d) *N*-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-piperidinyl)-1,2,3,4-tetrahydro-5-

pyrimidinyl]carbonyl}glycine. A mixture of phenylmethyl 4-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2*H*)-pyrimidinyl)-1-piperidinecarboxylate (530 mg, 1.24 mmol) and diisopropylethylamine (536 μ L, 3.1 mmol) in chloroform (50 mL) was treated with ethyl isocyanatoacetate (225 μ L, 2.0 mmol) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in isopropanol (30 mL), the solution flushed with argon and 10% palladium on charcoal catalyst (100 mg) added. The mixture was shaken in a hydrogen atmosphere at 50 psi for 2 hours. The mixture was filtered, evaporated and treated with 1 molar sodium hydroxide solution overnight. Acidified and extracted into ethyl acetate. Preparative HPLC (10 to 80% acetonitrile-water-0.1%TFA) gave the title compound (120 mg, 24%). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 13.17 (s, 1 H), 10.18 (s, 1 H), 8.74 (d, $J=11.12$ Hz, 1 H), 8.32 - 8.40 (m, 1 H), 8.29 (s, 1 H), 4.95 (t, $J=12.63$ Hz, 1 H), 4.63 (t, $J=12.63$ Hz, 1 H), 4.15 (d, $J=5.81$ Hz, 2 H), 3.36 (d, $J=12.13$ Hz, 2 H), 3.02 (q, $J=12.55$ Hz, 2 H), 2.61 - 2.73 (m, 2 H), 2.20 - 2.31 (m, 2 H), 1.79 (d, $J=12.38$ Hz, 4 H), 1.62 (s, 3 H), 1.22 - 1.34 (m, 2 H), 1.10 (d, $J=16.42$ Hz, 1 H).

Example 115



N-({3-(2-Cyclopropylethyl)-1-[4-(2-furanyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine

115a) 1-(2-Cyclopropylethyl)-3-[4-(2-furanyl)phenyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione.


Cyclopropylethylamine hydrochloride (693 mg, 5.67 mmol) in chloroform (50 mL) was treated with diisopropylethylamine (1.04 mL, 6.0 mmol) followed by 2-(4-isocyanatophenyl) furan (1.05 g, 5.67 mmol). The mixture was stirred for 2 hours, malonyl dichloride (665 μ L, 6.84 mmol) was added and the mixture heated at 63°C for 2 hours. The mixture was washed with 1 molar hydrochloric acid and purified by flash chromatography (0-3.5% methanol in dichloromethane) to give the title compound (330 mg, 17%). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 7.75 (d, $J=8.59$ Hz, 2 H), 7.59 - 7.63 (m, 1 H), 7.55 - 7.59 (m, 1 H), 7.27 (d, $J=8.59$ Hz, 2 H), 7.18 (dd, $J=5.05$,

3.54 Hz, 1 H), 3.88 (s, 2 H), 3.84 (t, 2 H), 1.44 (q, $J=7.33$ Hz, 2 H), 0.63 - 0.76 (m, 1 H), 0.36 - 0.44 (m, 2 H), 0.01 - 0.07 (m, 2 H)

115b) *N*-({3-(2-Cyclopropylethyl)-1-[4-(2-furanyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-

5 tetrahydro-5-pyrimidinyl}carbonyl}glycine. A mixture 1-(2-cyclopropylethyl)-3-[4-(2-furanyl)phenyl]-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (330 mg, 0.976 mmoles) and diisopropylethylamine (337 μ L, 1.95 mmoles) in dichloromethane (80 mL) was treated with ethyl isocyanatoacetate (131 μ L, 1.17 mmoles) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was dissolved in ethanol (5 mL) and treated with 6 molar sodium hydroxide (2.0 mL). The mixture was stirred for 2 hour, acidified and extracted with ethyl acetate (x2), dried and evaporated. Flash chromatography (dichloromethane to 3.5% methanol-0.1% acetic acid); material still impure, re-chromatographed (hexane-ethyl acetate) gave the title compound (30 mg, 7%). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 13.10 (s, 1 H), 10.08 (br. s., 1 H), 7.80 (s, 2 H), 7.78 (s, 1 H), 7.36 (d, $J=7.33$ Hz, 2 H), 7.04 (d, $J=3.28$ Hz, 1 H), 6.64 (dd, $J=3.28$, 1.77 Hz, 1 H), 4.14 (d, $J=5.81$ Hz, 2 H), 3.94 (t, 2 H), 1.50 (q, $J=6.65$ Hz, 2 H), 0.63 - 0.77 (m, 1 H), 0.36 - 0.46 (m, 2 H), -0.01 - 0.07 (m, 2 H).

Example 116



20 *N,N'*-Bis(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl}glycine


116a) *N,N'*-Bis(1,1-dimethylpropyl)urea. A mixture of carbonyldiimidazole (3.0 g, 18.5 mmoles) and *t*-amylamine (4.7 mL, 40 mmoles) in dimethylformamide (25 mL) was heated at 70°C for 3 hours. The mixture was cooled and partitioned between ethyl acetate and 1 molar hydrochloric acid. The aqueous was extracted with ethyl acetate and the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated to a solid (2.9 g, 78%). ^1H NMR (400 MHz, DMSO- d_6) δ ppm 5.37 (s, 2 H), 1.55 (q, $J=7.33$ Hz, 4 H), 1.13 (s, 12 H), 0.76 (t, $J=7.45$ Hz, 6 H).

116b) 1,3-Bis(1,1-dimethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. *N,N'*-bis(1,1-dimethylpropyl)urea (1.6 g, 8.0 mmoles) in chloroform (60 mL) was treated with malonyl dichloride (935 μ L, 9.6 mmoles) and heated at 70°C for 3 hours. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated. Flash chromatography (hexane - 50% ethyl

acetate in hexane) gave the title compound (960 mg, 44%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 3.49 (s, 2 H), 2.04 (q, *J*=7.41 Hz, 4 H), 1.55 (s, 12 H), 0.85 (t, *J*=7.45 Hz, 6 H).

- 5 116c) *N*-{[1,3-Bis(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of 1,3-bis(1,1-dimethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (960 mg, 3.5 mmol) and diisopropylethylamine (1.21 mL, 7.0 mmol) in dichloromethane (50 mL) was treated with ethyl isocyanatoacetate (482 μ L, 4.3 mmol) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and
- 10 evaporated. The residue was dissolved in ethanol (10 mL) and treated with 6 molar sodium hydroxide (5.0 mL). The mixture was stirred for 72 hour, acidified and extracted with ethyl acetate (x2), dried and evaporated. The residue was stored at -10°C overnight, crystallized. The solid was slurried in hexane, collected, washed with hexane to give the title compound (600 mg, 46%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.71 (br. s, 1 H), 10.12 (t, *J*=6.06 Hz, 1 H), 4.08 (d, *J*=5.81
- 15 Hz, 2 H), 2.00 - 2.10 (m, 4 H), 1.54 (s, 12 H), 0.79 (m, 6 H).

Example 117




N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

- 20 117a) Phenylmethyl 3-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2*H*)-pyrimidinyl)-1-piperidinecarboxylate. A mixture of benzyl 3-aminopiperidine-1-carboxylate hydrochloride (1.51 g, 5.57 mmol), diisopropylethylamine (965 μ L, 5.57 mmol) and cyclohexylisocyanate (708 μ L, 5.57 mmol) were stirred together in dichloromethane (60 mL) overnight. The mixture was
- 25 washed with 1 molar hydrochloric acid (x2) and the solution dried. Malonyl dichloride (650 μ L, 6.68 mmol) was added and the mixture was heated under gentle reflux for 4 hours. The mixture was washed with 1 molar hydrochloric acid (x2) and the solution dried and evaporated. The title compound was obtained as a solid from diethyl ether (1.0 g, 42%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.24 - 7.47 (m, 5 H), 5.09 (s, 2 H), 4.35 - 4.58 (m, 2 H), 3.98 (d, 2 H), 3.68 (d, *J*=4.29
- 30 Hz, 2 H), 3.35 - 3.60 (m, 1 H), 2.32 (q, 1 H), 2.07 - 2.21 (m, 2 H), 1.66 - 1.87 (m, 5 H), 1.53 - 1.65 (m, 3 H), 1.36 - 1.50 (m, 1 H), 1.26 (q, *J*=13.05 Hz, 2 H), 1.03 - 1.15 (m, 1 H)

117b) Phenylmethyl 3-[3-cyclohexyl-5-({[2-(ethyloxy)-2-oxoethyl]amino}carbonyl)-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]-1-piperidinecarboxylate. A mixture of phenylmethyl 3-(3-cyclohexyl-2,4,6-trioxotetrahydro-1(2H)-pyrimidinyl)-1-piperidinecarboxylate (1.0 g, 3.5 mmole) and diisopropylethylamine (1.2 mL, 7.0 mmoles) in dichloromethane (60 mL) was treated with ethyl isocyanatoacetate (450 μ L, 4.0 mmoles) and stirred overnight. The mixture was washed with 1 molar hydrochloric acid (x2), dried and evaporated to a glassy solid (1.3 g, 67%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 10.17 (br. s., 1 H), 7.15 - 7.51 (m, 5 H), 4.93 - 5.26 (m, 2 H), 4.50 - 4.79 (m, 2 H), 4.17 - 4.27 (m, 2 H), 4.08 - 4.17 (m, 2 H), 3.93 - 4.07 (m, 2 H), 3.51 - 3.73 (m, 1 H), 2.58 - 2.85 (m, 1 H), 2.33 - 2.48 (m, 1 H), 2.11 - 2.34 (m, 2 H), 1.68 - 1.86 (m, 4 H), 1.62 (d, *J*=11.62 Hz, 3 H), 1.35 - 1.53 (m, 1 H), 1.24 - 1.34 (m, 2 H), 1.16 - 1.26 (m, 4 H), 1.02 - 1.18 (m, 1 H)

117c) N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine hydrobromide. Phenylmethyl 3-[3-cyclohexyl-5-({[2-(ethyloxy)-2-oxoethyl]amino}carbonyl)-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl]-1-piperidinecarboxylate (1.2 g, 2.15 mmoles) was stirred in a mixture of acetic acid (30 mL) and 48% hydrobromic acid (5.0 mL) for 40 hours – reaction incomplete. The mixture was then heated at 60°C for 2 hours, diluted with water and extracted with ethyl acetate (x5). The combined extracts were dried and evaporated, and recrystallized from diethyl ether – hexane to give the title compound (160 mg, 20%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 12.84 (br. s., 1 H), 10.11 (s, 1 H), 8.86 (s, 1 H), 5.12 (s, 1 H), 4.63 (t, *J*=12.00 Hz, 1 H), 4.09 (s, 2 H), 3.66 (t, *J*=11.37 Hz, 1 H), 3.28 (d, *J*=10.61 Hz, 2 H), 2.77 (t, *J*=11.12 Hz, 1 H), 2.36 (dd, *J*=12.38, 3.54 Hz, 1 H), 2.22 - 2.32 (m, 2 H), 1.89 (d, *J*=12.63 Hz, 1 H), 1.69 - 1.81 (m, 4 H), 1.55 - 1.67 (m, 4 H), 1.27 (q, *J*=12.88 Hz, 2 H), 1.11 (q, *J*=12.97 Hz, 1 H)


Example 118



N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(1-{[(phenylmethyl)oxy]carbonyl}-3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

Phenylmethyl 3-[3-cyclohexyl-5-({[2-(ethyloxy)-2-oxoethyl]amino}carbonyl)-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]-1-piperidinecarboxylate (100 mg, 0.18 mmoles) was dissolved in ethanol (3.0 mL) and treated with 6 molar sodium hydroxide (1.5 mL). The mixture was stirred for 2 hours, acidified and extracted with ethyl acetate (x2). The combined extracts were washed with 1 molar hydrochloric acid, dried and evaporated to a foam (80 mg, 84%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (s, 1 H), 10.17 (s, 1 H), 7.30 - 7.40 (m, 5 H), 5.10 (s, 2 H), 4.57 - 4.69 (m, 2 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.95 - 4.05 (m, 2 H), 3.64 (s, 1 H), 3.37 (s, 1 H), 2.73 (s, 1 H), 2.36 - 2.48 (m, 1 H), 2.25 (q, *J*=11.62 Hz, 2 H), 1.70 - 1.82 (m, 4 H), 1.62 (d, *J*=11.37 Hz, 3 H), 1.38 - 1.50 (m, 1 H), 1.21 - 1.33 (m, 2 H), 1.06 - 1.18 (m, 1 H)


Example 119



N-{[1-(1-Acetyl-3-piperidiny)-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

A solution of *N*-{[3-cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidiny)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine (500 mg, 1.26 mmoles) in acetic acid (5.0 mL) and acetic anhydride (5.0 mL) was heated at 130°C for 2 hours. The mixture was cooled, diluted with ethyl acetate and washed with 1 molar hydrochloric acid (x3), dried and evaporated. Flash chromatography (dichloromethane to 4% methanol-0.1% acetic acid in dichloromethane) and recrystallization from ethanol – water gave the title compound (170 mg, 31%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.17 (s, 1 H), 4.46 - 4.73 (m, 2 H), 4.25 - 4.46 (m, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 3.67 - 3.92 (m, *J*=4.55 Hz, 1 H), 3.24 - 3.43 (m, 1 H), 2.94 (t, *J*=12.63 Hz, 1 H), 2.34 - 2.48 (m, 1 H), 2.25 (m, 2 H), 1.97, 2.02 (2 x s, 3 H), 1.69 - 1.87 (m, 4 H), 1.62 (m, 3 H), 1.41 - 1.57 (m, 1 H), 1.19 - 1.37 (m, 2 H), 0.97 - 1.18 (m, 1 H)


Example 120



N-[(1-Cyclohexyl-3-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 4-fluoro-2-trifluoromethylbenzyl bromide (455 mg, 1.77 mmoles) in dimethylacetamide (6 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from hexane gave the title compound (184 mg, 38%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.11 (br. s., 1 H), 7.67 (dd, *J*=9.09, 2.78 Hz, 1 H), 7.45 (ddd, *J*=8.40, 2.65 Hz, 1 H), 7.29 (dd, *J*=8.59, 5.31 Hz, 1 H), 5.13 (s, 2 H), 4.64 (t, *J*=12.00 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.24 (q, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.53 - 1.73 (m, 3 H), 1.28 (q, *J*=12.72 Hz, 2 H), 1.10 (q, *J*=12.63 Hz, 1 H)

Example 121




N-[(3-[(2-Bromophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 2-bromobenzyl bromide (480 mg, 1.92 mmoles) in dimethylacetamide (6 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from ethanol-water gave the title compound (150 mg,

38%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 10.12 (br. s., 1 H), 7.65 (dd, *J*=7.96, 1.14 Hz, 1 H), 7.32 (ddd, *J*=7.52, 1.14 Hz, 1 H), 7.22 (ddd, *J*=7.64, 1.64 Hz, 1 H), 7.03 (dd, *J*=7.58, 1.26 Hz, 1 H), 5.00 (s, 2 H), 4.65 (t, *J*=12.13 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.25 (q, 2 H), 1.79 (d, *J*=12.88 Hz, 2 H), 1.54 - 1.72 (m, 3 H), 1.28 (q, *J*=13.14 Hz, 2 H), 1.10 (q, *J*=12.38 Hz, 1 H)


Example 122



N-((1-Cyclohexyl-3-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl)glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 2,6-dichlorobenzyl bromide (440 mg, 2.0 mmoles) in dimethylacetamide (6 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from ethanol-water gave the title compound (150 mg, 32%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.07 (br. s., 1 H), 9.98 (br. s., 1 H), 7.43 (dd, 2 H), 7.30 (dd, 1 H), 5.26 (s, 2 H), 4.60 (t, *J*=12.00 Hz, 1 H), 2.14 - 2.31 (m, 2 H), 1.77 (d, *J*=12.88 Hz, 2 H), 1.47 - 1.66 (m, 3 H), 1.27 (q, 2 H), 1.10 (q, 1 H)


Example 123



N-[(3-{[2-Bromo-5-(methoxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 2-bromo-5-methoxybenzyl bromide (560 mg, 2.0 mmoles) in dimethylacetamide (6 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from acetic acid-water gave the title compound (150 mg, 29%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.04 (br. s., 1 H), 10.12 (br. s., 1 H), 7.55 (d, *J*=8.84 Hz, 1 H), 6.84 (dd, *J*=8.84, 3.03 Hz, 1 H), 6.50 (d, *J*=2.78 Hz, 1 H), 4.94 (s, 2 H), 4.65 (t, *J*=11.75 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 3.69 (s, 3 H), 2.25 (q, 2 H), 1.79 (d, *J*=13.14 Hz, 2 H), 1.54 - 1.74 (m, 3 H), 1.28 (q, *J*=12.72 Hz, 2 H), 1.10 (q, *J*=12.88 Hz, 1 H)

Example 124




N-[(3-{[2,4-Bis(trifluoromethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 2,4-bis(trifluoromethyl)benzyl bromide (375 uL, 2.0 mmoles) in dimethylacetamide (6 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from acetic acid-water gave the

title compound (180 mg, 34%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 8.06 (s, 1 H), 7.98 (d, *J*=8.59 Hz, 1 H), 7.53 (d, *J*=8.34 Hz, 1 H), 5.23 (s, 2 H), 4.64 (t, *J*=12.00 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.24 (q, 2 H), 1.78 (d, *J*=12.63 Hz, 2 H), 1.52 - 1.73 (m, 3 H), 1.28 (q, *J*=13.05 Hz, 2 H), 1.10 (q, 1 H).

5

Example 125



N-({3-[(2-Bromo-5-fluorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine


10 A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (750 mg, 5.35 mmoles) and 2-bromo-5-fluorobenzyl bromide (375 uL, 2.0 mmoles) in dimethylacetamide (6 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1

15 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Recrystallization from acetic acid-water gave the title compound (160 mg,

20 31%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.10 (br. s., 1 H), 10.10 (br. s., 1 H), 7.69 (dd, *J*=8.59, 5.31 Hz, 1 H), 7.11 (ddd, *J*=8.53, 3.16 Hz, 1 H), 7.05 (dd, *J*=9.60, 2.78 Hz, 1 H), 4.95 (s, 2 H), 4.63 (t, *J*=12.38 Hz, 1 H), 4.13 (d, *J*=5.81 Hz, 2 H), 2.24 (q, 2 H), 1.79 (d, *J*=13.14 Hz, 2 H), 1.52 - 1.74 (m, *J*=27.54, 11.62 Hz, 3 H), 1.28 (q, *J*=12.88 Hz, 2 H), 1.10 (q, *J*=12.97 Hz, 1 H).

25

Example 126




N-[(3-{[2-Bromo-4-(1,1-dimethylethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (740 mg, 5.35 mmoles) and 2-bromo-1-(bromomethyl)-4-(1,1-dimethylethyl)benzene (612 mg, 2.0 mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (1.0 mL) and 6 molar sodium hydroxide (1.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid, dried and evaporated. Preparative HPLC (50-90% acetonitrile-water-0.1% TFA) gave the title compound (40 mg, 7.5%).

¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.17 (br. s., 1 H), 10.14 (br. s., 1 H), 7.59 (d, *J*=1.52 Hz, 1 H), 7.33 (dd, *J*=8.08, 1.52 Hz, 1 H), 6.92 (d, *J*=8.08 Hz, 1 H), 4.96 (s, 2 H), 4.65 (t, *J*=11.75 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.25 (q, *J*=11.54 Hz, 2 H), 1.79 (d, *J*=12.13 Hz, 2 H), 1.53 - 1.73 (m, 3 H), 1.20 - 1.38 (m, 11 H), 1.11 (q, 1 H)

Example 127




N-[(1-Cyclohexyl-6-hydroxy-3-[(2-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine

A mixture of ethyl *N*-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycinate (340 mg, 1.0 mmoles), *pulv.* potassium carbonate (740 mg, 5.35 mmoles) and 2-methylbenzene (268 μL, 2.0 mmoles) in dimethylformamide (5 mL) was vigorously stirred at 100°C for 3 hours. The mixture was poured into 1 molar hydrochloric acid and extracted with ethyl acetate (x2). The combined organic solutions were washed with 1 molar hydrochloric acid and evaporated. The residue was purified by flash chromatography (10-50% ethyl acetate in hexane), the required fractions evaporated, dissolved in ethanol (5 mL) and 1 molar sodium hydroxide solution (3.0 mL) added. The mixture was stirred overnight, acidified and extracted with ethyl acetate (x2), the combined extracts washed with 1 molar hydrochloric acid,

dried and evaporated. Preparative HPLC (20-90% acetonitrile-water-0.1% TFA) gave the title compound (12 mg, 3.0%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.11 (br. s., 1 H), 10.15 (br. s., 1 H), 7.00 - 7.29 (m, 3 H), 6.89 (d, *J*=6.82 Hz, 1 H), 4.96 (s, 2 H), 4.65 (t, *J*=12.25 Hz, 1 H), 4.13 (d, *J*=5.56 Hz, 2 H), 2.35 (s, 3 H), 2.26 (q, 2 H), 1.78 (d, *J*=12.13 Hz, 2 H), 1.51 - 1.72 (m, 3 H),
 5 1.28 (q, 2 H), 1.10 (q, 1 H).

Example 128




N-{[1-Cyclohexyl-3-(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine

128a) 1-Cyclohexyl-3-(1,1-dimethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of *t*-amylamine (1.18 mL, 10 mmoles) and cyclohexyl isocyanate (1.28 mL, 10 mmoles) in chloroform (50 mL) was stirred overnight. Malonyl dichloride (1.16 mL, 12 mmoles) was added and the mixture was heated at 50°C for 3 hours. The mixture was evaporated and flash chromatographed (ethyl acetate 10-50% in hexane) to give the title compound (1.9 g, 68%). ¹H NMR (400 MHz, CHLOROFORM-*d*) δ ppm 4.54 (tt, *J*=12.25, 3.66 Hz, 1 H), 3.56 (s, 2 H), 2.23 (ddd, *J*=24.88, 12.51, 3.54 Hz, 2 H), 2.06 (q, *J*=7.58 Hz, 2 H), 1.77 - 1.91 (m, 2 H), 1.52 - 1.72 (m, 9 H), 1.35 (qt, *J*=13.09, 3.28, 3.16 Hz, 2 H), 1.22 (qt, *J*=12.87, 12.66, 3.28 Hz, 1 H), 0.83 (t, *J*=7.45 Hz, 3 H)

128b) *N*-{[1-Cyclohexyl-3-(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine. A mixture of 1-cyclohexyl-3-(1,1-dimethylpropyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (1.9 g, 6.8 mmoles), diisopropylethylamine (2.35 mL, 13.6 mmoles) and ethyl isocyanatoacetate (915 uL, 8.16 mmoles) in dichloromethane (60 mL) was stirred for 72 hours. The mixture was washed with 1 molar hydrochloric acid (x2) and evaporated. The residue was dissolved in ethanol (10 mL), treated with 6 molar sodium hydroxide (5 mL) and stirred overnight. The mixture was diluted with ethyl acetate, washed with 1 molar hydrochloric acid (x2), dried and evaporated. The residue was crystallized from a small amount of acetic acid to give the title compound (960 mg, 37%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.06 (br. s., 1 H), 10.09 (br. s., 1 H), 4.54 (t, *J*=11.12 Hz, 1 H), 4.10 (d, *J*=5.81 Hz, 2 H), 2.22 (qd, 1 H), 2.06 (q, *J*=7.33 Hz, 2 H), 1.78 (d, *J*=12.38 Hz, 2 H), 1.46 - 1.69 (m, 9 H), 1.28 (q, *J*=13.05 Hz, 2 H), 1.11 (q, *J*=12.88 Hz, 1 H), 0.77 (t, *J*=7.45 Hz, 3 H)

Example 129



N-([1,3-Bis(2,6-dichlorophenyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine

- 5 129a) N,N'-Bis(2,6-dichlorophenyl)urea. 2,6 dichloroaniline (3.47 g, 21.4 mmol) and carbonyldiimidazole (3.24 g, 20 mmol) were heated together in dimethylformamide (75 mL) for 4 hours. The mixture was cooled and partitioned between ethyl acetate and 1 molar hydrochloric acid, which produced a solid. The solid was collected washed with ethyl acetate, hexane and dried to give the title compound (940 mg, 27%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 8.44 (s, 2 H),
 10 7.52 (d, *J*=8.08 Hz, 4 H), 7.28 - 7.35 (m, 2 H)
- 129b) 1,3-Bis(2,6-dichlorophenyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione. A mixture of *N,N'*-bis(2,6-dichlorophenyl)urea (850 mg, 2.43 mmol) and malonyl dichloride (240 μL, 2.47 mmol) in chloroform (500 mL) was heated under reflux for 3 hours. Another aliquot of malonyl
 15 dichloride (240 μL, 2.47 mmol) was added and heating continued for a further 2 hours. The mixture was filtered, evaporated and purified by flash chromatography (dichloromethane to 2% methanol in dichloromethane) to give the title compound (200 mg, 20%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 7.66 (d, *J*=8.08 Hz, 4 H), 7.53 (t, *J*=8.08 Hz, 2 H), 4.93 (br. s, 2 H)
- 20 129c) N-([1,3-Bis(2,6-dichlorophenyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl)glycine. A mixture of 1,3-bis(2,6-dichlorophenyl)-2,4,6(1*H*,3*H*,5*H*)-pyrimidinetrione (200 mg, 0.478 mmol), diisopropylethylamine (210 μL, 0.96 mmol) and ethyl isocyanatoacetate (126 μL, 0.574 mmol) in dichloromethane (50 mL) was stirred overnight. Reaction was very slow, therefore additional diisopropylethylamine (1.0 mL, 3.4 mmol) and
 25 ethyl isocyanatoacetate (500 μL, 2.6 mmol) was added and the mixture was heated batchwise (3 x 20 mL) in a microwave reactor at 120°C for 20 minutes. The combined reaction mixtures was washed with 1 molar hydrochloric acid (x2) and evaporated. The residue was dissolved in ethanol (5 mL), treated with 6 molar sodium hydroxide (5 mL) and stirred for 1 hour. The mixture was diluted with ethyl acetate, washed with 1 molar hydrochloric acid (x2), dried and evaporated. The
 30 residue was crystallized from a small amount of acetic acid to give the title compound (138 mg,

55%). ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 13.25 (br. s., 1 H), 10.11 (t, *J*=5.68 Hz, 1 H), 7.67 - 7.76 (m, 4 H), 7.59 (dd, *J*=8.84, 7.58 Hz, 2 H), 4.18 (d, *J*=5.56 Hz, 2 H).

Biological Background:

5 The following references set out information about the target enzymes, HIF prolyl hydroxylases, and methods and materials for measuring inhibition of same by small molecules.

M. Hirsilä, P. Koivunen, V. Günzler, K. I. Kivirikko, and J. Myllyharju “Characterization of the Human Prolyl 4-Hydroxylases That Modify the Hypoxia-inducible Factor” *J. Biol. Chem.*, **2003**, 278, 30772-30780.

10 C. Willam, L. G. Nicholls, P. J. Ratcliffe, C. W. Pugh, P. H. Maxwell “The prolyl hydroxylase enzymes that act as oxygen sensors regulating destruction of hypoxia-inducible factor α” *Advan. Enzyme Regul.*, **2004**, 44, 75–92

M. S. Wiesener, J. S. Jürgensen, C. Rosenberger, C. K. Scholze, J. H. Hörstrup, C. Warnecke, S. Mandriota, I. Bechmann, U. A. Frei, C. W. Pugh, P. J. Ratcliffe, S. Bachmann, P. H. 15 Maxwell, and K.-U. Eckardt “Widespread hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs” *FASEB J.*, **2003**, 17, 271-273.

S. J. Klaus, C. J. Molineaux, T. B. Neff, V. Guenzler-Pukall, I. Lansetmo Parobok, T. W. Seeley, R. C. Stephenson “Use of hypoxia-inducible factor α (HIFα) stabilizers for enhancing erythropoiesis” *PCT Int. Appl.* (**2004**), WO 2004108121 A1

20 C. Warnecke, Z. Zaborowska, J. Kurreck, V. A. Erdmann, U. Frei, M. Wiesener, and K.-U. Eckardt “Differentiating the functional role of hypoxia-inducible factor (HIF)-1α and HIF-2α (EPAS-1) by the use of RNA interference: erythropoietin is a HIF-2α target gene in Hep3B and Kelly cells” *FASEB J.*, **2004**, 18, 1462-1464.

25 For the expression of *EGLN3* see:

R. K. Bruick and S. L. McKnight “A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF” *Science*, **2001**, 294, 1337-1340.

For the expression of HIF2 α -CDD see:

a) P. Jaakkola, D. R. Mole, Y.-M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. von Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe "Targeting of HIF- α to the von Hippel-Lindau Ubiquitylation Complex by O₂-Regulated Prolyl Hydroxylation" *Science*, **2001**, 292, 468-472.

b) M. Ivan, K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, W. G. Kaelin Jr. "HIF α Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O₂ Sensing" *Science*, **2001**, 292, 464-468.

For the expression of VHL, elongin b and elongin c see:

A. Pause, S. Lee, R. A. Worrell, D. Y. T. Chen, W. H. Burgess, W. M. Linehan, R. D. Klausner "The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins" *Proc. Natl. Acad. Sci. USA*, **1997**, 94, 2156-2161.

Biological Assay(s)

EGLN3 Assay

Materials:

His-MBP-EGLN3 (6HisMBPAttB1EGLN3(1-239)) was expressed in *E. Coli* and purified from an amylose affinity column. Biotin-VBC [6HisSumoCysVHL(2-213), 6HisSumoElonginB(1-118), and 6HisSumoElonginC(1-112)] and His-GB1-HIF2 α -CDD (6HisGB1tevHIF2A(467-572)) were expressed from *E. Coli*.

Method:

Cy5-labelled HIF2 α CDD, and a biotin-labeled VBC complex were used to determine EGLN3 inhibition. EGLN3 hydroxylation of the Cy5CDD substrate results in its recognition by the biotin-VBC. Addition of a Europium/streptavidin (Eu/SA) chelate results in proximity of Eu to Cy5 in the product, allowing for detection by energy transfer. A ratio of Cy5 to Eu emission (LANCE Ratio) is the ultimate readout, as this normalized parameter has significantly less variance than the Cy5 emission alone.

Then 50nL of inhibitors in DMSO (or DMSO controls) were stamped into a 384-well low volume Corning NBS plate, followed by addition of 2.5 μ L of enzyme [50 mL buffer (50 mM HEPES/50 mM KCl) + 1 mL of a 10 mg/mL BSA in buffer + 6.25 μ L of a 10mg/mL FeCl₂ solution in water + 100 μ L of a 200 mM solution of ascorbic acid in water + 15.63 μ L EGLN3] or control [50 mL buffer + 1 mL of a 10 mg/mL BSA in buffer + 6.25 μ L of a 10mg/mL FeCl₂ solution in water + 100 μ L of a 200 mM solution of ascorbic acid in water]. Following a 3 minutes

incubation, 2.5 μ L of substrate [50mL Buffer + 68.6 μ L biotin-VBC + 70.4 μ L Eu (at 710 μ g/mL stock) + 91.6 μ L Cy5CDD + 50 μ L of a 20 mM solution of 2-oxoglutaric acid in water + 0.3mM CHAPS] was added and incubated for 30 minutes. The plate was loaded into a PerkinElmer Viewlux for imaging. For dose response experiments, normalized data were fit by ABASE/XC50 using the equation $y = a + (b-a)/(1+(10^x/10^c)^d)$, where a is the minimum % activity, b is the maximum % activity, c is the pIC₅₀, and d is the Hill slope.

All exemplified compounds herein (Examples 1 to 129) have demonstrated *in vitro* EGLN3 inhibitory activity in this assay and have IC₅₀'s in the range of 0.8 nanomolar to 20 micromolar. This range represents the data accumulated as of the time of filing this application. Later testing may show variations in IC₅₀ data due to variations in reagents, conditions and variations in the method(s) used from those given herein above. Thus, these values are to be viewed as illustrative rather than absolute.

Measure Epo protein produced by Hep3B cell line using ELISA method.

Hep3B cells obtained from the American Type Culture Collection (ATCC) are seeded at 2×10^4 cells/well in Dulbecco's Modified Eagle Medium (DMEM) + 10% FBS in 96-well plates. Cells are incubated at 37degC/5% CO2/90% humidity (standard cell culture incubation conditions). After overnight adherence, medium is removed and replaced with DMEM without serum containing test compound or DMSO negative control. Following 48 hours incubation, cell culture medium is collected and assayed by ELISA to quantitate Epo protein.


Of the exemplified compounds tested to date all, except Examples 8, 9, 31, 35, 39, 88, 91, 93, and 94, have demonstrated EC₅₀'s in the Hep3B ELISA assay in the range of 0.4 micromolar to 100 micromolar using the reagents and under the conditions outlined herein above. Examples 8, 9, 31, 35, 39, 88, 91, 93, and 94, have demonstrated EC₅₀'s in the Hep3B ELISA assay of greater than 100 micromolar, the maximum concentration tested. This range represents the data accumulated as of the time of the filing of this application. Later testing may show variations in EC₅₀ data due to variations in reagents, conditions and variations in the method(s) used from those given herein above. Thus, these values are to be viewed as illustrative rather than absolute.

These compound are believed to be useful in therapy as defined above and to not have unacceptable or untoward effects when used in compliance with a permitted therapeutic regime.

The foregoing examples and assay have been set forth to illustrate the invention, not limit it. What is reserved to the inventors is to be determined by reference to the claims.

What is claimed is:

1. A compound according to formula (I):



5

wherein:

R¹ and R⁴ are each independently selected from the group consisting of hydrogen, -NR⁵R⁶, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkyl-C₁-C₁₀alkyl, C₅-C₈cycloalkenyl, C₅-C₈cycloalkenyl-C₁-C₁₀alkyl, C₃-C₈heterocycloalkyl, C₃-C₈heterocycloalkyl-C₁-C₁₀alkyl, aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl;

R² is -NR⁷R⁸ or -OR⁹;

R³ is H or C₁-C₄alkyl;

where R⁵ and R⁶ are each independently selected from the group consisting of hydrogen, C₁-C₁₀alkyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkyl-C₁-C₁₀alkyl, C₃-C₈heterocycloalkyl, C₃-C₈heterocycloalkyl-C₁-C₁₀alkyl, aryl, aryl-C₁-C₁₀alkyl, heteroaryl, heteroaryl-C₁-C₁₀alkyl, -C(O)C₁-C₄alkyl, -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -C(O)aryl, -C(O)heteroaryl and -S(O)₂C₁-C₄alkyl, or, when R⁵ and R⁶ are attached to the same nitrogen, R⁵ and R⁶ taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom selected from oxygen, nitrogen and sulphur,

R⁷ and R⁸ are each independently selected from the group consisting of hydrogen, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, aryl and heteroaryl, and

R⁹ is H or a cation, or C₁-C₁₀alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C₃-C₆cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;

where any carbon or heteroatom of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹ is unsubstituted or is substituted with one or more substituents independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, halogen, -OR¹⁰, -NR⁵R⁶, oxo, cyano, nitro, -C(O)R¹⁰, -C(O)OR¹⁰, -SR¹⁰,

-S(O)R¹⁰, -S(O)₂R¹⁰, -NR⁵R⁶, -CONR⁵R⁶, -N(R⁵)C(O)R¹⁰, -N(R⁵)C(O)OR¹⁰,
 -OC(O)NR⁵R⁶, -N(R⁵)C(O)NR⁵R⁶, -SO₂NR⁵R⁶, -N(R⁵)SO₂R¹⁰, C₂-C₁₀alkenyl,
 C₂-C₁₀alkynyl, C₃-C₆cycloalkyl, C₃-C₆heterocycloalkyl, aryl, C₁-C₆alkyl-aryl, heteroaryl
 and C₁-C₆alkyl-heteroaryl, wherein R⁵ and R⁶ are the same as defined above and R¹⁰ is
 5 selected from hydrogen, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, -C(O)C₁-C₄alkyl,
 -C(O)aryl, -C(O)heteroaryl, -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -S(O)₂C₁-
 C₄alkyl, C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, C₆-C₁₄aryl, aryl-C₁-C₁₀alkyl, heteroaryl
 and heteroaryl-C₁-C₁₀alkyl;

and/or a pharmaceutically acceptable salt or solvate thereof.

10

2. A compound according to claim 1 wherein:

X is O;

Y is O;

R¹ and R⁴ are each independently selected from the group consisting of hydrogen,

15 C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₈cycloalkyl, C₃-C₈cycloalkyl-C₁-C₁₀alkyl,
 C₅-C₈cycloalkenyl, C₅-C₈cycloalkenyl-C₁-C₁₀alkyl, C₃-C₈heterocycloalkyl, C₃-C₈heterocycloalkyl-
 C₁-C₁₀alkyl, aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl;

R² is -NR⁷R⁸ or -OR⁹;

R³ is H or C₁-C₄alkyl;

20

where R⁷ and R⁸ are each independently selected from the group consisting of hydrogen,
 C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, aryl
 and heteroaryl, and

R⁹ is H or a cation, or C₁-C₁₀alkyl which is unsubstituted or substituted with one or more
 substituents independently selected from the group consisting of C₃-C₆cycloalkyl,

25

heterocycloalkyl, aryl and heteroaryl,

where any carbon or heteroatom of R¹, R², R³, R⁴, R⁷, R⁸, R⁹ is unsubstituted or is
 substituted with one or more substituents independently selected from C₁-C₆alkyl,

C₁-C₆haloalkyl, halogen, -OR¹⁰, -NR⁵R⁶, oxo, cyano, nitro, -C(O)R¹⁰, -C(O)OR¹⁰, -SR¹⁰,
 -S(O)R¹⁰, -S(O)₂R¹⁰, -NR⁵R⁶, -CONR⁵R⁶, -N(R⁵)C(O)R¹⁰, -N(R⁵)C(O)OR¹⁰,

30

-OC(O)NR⁵R⁶, -N(R⁵)C(O)NR⁵R⁶, -SO₂NR⁵R⁶, -N(R⁵)SO₂R¹⁰, C₂-C₁₀alkenyl,

C₂-C₁₀alkynyl, C₃-C₆cycloalkyl, C₃-C₆heterocycloalkyl, aryl, C₁-C₆alkyl-aryl, heteroaryl
 and C₁-C₆alkyl-heteroaryl, wherein R⁵ and R⁶ are as defined in claim 1 and R¹⁰ is selected

from hydrogen, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, -C(O)C₁-C₄alkyl, -C(O)aryl,
 -C(O)heteroaryl, -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -S(O)₂C₁-C₄alkyl,

35

C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, C₆-C₁₄aryl, aryl-C₁-C₁₀alkyl, heteroaryl and
 heteroaryl-C₁-C₁₀alkyl;

and/or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 wherein:

X is O;

5 Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl, C_5 - C_8 cycloalkenyl, C_5 - C_8 cycloalkenyl- C_1 - C_{10} alkyl, C_3 - C_8 heterocycloalkyl, C_3 - C_8 heterocycloalkyl- C_1 - C_{10} alkyl, aryl, aryl- C_1 - C_{10} alkyl, heteroaryl and heteroaryl- C_1 - C_{10} alkyl;

10 R^2 is $-OR^9$;

R^3 is H or C_1 - C_4 alkyl;

R^9 is H or a cation, or C_1 - C_{10} alkyl which is unsubstituted or is substituted with one or more substituents independently selected from the group consisting of C_3 - C_6 cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

15 where any carbon or heteroatom of R^1 , R^2 , R^3 , R^4 , R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_6 cycloalkyl,

20 C_3 - C_6 heterocycloalkyl, aryl, C_1 - C_6 alkyl-aryl, heteroaryl and C_1 - C_6 alkyl-heteroaryl, wherein R^5 , and R^6 are the same as defined in claim 1 and R^{10} is selected from hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, $-C(O)C_1$ - C_4 alkyl, $-C(O)$ aryl, $-C(O)$ heteroaryl, $-C(O)C_3$ - C_6 cycloalkyl, $-C(O)C_3$ - C_6 heterocycloalkyl, $-S(O)_2C_1$ - C_4 alkyl, C_3 - C_8 cycloalkyl, C_3 - C_8 heterocycloalkyl, C_6 - C_{14} aryl, aryl- C_1 - C_{10} alkyl, heteroaryl and heteroaryl- C_1 - C_{10} alkyl;

25 and/or a pharmaceutically acceptable salt or solvate thereof.

4. A compound according to claim 1 wherein:

X is O;

Y is O;

30 R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl, C_5 - C_8 cycloalkenyl, C_5 - C_8 cycloalkenyl- C_1 - C_{10} alkyl, C_3 - C_8 heterocycloalkyl, C_3 - C_8 heterocycloalkyl- C_1 - C_{10} alkyl, aryl, aryl- C_1 - C_{10} alkyl, heteroaryl and heteroaryl- C_1 - C_{10} alkyl;

R^2 is $-OR^9$;

35 R^3 is H;

R^9 is H or a cation;

where any carbon or heteroatom of R¹, R², R³, R⁴ is unsubstituted or is substituted with one or more substituents independently selected from C₁-C₆alkyl, C₁-C₆haloalkyl, halogen, -OR¹⁰, -NR⁵R⁶, oxo, cyano, nitro, -C(O)R¹⁰, -C(O)OR¹⁰, -SR¹⁰, -S(O)R¹⁰, -S(O)₂R¹⁰, -NR⁵R⁶, -CONR⁵R⁶, -N(R⁵)C(O)R¹⁰, -N(R⁵)C(O)OR¹⁰, -OC(O)NR⁵R⁶, -N(R⁵)C(O)NR⁵R⁶, -SO₂NR⁵R⁶, -N(R⁵)SO₂R¹⁰, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, C₃-C₆cycloalkyl, C₃-C₆heterocycloalkyl, aryl, C₁-C₆alkyl-aryl, heteroaryl and C₁-C₆alkyl-heteroaryl, wherein R⁵, and R⁶ are the same as defined in claim 1 and R¹⁰ is selected from hydrogen, C₁-C₁₀alkyl, C₂-C₁₀alkenyl, C₂-C₁₀alkynyl, -C(O)C₁-C₄alkyl, -C(O)aryl, -C(O)heteroaryl, -C(O)C₃-C₆cycloalkyl, -C(O)C₃-C₆heterocycloalkyl, -S(O)₂C₁-C₄alkyl, C₃-C₈cycloalkyl, C₃-C₈heterocycloalkyl, C₆-C₁₄aryl, aryl-C₁-C₁₀alkyl, heteroaryl and heteroaryl-C₁-C₁₀alkyl; and/or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to claim 1 which is selected from:

N- {[1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[1- {[2,4-bis(methyloxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[6-hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine; and

N- [(1-(1,1-dimethylethyl)-3- {[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

and/or a pharmaceutically acceptable salt or solvate thereof.

6. A compound according to claim 1 which is selected from:

N- {[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N- {[6-Hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-[(3-Cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

5 *N*-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-[(3,4-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

10 *N*-{[6-Hydroxy-1-{[3-(methyloxy)phenyl]methyl}-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-[(2,6-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[6-Hydroxy-1-methyl-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

15 *N*-{[1-Cyclohexyl-3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

20 *N*-{[1-Hexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Ethyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

25 *N*-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Butyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[6-Hydroxy-2,4-dioxo-1-(2-phenylethyl)-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

30 *N*-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-1-(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl] glycine;

35 *N*-{[6-Hydroxy-1,3-bis(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-[(2-Bromophenyl)methyl]-1-(1,1-dimethylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

5 *N*-[(1-(2,4-dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2-Bromophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

10 *N*-[(1-(2-Biphenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

15 *N*-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(2-thienyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-[3-(4-morpholinyl)propyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

20 *N*-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(3-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Cyclohexyl-3-[(2-fluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-[(2-Chlorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

25 *N*-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Cyclohexyl-3-[(2,4-dimethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

30 *N*-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trifluorophenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-Cyclohexyl-6-hydroxy-3-{[4-(1-methylethyl)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-Cyclohexyl-3-[(2-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

35 *N*-{[1-Cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trimethylphenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[1-Cyclohexyl-3-(2-cyclohexylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

5 *N*-([3-{[3,5-Bis(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[1-Cyclohexyl-6-hydroxy-3-(2-naphthalenylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

10 *N*-({1-Cyclohexyl-6-hydroxy-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[3-(4-Biphenylmethyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-([3-{[4-(1,3-Benzoxazol-2-yl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

15 *N*-({3-[2-(4-Biphenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1,3-Bis {[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

20 *N*-[1-Cyclohexyl-6-hydroxy-3-(4-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)cyclohexyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

25 *N*-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[1-Cyclohexyl-3-(cyclohexylmethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

30 *N*-[(3-Cycloheptyl-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-[(1*R*,2*R*,4*S*)-Bicyclo[2.2.1]hept-2-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

35 *N*-[1-Cyclohexyl-6-hydroxy-3-(3-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-Cyclohexyl-1-cyclopropyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-Cyclobutyl-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

5

N-[(3-Cyclohexyl-1-cyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-Hydroxy-1,3-bis(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

10

N-[(6-Hydroxy-1,3-bis{[2-(methyloxy)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1,3-Bis[(2-chlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1,3-Dihexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

15

N-{[1-Cyclohexyl-6-hydroxy-3-(2-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(2-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(1-Cyclohexyl-3-hexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

20

N-[(1,3-Dicycloheptyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-Dicyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

25

N-{[1-Cyclohexyl-3-(2,3-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

4-[5- {[Carboxymethyl]amino}carbonyl]-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-Cyclohexyl-3-(4-ethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

30

cis-4-[3-Cyclohexyl-5-([2-(ethyloxy)-2-oxoethyl]amino)carbonyl]-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-Cyclohexyl-6-hydroxy-3-(1-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

35

3-[5- {[Carboxymethyl]amino}carbonyl]-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-Cyclohexyl-6-hydroxy-3-{2-[4-(methyloxy)phenyl]-2-oxoethyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

5 *N*-({1-Cyclohexyl-6-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-3-(3,3-dimethyl-2-oxobutyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

10 *N*-({1-Cyclohexyl-3-[2-(4-fluorophenyl)-2-oxoethyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[2-(4-Cyanophenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[2-(1-Benzofuran-2-yl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

15 *N*-{[3-Cyclohexyl-6-hydroxy-1-(1-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-Cyclohexyl-1-(4,4-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

20 *N*-({1-Cyclohexyl-3-[(2,3-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

Ethyl *N*-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycinate;

N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycine;

25 6-[5- {[(Carboxymethyl)amino]carbonyl} -3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]hexanoic acid;

6-[5- {[(Carboxymethyl)amino]carbonothioyl} -3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]hexanoic acid;

30 *N*-({1-Cyclohexyl-3-[(3,4-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-Cyclohexyl-6-hydroxy-1-[*trans*-4-(methyloxy)cyclohexyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

35 *N*-({1-[1,1'-Bi(cyclohexyl)-4-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[6-Hydroxy-2,4-dioxo-1,3-bis(1-propylbutyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

5 *N*-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-phenylcyclohexyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({1-Cyclohexyl-3-[(3,4-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

10 *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-(2-Cyclopropylethyl)-6-hydroxy-1-(3-nitrophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-2,4-dioxo-1-[4-(2-thienyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

15 *N*-{[1,3-Bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-[(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

20 *N*-[(1,3-Dibutyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1,3-Bis(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[6-Hydroxy-1,3-bis(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

25 *N*-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

30 *N*-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-({3-(2-Cyclopropylethyl)-1-[4-(2-furanyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1,3-Bis(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;


35 *N*-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(1-[[[(phenylmethyl)oxy]carbonyl]-3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[1-(1-Acetyl-3-piperidinyl)-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[1-(1-Cyclohexyl-3-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;
N-{[3-[(2-Bromophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[1-Cyclohexyl-3-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[3-{[2-Bromo-5-(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[3-{[2,4-Bis(trifluoromethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[3-[(2-Bromo-5-fluorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[3-{[2-Bromo-4-(1,1-dimethylethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[1-Cyclohexyl-6-hydroxy-3-[(2-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
N-{[1-Cyclohexyl-3-(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine; and
N-{[1,3-Bis(2,6-dichlorophenyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl} glycine;
 and/or a pharmaceutically acceptable salt or solvate thereof.

7. A pharmaceutical composition which comprises a compound as described in claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.

8. A use of a compound as described in claim 1 in the preparation of the medicament for treating anemia in a mammal.
9. The use of claim 8 wherein the mammal is a human.
10. A use of a compound as described in claim 1 in the preparation of a medicament for inhibiting HIF prolyl hydroxylases in a mammal.
11. The use of claim 10 wherein the mammal is a human.
12. A use of a compound as described in claim 1 in the preparation of a medicament for treating Ischemia in a mammal.
13. The use of claim 12 wherein the mammal is a human.
14. A use of a compound as described in claim 1 in the preparation of a medicament for treating myocardial infarction in a mammal.
15. The use of claim 14 wherein the mammal is a human.
16. A use of a) a compound as described in claim 1; and b) EPO or a derivative thereof, in the preparation of a medicament for treating diseases of the hematopoietic system.
17. A compound as described in claim 1 for use in treating anemia in a mammal.
18. The compound of claim 17 wherein the mammal is a human.
19. A compound as described in claim 1 for use in inhibiting HIF prolyl hydroxylases in a mammal.
20. The compound of claim 19 wherein the mammal is a human.

21. A compound as described in claim 1 for use in treating Ischemia in a mammal.
22. The compound of claim 21 wherein the mammal is a human.
23. A compound as described in claim 1 for use in treating myocardial infarction in a mammal.
24. The compound of claim 23 wherein the mammal is a human.
25. A compound as described in claim 1 and EPO or a derivative thereof, for use in treating diseases of the hematopoietic system.
26. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound as described in claim 1 which process comprises bringing the compound as described in claim 1 into association with a pharmaceutically acceptable carrier or diluent.
27. A process for preparing a compound of formula (I)



wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, $-NR^5R^6$, $C_1-C_{10}alkyl$, $C_2-C_{10}alkenyl$, $C_2-C_{10}alkynyl$, $C_3-C_8cycloalkyl$, $C_3-C_8cycloalkyl-C_1-C_{10}alkyl$, $C_3-C_8cycloalkenyl$, $C_3-C_8cycloalkenyl-C_1-C_{10}alkyl$, $C_3-C_8heterocycloalkyl$, $C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl$, aryl, aryl- $C_1-C_{10}alkyl$, heteroaryl and heteroaryl- $C_1-C_{10}alkyl$;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1-C_4alkyl ;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, $C_1-C_{10}alkyl$, $C_3-C_8cycloalkyl$, $C_3-C_8cycloalkyl-C_1-C_{10}alkyl$, $C_3-C_8heterocycloalkyl$, $C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl$, aryl, aryl- $C_1-C_{10}alkyl$, heteroaryl, heteroaryl- $C_1-C_{10}alkyl$, $-CO(C_1-C_4alkyl)$, $-CO(C_3-C_6cycloalkyl)$, $-CO(C_3-C_6heterocycloalkyl)$, $-CO(aryl)$, $-CO(heteroaryl)$ and $-SO_2(C_1-C_4alkyl)$, or, when R^5 and R^6 are attached to the same nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom

selected from oxygen, nitrogen and sulphur,

R^7 and R^8 are each independently selected from the group consisting of hydrogen, $C_1-C_{10}alkyl$, $C_2-C_{10}alkenyl$, $C_2-C_{10}alkynyl$, $C_3-C_8cycloalkyl$, $C_3-C_8heterocycloalkyl$, aryl and heteroaryl, and

R^9 is H or a cation, or $C_1-C_{10}alkyl$ which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of $C_3-C_6cycloalkyl$, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;


where any carbon or heteroatom of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl ,

$C_1-C_6haloalkyl$, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, $C_2-C_{10}alkenyl$,

$C_2-C_{10}alkynyl$, $C_3-C_6cycloalkyl$, $C_3-C_6heterocycloalkyl$, aryl, $C_1-C_6alkyl-aryl$, heteroaryl and $C_1-C_6alkyl-heteroaryl$, wherein R^5 and R^6 are the same as defined above and R^{10} is

selected from hydrogen, $C_1-C_{10}alkyl$, $C_2-C_{10}alkenyl$, $C_2-C_{10}alkynyl$, $-CO(C_1-C_4alkyl)$, $-CO(aryl)$, $-CO(heteroaryl)$, $-CO(C_3-C_6cycloalkyl)$, $-CO(C_3-C_6heterocycloalkyl)$, $-SO_2(C_1-C_4alkyl)$, $C_3-C_8cycloalkyl$, $C_3-C_8heterocycloalkyl$, $C_6-C_{14}aryl$, aryl- $C_1-C_{10}alkyl$, heteroaryl and heteroaryl- $C_1-C_{10}alkyl$;


comprising treating a compound of formula A:



wherein R^1 and R^4 are the same as for those groups in formula (I) with glycine and an appropriate base in an appropriate solvent under conventional thermal conditions or by microwave irradiation, to form the compound of formula (I).

5

28. A process for preparing a compound of formula (I)



10 wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, $-NR^5R^6$, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl, C_5 - C_8 cycloalkenyl, C_5 - C_8 cycloalkenyl- C_1 - C_{10} alkyl, C_3 - C_8 heterocycloalkyl, C_3 - C_8 heterocycloalkyl- C_1 - C_{10} alkyl, aryl, aryl- C_1 - C_{10} alkyl, heteroaryl and heteroaryl- C_1 - C_{10} alkyl;

15 R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1 - C_4 alkyl;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_3 - C_8 cycloalkyl, C_3 - C_8 cycloalkyl- C_1 - C_{10} alkyl, C_3 - C_8 heterocycloalkyl, C_3 - C_8 heterocycloalkyl- C_1 - C_{10} alkyl, aryl, aryl- C_1 - C_{10} alkyl, heteroaryl, heteroaryl- C_1 - C_{10} alkyl, $-CO(C_1$ - C_4 alkyl), $-CO(C_3$ - C_6 cycloalkyl), $-CO(C_3$ - C_6 heterocycloalkyl), $-CO$ (aryl), $-CO$ (heteroaryl) and $-SO_2(C_1$ - C_4 alkyl), or, when R^5 and R^6 are attached to the same nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom selected from oxygen, nitrogen and sulphur,

25 R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_3 - C_8 cycloalkyl, C_3 - C_8 heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1 - C_{10} alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3 - C_6 cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

5 Y is O or S;

where any carbon or heteroatom of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1 - C_6 alkyl,

C_1 - C_6 haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$,

10 $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2 - C_{10} alkenyl,


C_2 - C_{10} alkynyl, C_3 - C_6 cycloalkyl, C_3 - C_6 heterocycloalkyl, aryl, C_1 - C_6 alkyl-aryl, heteroaryl and C_1 - C_6 alkyl-heteroaryl, wherein R^5 and R^6 are the same as defined above and R^{10} is

selected from hydrogen, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, $-CO(C_1$ - C_4 alkyl),

$-CO(aryl)$, $-CO(heteroaryl)$, $-CO(C_3$ - C_6 cycloalkyl), $-CO(C_3$ - C_6 heterocycloalkyl), $-SO_2(C_1$ -

15 C_4 alkyl), C_3 - C_8 cycloalkyl, C_3 - C_8 heterocycloalkyl, C_6 - C_{14} aryl, aryl- C_1 - C_{10} alkyl, heteroaryl and heteroaryl- C_1 - C_{10} alkyl;

comprising treating a compound of formula B:



B

wherein R^1 and R^4 are the same as for those groups in formula (I) with an alkali, in an appropriate
20 solvent at a suitable temperature to form the compound of formula (I).